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General introduction 
Alzheimer's disease (AD) is acknowledged as the most common form of dementia in the 
elderly. In 1906 Alois Alzheimer, Director of the Cerebral Anatomical Laboratory of the 
Ludwig-Maximilians University Munich, presented for the first time his observations 
about amyloid plaques, neurofibrillary tangles, and arteriosclerotic changes, the neuropa-
thological hallmarks of what later was termed AD, as found in the post mortem brain of his 
55-year old patient Auguste D(eter). Her illness lasted just 5 years in which she developed 
the neuropathology and progressive cognitive impairment, hallucinations, delusions, and 
impaired social functioning. 
Hundred years later, in 2006, approximately 26.6 million people worldwide suffered from 
AD and because of the growing life expectancy we can expect that the global prevalence 
of Alzheimer's will quadruple by 2050 to more than 100 million, which means that 1 in 85 
persons worldwide will be affected by this disease. 
Alzheimer's disease pathology 
Clinical features 
Alzheimer's disease (AD) affects a person's ability to carry out daily activities and is cha­
racterized by severe cognitive impairment, memory loss, anomia (problems with word 
finding), apraxia (problems with complex movements), impaired executive functioning 
(difficulties with everyday decision making) and personality changes (for example mis­
trust, aggression and delusions). 
Νeuropathological features 
Neuropathologically AD is characterized by intracellular neurofibrillary tangles extracel­
lular amyloid plaques, cerebrovascular alterations and neurodegeneration. 
Plaques and tangles 
It took over 70 years from the first description of the amyloid plaques in 1906 until it was 
discovered in the eighties, that the plaques consist of aggregates of extracellular loads of 8 
nm filaments of small peptides called amyloid-ß (Aß) [1]. Early in the course of the disease 
specific brain regions like the forebrain and medial temporal lobe structures (hippocampus, 
amygdala and entorhinal cortex) are affected with extracellular lesions characterized by 
Fig. 1 Immunohistochemical staining of senile plaques and tangles 
accumulation of Aß peptide [2,3]· A second lesion described by Alzheimer, are the neuro-
fibrillary tangles (NFT), which are composed of aggregates of abnormally hyperphospho-
rylated tau protein, occurring both in neuronal cell bodies and in axons and dendrites [4]. 
The tau protein is normally predominantly involved in the assembly and stabilization of 
microtubules. It is suggested that NFT's are correlated with cognitive decline in AD [4,5]. 
Synaptic loss and neuwdegeneration. 
The amyloid deposits form a good diagnostic marker but do not correlate well with neuro-
nal damage and cognitive decline. Synaptic loss however is an early pathological hallmark 
of AD which is age dependent and largely independent of amyloid-ß [6,7]. Studies in early 
stage AD patients suggest that the neurodegenerative process initiates in the entorhinal 
cortex resulting in denervation in the hippocampus followed by loss of synapses in the mo-
lecular layer of the dentate gyrus and the nucleus basalis of Meynert [8]. Amyloid plaques 
formation and development of neurofibrillary tangles and gliosis accompany this process. 
In comparison it has been found in transgenic mice models of AD that synaptic loss and 
memory impairment precede amyloid deposits in the limbic system [9]. Also in other stu-
dies it has been found that AD is associated with disruption of synaptic contacts in specific 
cortical and subcortical areas and in early AD first 20% loss synapses in the outer molecu-
lar layer of the hippocampal dentate gyrus has been observed [8]. In later stages of AD, also 
loss in neocortex and even more damaged synapses has been found in the outer molecular 
layer of the dentate gyrus. Synaptic loss is correlated with memory impairment being a 
prodromal stage in the process of AD [10] and it is accompanied with abnormal processing 
of APP and soluble amyloid-ß consecutively resulting in plaque formation [9]. 
Microvascular changes 
When Alois Alzheimer presented for the first time his observations as found in the post 
mortem brain of Auguste D(eter), he described besides amyloid plaques and tangles also 
some arteriosclerotic changes. Vascular alterations in AD did not receive much attention in 
the past. However in the last decades vascular factors finally got some renewed attention. 
For example, AD and vascular dementia share the same risk factors [11,12], and pharma-
cotherapy improving cerebrovascular insufficiency decreases AD symptoms [13]. There 
is also evidence showing that cerebral perfusion is decreased in AD patients [14]. Besides 
haemodynamic changes, various microvascular abnormalities have been observed in AD 
patients, such as atrophic thin vessels, glomerular loop formations, fragmented vessels 
and twisted vessels, basement membrane thickening, pericyte degeneration, endothelial 
cell shape changes and luminal buckling (see ref [15] for review). A decrease in vascular 
density is also frequently observed [16]. In addition, in 80-90% percent of patients with AD 
also cerebral amyloid angiopathy (CAA) is noted. CAA is characterized by the deposition 
of Aß in the media and adventitia of meningeal and cerebral arteries and arterioles, and 
sometimes in capillaries and veins. It is suggested that CAA causes severe impairments of 
de vascular wall [17]. 
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Generation of amyloid-ß 
Amyloid-ß is generated by sequential cleavage of the transmembrane amyloid precursor 
protein (APP), by groups of enzymes named α-, β- and γ-secretase. The cleavage and pro­
cessing of APP can be divided into a non-amyloidogenic pathway and an amyloidogenic 
pathway. In the most common pathway, the non-amyloidogenic pathway, APP is cleaved 
by the a-secretase, producing a large amino (N)-terminal ectodomain (sAPPa), which is 
secreted into the extracellular medium. Because this cleavage occurs inside the amyloid-ß 
region, formation of amyloid-ß is prohibited. Three enzymes with a-secretase activity have 
been identified, all belonging to the ADAM family (a disintegrin- and metalloproteinase-
family enzyme. 
In the amyloidogenic pathway, amyloid-ß is generated by an initial cleavage of APP at the 
N-terminus by a ß-secretase (BACE; ß-site APP cleaving enzyme) followed by a cleavage 
in the transmembrane domain by a γ -secretase. The γ-secretase is a complex of enzymes 
composed of presenilin 1 or 2 (PS1 and PS2). γ-secretase cleaves at positions 40 and 42 
of the amyloid-ß protein, generating amyloid-ß 40 and amyloid-ß 42, respectively. Ap-
proximately 10% of the residues exist of amyloid-ß 42 whereas the predominant amount 
produced, exists of amyloid-ß40. The amyloid-ß42 is the principal isoform in amyloid 
plaques because of its fibrillary nature. 
AFP processing 
i i 
Non-amyloidogenic pathway Amyloidogenic pathway 
Figi. Processing of the Amyloid precursor protein (APP). 
Proteolytic cleavage of APP bv the a-secretase (such as ADAM10). within the Aß sequence, precldes 
formation of amyloidogenic peptides (non amyloidogenic pathway).Cleavage of APP by β (BACE 
I and 2) and subsequently γ-secretases, causes the production of the Aß peptide (amyloidogenic 
pathway). 
Genetics of Alzheimer's disease 
Ageing is the major risk factor for AD, reflected in increasing prevalence with advanced 
age. Less than 1% of people of 60-64 yrs old have AD whereas 40% of people older than 
85 yrs are affected [18]. The cut-off to distinguish between early onset and late onset AD 
is arbitrarily set at 60-65 years. 
The early onset, or presenile Alzheimer's disease, often have a positive family history 
which is the second most important risk factor for AD [19] Early-onset AD has so far been 
linked to mutations in the genes for the amyloid precursor protein (APP) on chromosome 
21, presenilin 1 (PS1) on chromosome 14, and presenilin 2 (PS2) on chromosome 1. The 
mutations in these genes affect the metabolism or stability of amyloid-ß, and they are thou-
ght to account for 40% of early-onset AD[ 19]. 
Late-onset or senile Alzheimer's disease accounts for 95% of all AD cases. The late-on-
set AD genes discovered until now, act as either risk factors and/or genetic modifiers. A 
number of potential susceptibility genes have been implicated as genetic risk factors for 
late-onset AD from which the apolipoprotein E gene is the best known. 
The apolipoprotein E gene on chromosome 19 encoding the cholesterol transport protein, 
apolipoprotein E (ApoE) was identified as risk factor in both familial and sporadic AD in 
which the ε4 allele of the APOE gene has been found associated with AD [19]. Carriers of 
one or two ε4 alleles of the APOE gene have a considerably higher risk to get AD on an 
earlier age of onset [20,21], whereas inheritance of the ε2 allele appears to be protective 
against AD. The mechanism by which the ApoE4 protein predisposes subjects to AD is 
not fully revealed. However evidence is accumulating, that E4 enhances amyloid-ß aggre-
gation by stimulating amyloidogenic processing of APP and reduces amyloid-ß clearance 
[22], impairs the cerebrovasculature [23,24] or causes neurodegeneration [25]. 
Risk factors and cause of Alzheimer's disease 
Many theories have been proposed about the cause of AD and the "amyloid cascade hypo-
thesis", in which amyloid deposition is seen as the primary pathway leading to neurodege-
neration and AD, is one of the most persistent [1]. However this hypothesis is still under 
debate because of conflicting results about for example the neurotoxicity of amyloid-ß 
deposition in vivo [26] and it has been found that also many non-demented persons show 
large amounts of AD pathology [4]. Amyloid deposition is not the earliest neuropathologi-
cal event observed in the disease [2,3] and is not always correlated to neuronal loss [27]. In 
transgenic mice it has been found that cognitive loss is independent of amyloid-ß overex-
pression and precedes amyloid-ß deposition [28]. 
Nowadays, more and more consensus is reached about vascular disorders being major risk 
factors for AD leading to the vascular hypothesis [26,29]. Many large epidemiological 
studies [11,30] have revealed that several risk factors for AD are vascular-related, (table 1) 
causing impaired cerebral perfusion, indicating that cerebral hypoperfusion may play an 
important role in the onset of AD [31,32]. 
Table 1. Risk factors for Alzheimer's disease 
Ageing Diabetes mellitus 
Presence of ΑΡΟΕε4 allele Stroke 
Hypertension Head injury 
Congestive heart failure Menopause 
Atrial fibrillation Lower education 
Atherosclerosis Depression 
Smoking Sedentary lifestyle 
Alcoholism Overweight 
High intake of saturated fat White matter lesions 
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Vascular risk factors 
Major vascular risk factors for AD are hypertension and atherosclerosis. Hypertension is a 
risk factor for stroke, ischemic white matter lesions, silent infarcts, general atherosclerosis, 
myocardial infarction and cardiovascular diseases, and often clusters with other vascular 
risk factors, including diabetes mellitus, obesity and hypercholesterolemia. Hypertension 
is present in approximately 50% of people above 70 years and predicts both AD and vas-
cular dementia already 20 years before onset of AD and elevated midlife systolic blood 
pressure of 160 mmHg or above is associated with lower brain weight, white matter lesions 
and greater numbers of senile plaques in hippocampus and neocortex [33-35] The deve-
lopment of atherosclerosis also takes decades before it manifests itself and it is logical to 
assume that diminished blood flow to the brain from stenosed or jammed carotid arteries 
leading to cognitive dysfunction is a process that likely precedes dementia symptoms by 
many years. Hypertension and atherosclerosis cause blood vessel wall pathology, leading 
to dysfunction in the blood brain barrier function, hypoperfusion, ischemia in the brain 
which may initiate the pathological process with cognitive impairment [36,37], ultimately 
leading to a significant increase in the incidence of AD [34] More and more evidence 
comes forward that cerebral ischemia plays an important role in development of AD and 
animal studies suggest that cerebral ischemia in the brain may lead to accumulation of 
APP and amyloid-ß [38]. De la Torre [39] proposed that aging in combination with a vas-
cular risk factor that further decreases cerebral perfusion promotes the Critically Attained 
Threshold of Cerebral Hypoperfusion (CATCH) which causes oxidative stress, decreased 
energy metabolism, followed by excessive glutamate production. All these events contri-
bute to progressive cognitive decline synaptic loss, senile plaques, neurofibrillary tangles, 
tissue atrophy and neurodegeneration [39,40] 
Lifestyle and diets 
Influencing vascular risk factors via diet and lifestyle may influence AD development 
Indeed a correlation exists between AD and dietary fat as important contributor to familiar 
atherosclerosis, and a good example is the link between cholesterol metabolism and deve-
lopment of AD [41-43]. On the contrary, omega-3 fatty acids from fish oil might beneficial-
ly influence cardiovascular disease by decreasing blood pressure [44], and atherosclerosis 
formation [45,46] The strongest evidence of a relation between omega-3 fatty acid intake 
and vascular disease is the occurrence of coronary heart disease which have been shown 
in many experiments and clinical trials (for review. Intervention with cholesterol lowering 
agents or fish oil diets to prevent or reduce atherosclerosis could also lessen the prevalen-
ce of AD Recently performed docosahexaenoic acid (DHA) trials show inhibition of the 
course of AD [47] and several trials on cholesterol lowering statins have shown beneficial 
effects on inhibition of AD [47-49] 
Western diets consist of high saturated fat and in combination with the sedentary lifestyles 
they have led to a growing incidence of obesity, hypercholesterolemia, and high blood 
pressure, causing atherosclerosis, coronary artery disease, and diabetes, major risk factors 
of AD, which are even more aggravated in people carrying the APOE ε4 alleles. 
Summarizing we could postulate that a combination of diet, lifestyle, vascular, genetic, 
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and amyloid related factors, which can enhance each other's contribution in the onset and 
course of AD will be more likely the cause of the disease than a single factor alone. 
Omega-3 fatty acids 
The long-chain polyunsaturated fatty acids exist of two key families: omega-3 and omega-
6, named after the place of the first double bond in the hydrocarbon chain. Especially doco-
sahexaenoic acid (DHA) is the most abundant (omega-3) fatty acid in the mammalian brain, 
and its levels in brain membrane lipids can be altered by diet, and with life stage, i.e. incre-
asing during development and decreasing with aging [50]. Very high levels of fatty acids 
and lipids can be found in the neuronal membrane and the myelin sheath. About 50% of the 
neuronal membrane is composed of poly unsaturated fatty acids, while in the myelin sheath 
lipids constitute about 70%. The omega-3 poly unsaturated fatty acids are mainly present 
in fish, shellfish, and sea mammals and are scarce in land animals and plants, whereas the 
omega-6 poly unsaturated fatty acids are derived mainly from vegetable oil. The precursors 
of the omega-3 and omega-6 poly unsaturated fatty acids cannot be synthesized endoge-
nously from carbohydrates and are therefore called essential fatty acids (BFA). The current 
Western diet is deficient in long-chain omega-3 fatty acids which caused a switch in the 
ratio of omega-6 to omega-3 intakes from 2 to more than 20 within a century [51]. This has 
negative consequences because an excess of omega-6, and a deficient amount of omega-3, 
is stimulating thrombogenesis, lowering immune response, increasing inflammation and 
decreasing neuronal membrane fluidity and function [52-55]. 
Omega-3 fatty acids and the brain. 
Particularly the omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), are incorporated into neuronal phospholipids (mostly phosphatidylethanola-
mine and phosphatidylserine) and in retinal pigment epithelium. Incorporation of omega-3 
fatty acids in the neuronal membrane increases fluidity of neuronal membranes and here-
with improves neurotransmission and signalling via increased receptor binding and en-
hancement of the number and affinity of receptors and function of ion channels [56,57]. 
Omega-3 fatty acids increase membrane fluidity by replacing omega-6 fatty acids and cho-
lesterol from the membrane maintaining an optimal membrane fluidity as obligatory for 
neurotransmitter binding and signalling within the cell [58]. Large amounts of DHA are 
necessary during brain development, for neural membrane production used for synaptoge-
nesis, axonal and dendritic outgrowth, in both brain and retina [59,60]. 
It will be clear from the above evaluated involvement of omega-3 fatty acids in neuronal 
functions, that they may play a role in cognitive development and memory-related learning 
via increase of neuroplasticity of nerve membranes, synaptogenesis and improvement of 
synaptic transmission. 
Omega-3 fatty acids and cardiovascular disease. 
In developed countries, consumption of the long-chain omega-3 poly unsaturated fatty 
acids DHA and EPA protects people against cardiovascular disease. These beneficial ef-
fects have been explained by the capacity to prevent arrhythmias [61], lowering plasma 
triacylglycerols [62,63], decreasing blood pressure [44], decreasing platelet aggregation , 
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improving vascular reactivity [62,64] and decreasing atherosclerosis [45] and inflamma-
tion [54]. Almost 30 years ago studies in Eskimos from Greenland suggested already that 
ingestion of omega-3 fatty acids protects against cardiovascular diseases. The Eskimos 
consumed diets very high in fat from seals, whales, and fish, which contained large quan-
tities of the long-chain polyunsaturated fatty acids EPA and DHA [65] In other studies it 
has been found that eating fish once a week significantly decreased coronary heart disease 
mortality rates [66] 
Omega-3 fatt\> acids and Alzheimer \ Disease 
A decreased level of plasma Docosahexaenoic acid (DHA) is associated with cognitive 
impairment with aging [67,68] and does not seem to be limited to AD patients [69,70]. 
There are several possible reasons for this decline a decrease in the ability of dietary fatty 
acids to cross the blood brain barrier due to impaired transport function in aging, or lipid 
peroxidation caused by enhanced free radicals [71], decreased dietary intake or impaired 
liver docosahexaenoic acid shuttling to the brain [72] The deficiency affected mostly the 
cortex and hippocampus, areas which mediate learning and memory 
Many animal, epidemiological and clinical studies showed that high DHA consumption is 
associated with reduced AD risk [73-76] In adult rats, learning and cognitive behavior are 
related to brain DHA status, which, in turn, is related to the levels of the dietary omega-
3 fatty acids [77] In fact administration of DHA seems to improve learning ability in 
amyloid-p-infused rats [78,79] and inhibit decline in avoidance learning ability in the AD 
model rats, associated with an increase in the cortico-hippocampal omega-3/omega-6 ratio, 
and a decrease in neuronal apoptotic products [80] Similarly, recent studies showed that 
dietary DHA in an aged AD mouse model could be protective against amyloid-ß produc-
tion, deposition in plaques and cerebral amyloid angiopathy [73,81]. In other transgenic 
AD mouse models DHA also protects against dendritic pathology [82] and prevents neuro-
nal apoptosis induced by soluble amyloid-ß peptides [83] , increases synaptic protein and 
phospholipid densities [84,85] and inhibits degradative endopeptidase activities [86]. 
Omega-3 Jattv acids and membrane fluidity 
DHA is able to shift cholesterol from the neuronal membrane, increasing membrane flui-
dity which favours sequencing of APP via the non/amyloidogenic pathway explaining the 
inhibition of amyloid-ß formation due to DHA supplementation according to the Wolozm 
theory [87] 
Omega-3 faltv acids and clinical studies 
Recently a large trial has been performed in which the favorable effects of DHA in AD 
become visible [47,75] and in the prospective follow-up study from the Framingham Heart 
Study it has been found that high DHA levels in plasma correlated with reduction in the 
risk of developing dementia [47,75] Moreover, also other epidemiologic studies suggest 
neuroprotective consequences of diets enriched in omega-3 fatty acids [88-90]. 
Cholesterol 
The strongest known risk factor in sporadic or late onset AD [20,91], is the genotype for 
10 
apolipoprotein E ε4 (ΑροΕ ε4), a major carrier of cholesterol in the central nervous system 
(CNS) and an important component of very low density lipoproteins (VLDL). Since ApoE 
is the major cholesterol transporter in the central nervous system a link between choles­
terol metabolism and AD is suggested. Subsequently, many genetic studies show associa­
tions between AD and other cholesterol related genes such as cholesterol 24-hydroxylase 
{CYP46A1), ATP-binding cassette transporter A1 (ABCA1), lipoprotein receptor-related 
protein (LRP) and liver X receptor (all reviewed in [92]). In addition, hypercholesterolemia 
is an important risk factor for vascular disorders, and a link between hypercholesterolemia, 
cardiovascular diseases and AD has been suggested [12,33,93-95]. Epidemiological stu­
dies have indicated that patients treated for cardiovascular disease with cholesterol lowe­
ring therapy (cholesterol synthesis inhibitors; statins) show diminished prevalence of AD 
[96] and less deterioration of cognitive function [97]. These data indicate that cholesterol 
is involved in AD pathogenesis, however at present, the mechanism is not completely clear 
and will be discussed below. 
Cholesterol metabolism. 
Cholesterol is an essentia! component of cell membranes and therefore plays an important 
role in the physical properties of the membrane such as membrane fluidity, membrane per­
meability and functioning of membrane associated proteins. Cholesterol is also a precursor 
of bile acids, and the precursor of all steroid hormones Cholesterol can be obtained from 
the diet or synthesized in the body, mainly in the liver and intestine but also in the brain. 
The first step in cholesterol biosynthesis is the conversion of 3 molecules of acetyl-CoA 
to 3-hydroxy-3-methyglutaryl-CoA (HMG-CoA) in the cytosol followed by the reduction 
of HMG-CoA to mevalonate. HMG-CoA reductase catalyzes this reaction, and is the rate-
limiting step in the cholesterol synthesis pathway, and is an important target for pharma­
ceutical interventions, such as with statins. Mevalonate can eventually be converted to 
cholesterol. Cholesterol homeostasis is maintained by strict regulation of synthesis, uptake 
and catabolism. Low levels of cholesterol induce the generation of transcription factors 
leading to increased transcription of target genes, such as HMG-CoA reductase. 
When cholesterol levels rise, HMG-CoA reductase production is inhibited and thus cho­
lesterol synthesis is reduced. Excessive cholesterol destined for storage is converted to 
cholesterol esters in the ER by the Acyl-CoA acyltransferase (ACAT) and stored in fat 
droplets. This process is important because the toxic accumulation of free cholesterol in 
various cell membrane fractions is herewith prevented. Excessive cholesterol allocated to 
elimination may be oxidized by CYP7a to bile acids or binds to the ATP-binding cassette 
transporter ABCA-1 which is responsible for the transportation of intracellular free-choles­
terol and phospholipids from the plasma membrane to lipid free high-density lipoproteins 
(HDL) acceptor molecules and ultimately to the liver [98]. 
Cholesterol in the brain. 
The human brain is the most cholesterol-rich organ of the human body. Almost 25% of the 
total unesterified cholesterol within the body is present in the brain, especially in the mye­
lin sheath and membranes of neurons and astrocytes. Since cholesterol is necessary for the 
formation of synapses [99], proper electrical transmission [100] and serves as an important 
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barrier against sodium leakage [101], cholesterol homeostasis is essential and is tightly 
regulated by controlling uptake, de novo synthesis, esterification, catabolism (oxidation) 
and release. 
Serum cholesterol is almost not able to pass the blood brain barrier [102] and the brain 
synthesizes its own cholesterol, mainly by astrocytes. Cholesterol binds to ApoE and may 
be taken up in neurons via LDL receptors, LDL receptor related protein (LRP), VLDL 
receptors, and ApoE receptor 2 amongst others [103]. The neurons internalize cholesterol 
via endosomes, which fuses with lysosomes causing release of free cholesterol. This in-
tracellular free cholesterol functions as a negative feedback loop to HMG-CoA reductase 
to reduce synthesis but may also be esterified by ACAT for efficient storage [104]. It also 
serves as an important source for synaptic plasticity and dendritic formation and remode-
ling [105]. Since there is no degradation mechanism for cholesterol in the brain, cholesterol 
is released from the brain after oxidation by for example CYP46 (24-hydroxylase) to 24S-
hydroxycholesterol (24S-OH) [71,106] which easily passes the blood brain barrier [101]. 
Cholesterol and amyloid metabolism. 
Since cholesterol is such an essential component in the brain and many epidemiological stu-
dies have suggested a role for cholesterol in AD development [12,33,93], it is not surprising 
that cholesterol has an impact on APP processing and subsequently on amyloid-ß produc-
tion (reviewed in [87]). Transgenic mice fed cholesterol containing diets showed increased 
amounts of neuritic plaques[107-109]. It has been suggested that cholesterol increases the 
activity of β- and γ-secretases [110,111], which reside in cholesterol rich lipid rafts and via 
this way increases the generation of amyloid-ß. α-secretases, which prevent amyloid-ß pro-
duction by cleaving APP within the amyloid-ß domain need cholesterol poor membranes, 
such as phospholipid rich long chain poly unsaturated fatty acids domains which are more 
fluid [112]. Altogether, this indicates that a high membrane cholesterol content favors amy-
loid-ß production and low membrane cholesterol content prevents amyloid-ß production 
[87]. Further, cell culture studies showed that reduction of intracellular cholesterol levels 
in rat hippocampal neurons inhibit the formation of amyloid-ß [48]. Cholesterol lowering 
agents (statins) increase processing of APP through the non-amyloidogenic a-secretase 
pathway in different cell lines because membrane fluidity increases with lower cholesterol 
concentrations, [112] and as a consequence decrease the amount of amyloid-ß via favored 
ß-secretase APP cleavage [48,111]. Moreover, increasing intracellular cholesterol levels in 
different cell lines upregulate amyloid-ß production [113]. It is suggested that the intracel-
lular cholesterol levels regulate the APP processing, in contrast to total cholesterol levels 
[114]. Whether cholesterol esters or free cholesterol are responsible for this involvement 
in APP processing is not completely clear. However, there is a study reporting that an in-
crease in cholesterol esters regulates the generation of amyloid-ß [114] and inhibitors of an 
enzyme catalyzing the formation of cholesterol esters (ACAT inhibitors) down regulated 
the generation of amyloid-ß [114]. It is however unclear how cholesterol esters modulate 
APP processing. Since the equilibrium between cellular cholesterol and cholesterol esters 
is maintained by ACAT, this enzyme may be a potential target in AD. 
Other processes that regulate cholesterol homeostasis also affect APP processing [49] such 
as involvement of LRP [115], NPC1 [116], liver X receptor [117,118] or ABCA [117] re-
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ceptors. The involvement of these receptors in APP metabolism will be discussed later. 
Cholesterol does not only influence amyloid-ß metabolism, vice versa amyloid-ß meta-
bolism is able to influence cholesterol metabolism. Amyloid-ß 42 causes accumulation of 
cholesterol in hippocampal neurons, and amyloid-ß42 is able to inhibit HMG-CoA reduc-
tase, and thus cholesterol synthesis. It is therefore possible, as Canevari et al. suggested 
[41], that changes in amyloid-ß40/amyloid-ß42 ratio in AD alter membrane lipid composi-
tion, alter the activity of membrane associated proteins and subsequently APP processing 
etc, causing a vicious circle. 
ApoE and cholesterol. 
Since ApoE is involved in AD development and is the major cholesterol transporter in the 
central nervous system, playing an important role in the mobilisation and redistribution of 
cholesterol and other brain lipids in repair, growth and maintenance of nerve cells, a link 
between cholesterol metabolism and AD is obvious. Nonetheless there is no consensus 
about the relation between cholesterol metabolism and ApoE4 in AD [119,120]. 
It is known that APOE4 carriers display high serum cholesterol levels [121,122] and se-
veral experimental animal studies have shown an association between elevated serum cho-
lesterol levels with AD and amyloid-ß levels [33,123,124]. In addition, other studies have 
shown that high brain cholesterol levels increase the amount of amyloid-ß depositions in 
animal models [107,109,125]. Therefore, it is possible that ApoE4 affects AD risk by cau-
sing high serum cholesterol, leading to increased brain cholesterol levels and ultimately 
results in increased amyloid-ß levels. However, many studies indicate there is no increase 
in brain cholesterol in APOE4 carriers [126] and brain cholesterol is not influenced by 
serum cholesterol because cholesterol does almost not cross the blood brain barrier into 
the central nervous system [102]. Thus, although ApoE4 is involved in brain cholesterol 
homeostasis it is unlikely to influence total brain cholesterol levels directly. For example a 
locally increased cholesterol concentration in the neuronal membrane via redistribution of 
brain cholesterol by ApoE4 provides an enriched environment for amyloid-ß production 
but does not change total brain cholesterol levels. 
Since carrying the ApoE4 isoform is a major risk factor for the development of atheros-
clerosis [122] via hypercholesterolemia, another plausible explanation for the relation bet-
ween cholesterol levels and ApoE4 in AD may be cerebrovascular diseases. The APOE ε4 
allele increases or aggravates serum cholesterol levels causing atherosclerosis and may 
subsequently cause hypoperfusion of specific brain regions followed by amyloid-ß deposi-
tions and neuronal degeneration, emphasizing a role for vascular disease in AD. 
Cholesterol and statins. 
The effect of cholesterol on amyloid-ß deposition and metabolism is also fortified by the 
beneficial role of statins in the development of AD. Statins are HMG-CoA reductase inhibi-
tors, inhibiting cholesterol synthesis by slowing down the enzyme (HMG-CoA reductase) 
catalyzing the rate-limiting step of the cholesterol synthesis pathway. As mentioned earlier, 
epidemiological studies have shown that treatment of cardiovascular patients with statins 
diminish the prevalence of AD [96] (also reviewed in [127]). 
It is possible that statins decrease cholesterol levels in the brain via an ApoE dependent 
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mechanism, since ApoE deficient mice do not benefit from statin treatment [128] A direct 
effect of statins on brain cholesterol levels is also possible since lipophilic statins are able 
to cross the blood brain barrier. Surprisingly, hydrophilic statins (such as pravastatin and 
atorvastatin) also show benefits in decreasing AD risk (Wolozin et al , 2000) This points 
more towards an indirect effect of statins on AD pathology 
It is also possible that statins affect peripheral 27-hydroxy cholesterol levels (27-OHC). 
270HC can cross the blood brain barrier and is taken up by the brain and in this way may 
influence brain sterol metabolism 
Other studies suggested that statins alter the bilayer distribution of cholesterol. Normal-
ly, neurons and glia cells display an asymmetrical distribution of cholesterol among the 
membrane leaflets, whereas the cytofascial leaflet contains the highest amount. Ageing 
or ApoE4 genotype decreases the amount of cholesterol in the cytofascial leaflet and it is 
suggested that statins reverse this effect hereby decreasing the production of amyloid-ß 
[72,129] via prevention of APP processing via the amyloidogenic pathway These data 
suggest that cholesterol distribution and not total cholesterol levels may be important to 
amyloid-ß production in the central nervous system [127]. 
All together, these findings led to prospective clinical trials of cholesterol-lowering statins 
in AD patients. However the results of these trials are conflicting [96,130-133]; [97,134-
137] and there is insufficient evidence to suggest the use of statins for treatment in patients 
with AD [138]. 
Cholesterol and as sociated genes 
The link between cholesterol and AD is also amplified by the finding that many other genes 
than ApoE are involved in cholesterol metabolism and have been shown to be associated 
with late onset AD. A few of the most important genes are discussed shortly below 
The ATP-binding cassette transporter AI The ATP binding cassette transporter ABCA1 is 
responsible for the transportation of intracellular free-cholesterol [98] and is involved in 
elimination of excess cholesterol. ABCA1 is expressed in neurons, astrocytes and micro-
glia after for example activation of the liver X receptor [139], and an increased expression 
is accompanied by cholesterol efflux from neurons and glia This affects APP processing, 
causing a decrease in amyloid-ß production. 
Individuals with a genetic polymorphism (R219K) in the ABC Al gene have 30% decre-
ased cholesterol in their cerebrospinal fluid, via modifying brain cholesterol metabolism 
and a 1.7 year delay in age of onset of AD. A large genetic association study in 1750 indi-
viduals of a European population showed an increased risk in developing both late onset 
and early onset AD with different polymorphisms of ABC Al [140] 
Liver X receptor The liver X receptor is a nuclear receptor which is expressed on neu-
rons, endothelial cells and glia cells [141,142] and following activation induces a variety 
of genes involved in pathways of cholesterol metabolism, transport and elimination (i e 
ABCA1, ApoE etc). An important liver X receptor target gene in the brain is ABCA1. 
Activation of liver X receptor has been shown to stimulate ABC Al levels and thereby de-
creasing amyloid-ß concentrations and cholesterol levels [139,143,144] In addition, an in 
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vivo study using a liver X receptor agonist showed lowered hippocampal amyloid-ß42 and 
improved memory in the Tg2576 transgenic mouse [145] and a study from Koldamova et 
al showed the liver X receptor ligand T0901317 decreases amyloid-ß production in vitro 
and in a mouse model of AD [118]. In summary, liver X receptor may be a potential target 
for the treatment of AD possibly by influencing cholesterol and lipid metabolism. 
Oxysterols. When excess of cholesterol is oxidized by members of the cytochrome p450 
family oxysterols are formed. Oxysterols are important in lipid gene expression since they 
can bind liver X receptor and ultimately regulate the transcription of many lipid genes. The 
most important oxysterols in this perspective are 24-hydroxy cholesterol (24-OHC) and 
27-hydroxy cholesterol (27-OHC). These oxysterols can easily pass the blood brain barrier 
and in this way can be utilized for further sterol biosynthesis. In the liver they are being 
further degraded to bile acids. 
Oxysterols may accumulate in vascular tissue, and in this way exert toxic effects, such as 
development of atherosclerotic plaques [146]. In AD cholesterol flux is elevated as shown 
by increased levels of 24-OHC [147], which may cause vascular problems in AD. Oxyste-
rols may also have effects on amyloid-ß formation [148]. 
Low-density lipoprotein receptor-related protein. Low-density lipoprotein receptor-related 
protein (LRP) is a low-density lipoprotein predominantly expressed in neurons, but also 
detected in capillaries and pericytes. LRP is involved in brain lipid and cholesterol distri-
bution, protection against atherosclerosis and neurodegeneration [149]. LRP is able to bind 
and internalize amyloid-ß- ApoE complexes facilitating degradation of secreted amyloid-
ß[42]. Moreover, LRP is a substrate, competing with APP for both BACE [150] and γ-se-
cretase activity [151]. LRP has also been shown tobe involved in amyloid-ß transport over 
the blood brain barrier to the periphery, and may thus be involved in amyloid-ß clearance 
[152]. However it has also been shown that LRP interacts with APP causing APP proces-
sing via the amyloidogenic pathway [115,153] and recently it has also been found that after 
internalization, aggregation of amyloid-ß takes place, stimulating amyloid-ß deposition. 
ACAT. Cellular cholesterol may be stored as either free cholesterol or cholesterol esters. 
Acyl-coenzyme cholesterol acyltransferase (ACAT) catalyzes the formation of cholesterol 
esters from free cholesterol and controls the equilibrium between cellular cholesterol and 
free cholesterol. Cholesterol esters are stored in lipid droplets and excessive accumulation 
of lipid droplets is a hallmark of early atherosclerosis but accumulation of free cholesterol 
in various cell membrane fractions is also toxic. 
It has been described that an increase in cholesterol esters seems to regulate the generation 
of amyloid-ß [114]. Additionally, mice lacking ACATI (i.e showing decreased levels of 
cholesterol esters) showed dramatically reduced amounts of amyloid-ß levels[l 14] [154]. 
LDL-receptor. In the brain the LDL-receptor is predominantly expressed in astrocytes, 
neurons and endothelial cells. This receptor mediates the endocytosis of cholesterol-rich 
LDL. LDL is directly involved in the development of atherosclerosis, due to accumulation 
of LDL-cholesterol in the blood. Dysfunction of the LDL-receptor can lead to hypercholes-
terolemia, which in tum is an important risk factor in AD [155] The most important ligand 
for LDL-receptor is ApoE and since ApoE is a major risk factor in early onset AD, this is 
subsequently also an important link between LDL-receptor and AD Mulder et al showed 
that LDL-receptor knock out mice have an impaired spatial memory and a decreased sy-
naptic density in the hippocampus [156]. This is in agreement with another recent study 
showing that lack of the LDL-receptor aggravates learning deficits and amyloid deposits 
inTg2576mice[157]. 
Cholesterol and brain vasculature 
Even though many possible mechanisms for the involvement of cholesterol in AD patho-
genesis are described above, the most important one has been neglected so far, i.e. the 
involvement of cholesterol on brain vasculature It is well known that cardiovascular risk 
factors such as hypertension, hyperhpidemia, diabetes mellitus and stroke are important 
risk factors for the development of AD [40] For example hypercholesterolemic patients 
have an increased risk of developing AD [12] and the prevalence of AD will be reduced by 
70% when these patients are treated with statins [96,132]. Longstanding elevated hyper-
cholesterolemia leads to accelerated atherosclerosis, this can express itself m a number of 
cardiovascular diseases such as stroke, myocardial infraction etc, but may also change the 
brains haemodynamics. 
There are studies describing altered haemodynamics in AD [158-160], and this in combi-
nation with high serum cholesterol being a risk factor may suggest an association between 
those two. Therefore, we and others suggest that high serum cholesterol may cause AD via 
brain hypoperfusion since cholesterol does almost not cross the blood brain barrier [102] 
and there is no evidence that AD patients have a disrupted blood brain barrier causing 
cholesterol transport into the brain. Therefore, it can be hypothesized that high cholesterol 
intake impairs the vasculature causing atherosclerosis, hypoperfusion of vulnerable brain 
areas, ultimately leading to an overproduction of amyloid-ß. 
The increased amyloid-ß production may also result in cerebral amyloid angiopathy further 
exacerbating cerebrovascular degeneration [161-163] De la Torre proposes that haemody-
namic changes occur first in the AD development [40] which ultimately causes AD patho-
logy. The hypothesis that brain circulation and vasculature are important in AD develop-
ment is also fortified by that fact that statins diminish the prevalence of AD, since statins 
diminish serum cholesterol levels and may thereby diminish blood vessel obstruction 
[164] Altogether, changes in brain vasculature and heamodynamics are still underexposed 
in AD, but may be a key regulator in AD pathogenesis 
Outline thesis 
Although the cause of late onset AD is not yet clear and the amyloid hypothesis is still the 
most accepted hypothesis, more and more evidence accumulates showing the involvement 
of the vasculature and cerebral hemodynamics in sporadic AD. 
We propose that AD pathology starts with impairment of the peripheral and consequently 
cerebral vasculature due to a combination of ageing, lifestyle, dietary factors and genetic 
background, which enhance each other in the onset and course of the disease Dietary fac-
tors such as cholesterol and DHA may influence the course of AD at many different levels, 
and might be important tools in developing preventive strategies against AD and vascular 
disease. 
The aims of this thesis were to 
• Investigate the mechanism by which cholesterol and DHA influence AD 
development. 
• Determine whether changes in cerebral circulation precede changes in Aß 
deposition or vice versa. 
• Investigate what may cause the changes in cerebral hemodynamics, and determine 
what the microvascular consequences are. 
in order to achieve the above mentioned aims we used a double transgenic APPswe/PS-
ldE9 Alzheimer mouse model. In this mouse model, APP695 harboring a human Aß do-
main with mutations K.595N and M596L linked to the Swedish familial AD pedigrees, and 
human PS1 with a deletion of exon 9, are expressed and controlled by independent mouse 
prion protein elements. This mouse line has rapid age-dependent accumulation of Aß into 
extracellular plaques starting from 4-6 months of age. Table 2 gives an overview of the 
most important techniques used in this thesis. 
Table2: techniques used in this thesis. 
Technique Determination of 
Immunohistochemistry amount ot'Aß and GLUT-l 
Contrast enhanced magnetic resonance imaging (MRI) Cerebral blood volume (CBV) 
Magnetic resonance spectroscopy (MRS) Cerebral blood (low (CBF) 
Gas chromatography-tandem mass spectrometry (GC-MS/MS) Sterol levels in brain tissue and serum 
Gas chromatography - flame ionization detector (GC-F1D) Fatty acid levels in brain tissue 
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) AdoMet and Adollcy levels in brain tissue 
Open Field. Morris water maze, 12 circular hole board Behavior and cognition 
Chapter 1. 
Chapter 1 reviewed the literature about AD pathology and the role of dietary factors such 
as DHA and cholesterol in AD. 
Chapter 2. 
Since different epidemiological studies have shown that cholesterol and DHA intake in-
fluence AD development we studied the long-term eftects of these dietary lipids on Aß 
pathology and the cerebral circulation in the brains of double transgenic APPswe/PSldE9 
mice. 
Chapter 3. 
Many different researchers underline the importance of vascular factors in AD. It is even 
suggested that changes in cerebral perfusion are a primary trigger in AD development. In 
addition both DHA and cholesterol may affect the degenerative processes in AD by influ-
encing Aß metabolism indirectly via the vasculature. In this study we therefore investiga-
ted the effects of cholesterol and DHA containing diets in young and old APPswe/PSldE9 
mice and wild type mice in order to investigate whether changes in hemodynamics precede 
changes in Aß deposition and cognitive impairment or vice versa. 
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Chapter 4. 
In chapter 1 and 2 an impaired cerebral perfusion has been shown (i.e decreased relative 
cerebral blood volume (rCBV)) in APPswe/PSldE9 mice. Here we investigated whether 
alterations in capillary density might be the cause of this decreased rCBV. 
In addition, because impaired cerebral perfusion may cause a hypometabohc state which 
probably has microvascular consequences, we determined the expression of glucose trans-
porter type-1 (GLUT-1), a transporter responsible for glucose transfer over the blood brain 
barrier We also investigated the relationship between Aß, GLUT-1 and hippocampal atrop-
hy in the brains of young and old APPswe/PSldE9 mice. 
Chapter 5. 
Until recently hyperhomocysteinemia was believed to be a risk factor for cardiovascular 
disorders and leading to cerebral hypoperfusion and accelerating AD development. Howe-
ver, this mechanism is now under debate, and it might be possible that other factors of the 
Hey cycle, such as s-Adenosylmethiomne (AdoMet) and s-aenosylhomocysteine (AdoH-
cy) play a more important role in vascular disease and subsequently AD development The-
refore in this study we investigated AdoMet and AdoHcy levels in the brain tissue of young 
and old APPswe/PsldE9 mice In addition we investigated whether dietary factors such as 
cholesterol and DH A alter AdoMet and AdoHcy levels, since it could be hypothesized that 
these nutritional components alter vascular health via alterations in AdoMet and AdoHcy 
levels and subsequently the progression of AD development. 
Chapter 6. 
In this chapter, we summarize and discuss the data presented in this thesis and we propose 
future plans. 
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Abstract 
High dietary cholesterol and low dietary docosahexaenoic acid (DHA) intake are risk fac-
tors for Alzheimer's disease (AD). However, it is unclear how these components influence 
the course of the disease. We investigated the effects of dietary lipids on amyloid-ß de-
position and blood circulation in the brains of 18-month-old APP/PS1 mice. Starting at 6 
months of age, mice were fed a regular rodent chow, a Typical Western Diet (TWD) con-
taining 1% cholesterol, or a diet with a high (0.5%) level of DHA for 12 months. Relative 
cerebral blood volume (rCBV) and flow (CBF) were determined with 2H MR spectroscopy 
and gradient echo contrast enhanced MRI. Deposition of amyloid-ß was visualised in fixed 
brain tissue with immunohistochemistry. The TWD diet increased plaque burden in the 
dentate gyrus of the hippocampus, but did not significantly reduce rCBV. In contrast, the 
DHA-enriched diet increased rCBV without changing blood flow indicating a larger cir-
culation in the brain probably due to vasodilatation and decreased the amount of vascular 
amyloid-ß deposition. Together, our results indicate that the long-term intake of dietary 
lipids can impact both brain circulation and amyloid-ß deposition, and support the involve-
ment of haemodynamic changes in the development of AD. 
Ì 6 
Introduction 
Worldwide, 15 million people suffer from Alzheimer's disease (AD). This number will 
continue to grow as a result of our aging population. Our western population is not only 
getting older, but has also developed a less healthy lifestyle with high cholesterol and high 
caloric diets, resulting in overweight with its associated disorders. Hypercholesterolemia 
for example is an important risk factor in vascular disorders, and a link between vascular 
risk factors, hypercholesterolemia and AD has been suggested [1-5]. Epidemiological stu-
dies have indicated that cholesterol lowering statins diminish the prevalence of AD [6] and 
cause less deterioration of cognitive functions [7]. Identification of the cholesterol trans-
porter apoiipoprotein E4 as a major genetic risk factor for hypercholesterolemia, vascu-
lar dementia and sporadic AD [8-10], also reinforces the relationship between cholesterol 
and AD. Further support for the link between high cholesterol intake and AD come from 
experimental animal studies. In cell culture studies, reduction of intracellular cholesterol 
levels in rat hippocampal neurons inhibits the formation of amyloid-ß (Aß) [11] and animal 
studies with double transgenic (amyloid precursor protein (APP) - Presenilin (PS)) mice 
have shown that high dietary cholesterol increases Aß accumulation [12] and cholesterol 
lowering agents increase processing of APP through the non-amyloidogenic a-secretase 
pathway in different cell lines via increased membrane fluidity [13]. 
Membrane fluidity can be influenced by alterations in membrane phospholipid and choles-
terol content [14-16], which in turn, can modulate the activity of membrane bound enzymes 
[ 17-20] such as the main enzymes cleaving the transmembrane protein APP to generate Aß 
(β- and γ- secretase). It has been suggested that these secretases require cholesterol-rich 
lipid domains (lipid rafts) within the membrane [21,22], whereas the non-amyloidogenic 
pathway by a-secretases needs cholesterol poor membranes, such as phospholipid domains 
which are more fluid [15,23]. 
Important components of membrane phospholipids that contribute to membrane fluidity are 
the omega-3 Long Chain Poly-Unsaturated Fatty Acids (n3 LCPUFAs), like docosahexae-
noic acid (DHA) and the omega-6 (n6) LCPUFAs (such as arachidonic acid). Further, 
increased DHA levels in membranes are known to augment membrane fluidity [24]. Epide­
miological studies show that sufficient DHA intake reduces the risk of developing AD [25-
27]. In support of this notion, two recent experimental studies reported decreased brain Aß 
levels in APP transgenic mice after dietary DHA supplementation [28,29]. In addition to its 
influence on Aß metabolism, DHA has also a positive effect on vascular health [30-32]. 
Taken together, these data indicate that high dietary cholesterol levels or low DHA levels 
are risk factors in AD. However, it remains unclear how these dietary factors may influ-
ence the development of AD. It can be hypothesized that high cholesterol intake impairs 
the vasculature causing hypoperfusion of vulnerable brain areas, ultimately leading to an 
overproduction of Aß. The increased Aß production may also result in cerebral amyloid 
angiopathy (CAA) further exacerbating cerebrovascular degeneration. [33-35]. In contrast, 
high intake of DHA may have a protective effect by improving vascular health and accor-
dingly cerebral perfusion. 
In a recently published study of our collaborators [29] it was found that a Typical Western 
Diet (TWD) containing 1% cholesterol increases hippocampal Aß levels in the double 
transgenic APP/PS1 mice at 10 months of age. In contrast, a DHA-ennched diet decreased 
hippocampal Aß levels of the same mice compared to the TWD group However, although 
these in vivo dietary effects could be detected with ELISA, immunohistochemically deter-
mined Aß plaque load was unaffected These findings raise the obvious question whether 
life-long dietary factors may have an even stronger impact on Aß pathology. 
In the present study we used the same APP/PS1 transgenic mice and the same effective die-
tary manipulations as Oksman et al. to study the long-term effects of dietary lipids on Aß 
accumulation and brain circulation This mouse line has rapid age-dependent accumulation 
of Aß into extracellular plaques but relatively little vascular deposition, which allows the 
assessment of dietary lipids on both parenchymal Aß accumulation and vascular function. 
We started the dietary manipulation at 6 months of age and continued up to 18 months To 
address the diet effects on brain circulation we measured relative cerebral blood volume 
(rCBV) and cerebral blood flow (CBF). Both parameters have been shown to be affected 
in AD [36-38] We used 2H MR spectroscopy with the freely diffusible tracer deuterium 
oxide, and susceptibility enhanced MRI, a technique that has been widely used in experi-
mental stroke studies in rats but never applied to APP transgenic mice before In addition 
immunohistochemical analysis of neuropathology and a chemical assessment of sterol and 
fatty acid profiles of the brain were performed The findings indicate that dietary lipids can 
impact both brain circulation and deposition of Aß in plaques and blood vessel walls. 
Materials and Methods 
Animals and diets 
The APPswe/PSldE9 founders were obtained from Johns Hopkins University, Baltimore, 
MD, USA (D Borchelt and J Jankowsky, Dept. Pathology) and a colony was established 
at the University of Kuopio Finland. In short, mice were created by co-injection of chime-
ric mouse/human APPswe (mouse APP695 harboring a human Aß domain and mutations 
K595N and M596L linked to Swedish familial AD pedigrees) and human PSl-dE9 (dele-
tion of exon 9) vectors controlled by independent mouse prion protein promoter elements. 
The two transfected genes co-integrated and co-segregate as a single locus [39]. This line 
was originally maintained in a hybrid background by backcrossing to C3HeJ χ C57BL6/J 
Fl mice (so-called pseudo F2 stage). For the present work, the breeder mice were back-
crossed to C57BL6/J for 5-6 generations to obtain mice for the current study 
Male APP/PS1 transgenic mice were assigned to different diet groups, which differ in 
the composition of the 5% fat added in the diets (table 1) The diets started at the age of 
6 months and were maintained for 12 months Before assigning the mice to the different 
experimental groups the mice were weighed 
One group of transgenic mice was fed a Typical Western Diet (TWD(tg), n=9), containing 
1% cholesterol, a high percentage of saturated fatty acids (44%) and long chain poly un­
saturated fatty acid (LCPUFA) ratio of n6/n3=23) The second group of transgenic mice 
i s 
(DHA(tg) n=8) received a DHA diet that was supplemented with 0.50% of n3 (PUFA) 
DHA, low in saturated fatty acids (19%), and LCPUFA ratio of n6/n3=3). The third trans-
genic (STD(tg) n=8) and the fourth wild type C57BL6/J (STD(wt) n=12) group received a 
control diet (Standard), containing 5% soy oil (low in saturated fatty acids ( 15%), LCPUFA 
ratio n6/n3=8)). 
Table 1. Sources and contents of fati) acids in the experimental diets 
diet components 
% soya oil 
% eoeonut oil 
% com oil 
% DHA 70EE 
% cholesterol 
diet content 
% total n3 









































SFA= saturated fatt\ acids, MUFA= Mono unsaturated fatty acids. PUFA= pol\ unsaturated fatty acids 
Throughout the experiments the animals were housed individually in a controlled envi-
ronment, food and water were available ad libitum. One DHA(tg) mouse died during the 
experiment and was not included in the analysis. 
The experiments were performed according to Dutch and Finnish federal regulations for 
animal protection and were approved by the Veterinary Authority Radboud University Nij-
megen. At 16 months the mice were transported to Radboud University Nijmegen, the 
Netherlands and at 18 months the experiments were performed. 
MR measurements / experimental protocol 
To study differences in brain haemodynamics, relative cerebral blood volume (rCBV) and 
cerebral blood flow (CBF) were determined in our experimental diet groups at 18 months 
of age. The CBF and the rCBV of the entire brain, were determined by MR Spectroscopy 
(MRS) in combination with administration of deuterium oxide as contrast agent, which 
can freely diffuse across the vascular membranes. To verify the MRS results and to obtain 
an indication about region differences, the rCBV was also determined in a subgroup of 
animals with a susceptibility-induced contrast MR1 technique using Ultra Small Particles 
of Iron Oxide (USPIO) as blood-pooled contrast agent. 
Before starting with the MR measurements, the mice were weighed. Following anesthe-
sia, all mice received an intravenous tail vein catheter for bolus injections of deuterium 
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oxide or USPIO During the MR experiments mice were anesthetized with 1.9% isoflurane 
(Abott, Cham, Switzerland) in a mixture of oxygen and N20 (1 2) through a nose cone 
The composition of the mixture was monitored continuously using a gas analyzer (Datas-
cope, Multinex) The body temperature was maintained at 37 2 ± 1 2 °C using a heated 
water pad and monitored with a rectal fluoroptic temperature probe Breathing of the ani­
mal was monitored using an optical respiratory gating apparatus (Sirecust 401, Siemens) 
MR measurements were performed on a 7 Tesla/200 mm horizontal bore MR spectrometer 
(Magnex Scientific, Abingdon, England) interfaced to a S M I.S console (Surrey Medical 
Imaging Systems, Surrey, England) The MR acquisition parameters were optimized in 
normal wild-type mice matched in weight and age to the animals participating in the pre­
sent study. 
2H MR Spectroscopy and data analysis 
Deuterium Oxide (D,0) 
Cerebral blood flow (CBF) and relative cerebral blood volume (rCBV) of the entire brain 
were estimated by 2H MR spectroscopy using the freely diffusible tracer D,0. Enrichment 
of the blood with D 20 ( D ^ 99.8% enriched; Merck, Darmstadt, Germany) was achieved 
by intravenous bolus injection into the tail vein of 0 3 ml D20 in saline within 4 seconds 
in all mice (STD(wt) n=6, STD(tg) n=6, DHA(tg) n=7, TWD(tg) n=8). An in-house-built 
2H elliptical shaped (15 χ 11 mm) surface head coil, which was tuned to 0,0 frequency 
(46 MHz), was used for excitation and signal reception The 2H MR spectra were obtained 
using a pulse-acquire sequence (flip angle of 90°, repetition time (TR) of 1000 ms, the array 
size of 100, and 2 number of averages per measurement). Since every measurement con­
tained 2 dummy scans, each measurement took 4 seconds, the total measurement time was 
400 seconds. After Fourier transformation the amplitude of the D 20 signal was monitored 
and evaluated as a function of time 
The concentration of Do0 m the brain as a function of time is given in arbitrary units (a u ). 
The rCBV was estimated by calculating the surface area under the bolus peak of each 
curve. A tangent line was drawn from 380 till 200 seconds (along the almost horizontal part 
of the MR curve) and extrapolated till the crossing with the increasing slope of the D,0 
curve (Fig 1). Thereafter the surface area of the bolus peak could be determined [40,41]. 
The rCBF was determined by using a nonlinear least squares fit of the data between 28 and 
68 sec (Fig 1) to a two-parameter single-exponential of the form: y=Ae-t/T [42] Τ is the 
exponential time constant governing the rate of blood flow washout of the deuterium label 
from the brain tissue. Τ can be related to blood flow per unit volume (or mass) of tissue 
through the central volume principle of tracer kmitics (CBF= λ/Τ) [43,44]. The coefficient 
λ is the ratio of the water weight of a unit mass ( 100g) of brain tissue to the water weight of 
a unit volume of blood, in this case 0.90 g/ml. [45] Thereafter peak height and time to peak 
(TTP) was determined (Fig 1). In 2 TWD(tg) and 2 DHA(tg) mice the rCBV measurement 
failed due to technical errors These mice are not included in further analysis of the rCBV. 
MR imaging using USPIO 
In order to verify our MRS results a second technique to measure rCBV, contrast enhanced 
M RI, in combination with the administration of a superparamagnetic blood-pool contrast 
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agent (USPIO), was performed on the four groups of mice (STD(wt) n=6, STD(tg) n=3, 
DHA(tg) n=3, TWD(tg) n=3). The USPIO contrast agent provides a valuable tool to cha­
racterize tissue vascularity since it remains intravascular for a prolonged period of time and 
highly enhances the transverse water proton MR relaxation rates (R2*). Previous studies 
have shown that magnetic susceptibility effects caused by USPIO can be used to assess re­
lative blood volume within tissues [46,47]. In particular, the enhancement in the transverse 
relaxation rate (AR2*) after administration of USPIO is proportional to the tissue blood 
volume. 
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Fig I. rCBVand CBF are determined along the D20 uptake graph in time. 
A tangent line was drawn from 380 hack to 200 seconds and prolonged till the crossing with the D20 
cune. Thereafter the surface area under the peak (A UP) of the curve could be determined. CBF was 
determined by unraveling the two-parameter single exponential of the form Y=Ae -t/T between 28 
and 68 seconds. TTP is the time used to reach a peak concentration of deuterium. rCBV= relative 
cerebral blood volume, CBF= cerebral blood flow, AUP= area under peak. TTP= time to peak. 
An elliptical shaped ( 15 χ 11 mm) surface coil was used for excitation and signal reception. 
The image acquisition protocol started with three gradient-echo scout images for slice posi­
tioning. Thereafter, multislice gradient-echo imaging was performed prior to and 1 minute 
after administration of a bolus injection with USPIO (AMI-277, Sinerem®, Guerbet Labo­
ratories, France, 170 μg Fe/mouse). Imaging parameters were: field of view (FOV) of 25 
mm χ 25 mm, matrix size of 256 χ 256, slice thickness of 1 mm, echo time (TE) of 7 ms, 
repetition time (TR) of 2000 ms and 2 averages per image, resulting in a total scan time 
of 17 minutes per multislice gradient-echo series. For each animal, pixel-by-pixel AR2* 
maps were obtained from the formula: AR2* =(l/TE)log(So
bef/So
a,1), where TE is the echo 
time, and So the signal amplitude pre-USPIO (S^
1) and post-USPIO (S/1), in the gradient 
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echo images. The mean AR2* were calculated by drawing a Region of Interest (ROI) on 
the AR2* maps and averaging the values of all pixels within the ROI. To assess the blood 
volume, regions of interest (ROIs) that included the entire hippocampus, cerebral cortex 
(all cortical areas above the corpus callosum) and the entire brain, were drawn on the ima­
ges. These ROIs are based on the mouse brain atlas of Franklin and Paxinos 1997 [48] in 
image 8 about -2.46 posterior to bregma. The change in AR2* in the hippocampus, cere­
bral cortex and entire brain is proportional to the rCBV in these regions. In some regions, 
AR2* was very low and due to image noise, negative values could be obtained in some 
regions. AR2* was then assumed to be zero. All algorithms were implemented in Matlab 
(Mathworks, Natick, MA, USA). Due to technical failures 1 STD(tg) and 1 DHA(tg) ani­
mal were omitted from further analysis. 
Because we ran into a power problem in the detection of differences in CBV between 
transgenic (STD tg) and wildtype (STD wt) mice on control diet, we executed CBV measu­
rements with identical susceptibility-induced contrast MRI techniques as used in this study 
in a larger group of 15-month-old mice within the framework of another experiment. The 
animals were kept under exactly the same conditions. One group of APP/PS1 transgenic 
mice (STD(tg) n=8) and a wildtype control group (STD(wt) n=13) received the same con­
trol diet (Standard) for the same length of time as described in section 2.1. 
Serum sterol analysis 
Directly after completion of the MR experiments, mice were anaesthetized with Nembutal 
(60mg/kg i.p.) (Ceva Santa Animals BV, Maassluis) and blood samples were collected via 
heart punction. Serum cholesterol levels were determined by gas-liquid chromatography-
flame ionization detection (GC-FID) as described previously [49]. 
Immunohistochemistry 
All mice used in the MRS experiment (STD(wt) n=6, STD(tg) n=6, DHA(tg) n=7, TWD(tg) 
n=8) were transcardially perfused (after blood sampling via heart punction) starting with 
a 0.1 M phosphate buffered saline (PBS) followed by Somogyi's fixative (4% parafor­
maldehyde, 0.05% glutaraldehyde and 0.2 % picric acid in 0.1 M phosphate buffer, PB). 
Following transcardial perfusion fixation, mice were decapitated and brains were dissected 
from the skull. The entire brain, without the spinal cord, was weighed and thereafter post 
fixed for 15 hours at 4 "C in Somogi's fixative. The brain tissue was then cryoprotected 
by immersion in 30% sucrose in PB at 4 0C. Series of 40 μπι coronal sections were cut 
through the brain using a sliding mircrotome (Microm HM 440, Walldorf, Germany). The 
Aß load was visualized using WO-2 antibody (mouse anti-human Αβ4-10, Τ Hartmann, 
Heidelberg, Germany). Immunohistochemistry was performed using standard free-floating 
labeling procedures. Briefly, first the sections were pretreated with sodium citrate solution 
at 85 "C for 30 minutes. Monoclonal mouse anti-Aß4-10 (1:20.000) was used as primary 
antibody. The sections were incubated overnight at room temperature on a shaker table. 
Following incubation the sections were rinsed thoroughly with PBS and transferred to the 
solution containing the secondary antibody; donkey-anti-mouse biotin 1:1500 (Jackson 
Immuno research). After 90 minutes of incubation the section were rinsed three times and 
transferred to a solution containing Vector ABC-elite 1:800 (Vector laboratories, Burlinga-
me) for again 90 minutes. Visualization of Aß plaques and CAA was achieved by incuba-
tion with DAB-Ni solution. All stained sections were mounted on gelatin-coated slides and 
dehydrated in alcohol series, cleared with xylol and mounted in Entellan. 
Quantification 
To determine the amount of Aß in the parenchyma of the frontal cortex (prelimbic area 
(PLA)), anterior cingulate gyrus (ACg 1 and 2) and in the hippocampus (CAI, CA3 and 
dentate gyrus (DG)), appropriate slices were digitized and quantified, using a Zeiss Axi-
oskop microscope equipped with hardware and software of Microbrightfield, (Williston, 
USA). These cortical regions were chosen because of their large amyloid load in humans 
and transgenic mice and their importance in memory and hippocampal functioning [50,51 ]. 
Quantitative analyses were done with a computer-assisted analysis system (Stereo Investi-
gator) using Cavalieri's probe. A contour was drawn along the borders of the hippocampal 
subregions. In the ACg and PLA a square box was placed, within the borders of intended 
brain areas. 
To determine the amount of Aß in the vasculature, a contour was placed in the frontal 
cortex (PLA), anterior cingulate gyrus (ACg 1 and 2) and in the hippocampus, respecti-
vely containing the middle prefrontal branches of the anterior cerebral artery, the anterior 
cerebral artery and the vessels in the hippocampal fissue. Brain regions were based on the 
mouse brain atlas of Franklin and Paxinos 1997 [48] and quantified in three sections, with 
200 μιτι distance between the sections. ACgl and 2 were quantified at level +1.10 up to 
+0.86 anterior to bregma, PLA was quantified at +1.98 upto +1.78 anterior to bregma. The 
hippocampus was quantified at -2.18 up to -2.46 posterior to bregma. 
All measurements were performed double blind by two investigators, Aß load was defined 
as the percentage of area covered by Aß. 
Preparation of brain homogenates and sterol analysis 
A subgroup of mice (which were used in the USPIO experiment; STD(wt) n=6, STD(tg) 
n=3, DHA(tg) n=3, TWD(tg) n=3) was sacrificed to determine brain sterol levels. The 
brains were snap-frozen in liquid nitrogen and were kept frozen at -80°C until homogeni-
zation. Thereafter the brains were homogenized and sterols were determined as described 
elsewhere [52,53]. 
Phospholipid and fatty acid analysis of brain homogenates 
Fatty acid analyses were performed with a part of the homogenate (described above). Total 
lipid was extracted from brain homogenates by methanol and chloroform. Subsequently, 
samples were centrifuged at 3000 rpm for 10 min and the lower phase (chloroform and 
lipids) was removed. Chloroform was added to the upper phase, samples were centrifuged 
again at 3000 rpm for 10 min and the lower phase was combined with the first one. The 
chloroform fractions were dried in a SpeedVac® and the lipid extracts were dissolved in 
125 μΐ chloroform. The phospholipids were separated from total lipid by SPE columns 
(Bond Elut NH2, Varian). The separation of the phospholipids from the brain homogenates 
was accomplished by a gradient of two mobile phases: 1 ) hexane: iso-propanole: acetic 
acid, 2) iso-propanole: water: acetic acid. Both mobile phases were supplied with 0.08% 
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of triethylamine. The gradient changed linearly from 95:5 to 10:90 within 28 min, and 1 
min after reaching the final ratio the gradient was changed back to the original composi­
tion at a flow rate of 1 ml/min. Peaks were identified by comparison with phospholipid 
standards obtained (3-sn-phosphatidic acid sodium salt, 3-sn-phosphatidyl-l-serine from 
bovine brain, 3-sn-phosphatidylethanolamine from bovine brain, L-a-phosphatidylcholine 
99% from bovine brain, L-a-phosphatidylinositol ammonium salt from bovine liver and 
sphingomyelin from bovine brain) from Sigma. Quantification of the phospholipids from 
the brain homogenates was performed by HPLC-LSD with a LiChrospher Diol-100 co­
lumn (250x4.6 mm, 5 μιη, Merck). 
To determine the fatty acid profile of each phospholipid, the phospholipid extract was 
methylated by adding 0.5 ml 10% BF3. The samples were heated at 100 UC for 60 min, 
and 2 ml hexane and 1 ml sodium hydroxide were added. After vortexing and centrifuging 
the samples for 5 min at 3000 rpm, the lower phase was vortexed and centrifugea with 2 
ml hexane for 5 mm at 300 rpm. Top phases of both steps were combined and hexane was 
evaporated from the samples by means of a SpeedVac®. The fatty acids were dissolved in 
125 μΐ iso-octane and analyzed on a GC-FID with a CP-SIL88 column (50 m χ 0.25 mm 
id. 0.22 μιτι film thicknesses). The n6/n3 ratio was calculated as a sum of analyzed n6 FAs 
divided by the sum of n3 FA. 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed with SPSS for windows 12.0 soft­
ware (SPSS Inc. Chicago, IL, USA). Genotype differences were determined by comparing 
transgenic and wild type mice on STD diet using an independent t-test, whereas diet ef­
fects among the three diet groups of transgenic mice were determined using the One-way 
ANOVA. The One-way ANOVA was also used to evaluate regional differences in Aß load. 
If the overall analysis revealed a significant difference, the separate groups were analyzed 
post hoc by using Tukey's HSD lest. Statistical significance was set at p< 0.05. 
Results 
Body and brain weight 
Mice were weighed before assigning them to the different diet groups. The body weight did 
not differ between the groups neither at the start (STD(wt) 32.1 ±1.0; STD(tg) 31.9 ±1.0; 
TWD(tg) 32.2 ± 1.2; DHA(tg) 32.4 ± 1.1 ) nor at the end of the experiment ( STD(wt) 40.7 ± 
1.7; STD(tg) 43.5 ±2.5; TWD(tg) 41.0 ± 2.0; DHA(tg) 45.0 ± 2.4). Thus, body weight was 
not affected by genotype (p=0.36) or dietary manipulations (p=0.56). Also brain weight 
did not differ between the genotypes (p=0.71 ) or diet groups (p=0.19; STD(wt) 0.46 ±0.01 
STD(tg) 0.47 ±0.01, TWD(tg) 0.47 ±0.01, DHA(tg) 0.49 ±0.01). 
No change in CBF but increased rCBV in animals fed DHA-enriched diet. 
The parameters that were derived from the D20 uptake graph in time (Table 2) show that 
genotype or diet interference did not significantly influence CBF (t-test; p=0.43 and ANO-
VA; p=0.45). However, the time to the reach the peak concentration of deuterium (TTP) 
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Table 2. Curve parameters along the D2O uptake graph in time. 
Genotype effects Dietary effects 
t-test ANOVA 
STD(wt) 
CBF (ml/1 OOgr/min) 
TTP (sec) 
Peak Height (a.u.) 
Curve Height at 20 sec 
Curve Height at 32 sec 
(a.u 
(a.u 
36 ± 8 
17 ±4.9 
11414±903 
) 10738 ±851 
.)10235 ±990 
STD(tg) 


















4 1 ± 8 










Curve parameters; cerebral blood flow (CBF), time to peak (TTP), peak height and curve height, were determined along the DIO uptake graph 
in time. STD(wt) n=6, STD(tg) n=6, DHA(tg) n=5, TWD(lg) n=6 were used for analysis. Values represent mean ± SEM. a= different from 
standard(tg). h=differentfrom TWD(tg), c=differentfrom DHA(tg) and *= trendp<0.07 
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was longer in DHA(tg) mice compared to TWD(tg) (p=0.04) and STD(tg) mice (p=0.07). 
Peak height (at TTP) and curve height at 20 s, which was the mean TTP for STD(wt), 
STD(tg) and TWD(tg) did not differ between the groups (genotype effect; p>0.40 and diet 
effect p>0.24). In contrast, peak height at 32 s (TTP for DHA(tg)) was increased (ANOVA 
p=0.04) in DHA(tg) mice compared to TWD(tg) (p=0.04) and STD(tg) (p=0.09). Altoge-
ther, a prolonged TTP in combination with a comparable peak height at 20 s and an incre-
ased peak height at 32 s shows a significant expanded peak surface area, which provides 







B. rCBV entire brun(D 20) C. rCBV (Il SPI») 
Std(wt) Std(tg) TWD(tg) DHA(tg) Sld(«t) Std(tg) TWD(tg) DHA(lg) 
Fig 2. Relative cerebral blood volume (rCBV). 
A: Cerebral uptake ofD20 after bolus injection. Each experimental group contained 6 mice except 
DHA group, which contains 5 transgenic mice. a.u.= arbitrary units. Vertical lines represent time to 
peak (TTP). B: D20 tracer bolus peak area. rCBVofthe whole brain is determined by estimating the 
area under the peak of each D20 spectrum in STD(wt), STD(tg), TWD(tg) and DHA(tg) fed animals. 
Values represent the mean and SEM. C: Cerebral changes in R2* relaxation upon administration of 
USPIO in STD(wt), STD(tg) TWD(tg) and DHA(tg) fed animals. The change inAR2* is proportional 
to the rCBV. a= different from STD(tg) (p=0.001). b= different from TWD(tg) (p=0.001). 
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Comparable results were also obtained by a second method, in which the area under the 
peak of each curve was directly measured by drawing a tangent line between 200 and 380 
s (Fig. 1 ). The rCB V in the DHA(tg) group was higher compared to the STD(tg) (38%) and 
TWD(tg) (43%)) group (Fig.2a and b). However, the increase in rCBV in DHA(tg) animals 
was not significant (ANOVA; p=0.11). No differences in rCBV were observed between the 
STD(wt) and STD(tg). 
To further explore possible regional differences in CBV, which cannot be determined with 
the MRS method and to support our MRS results, a subgroup of animals (not used for 
MRS) were exposed to a susceptibility-induced contrast-imaging technique. 
In correspondence with the MRS experiments, no differences were observed in rCBV bet-
ween the transgenic and wild type animals fed the STD diet (p<0.7) in any of the regions. 
However in the large group of 15-month-old wildtype and APP/PS1 transgenic mice a 














Fig 3. Relative cerebral blood volume (rCBV) in 15 month oldAPP/PSl and wildtype mice. 
Cerebral changes in R2* relaxation upon administration ofUSP/O in 15 month oldSTDlwt) 
and STD(tg) animais. The change in AR2* is proportional to the rCBV. a= different from 
STD(wt) (p=0.017>. 
type controls (p=0.017) was observed (Fig.3). A decrease of rCBV was also detected in the 
hippocampus of these 15-month-old mice and was of the same magnitude (29%)), although 
not significant (p=0.18). 
Further, a non significant decrease in the rCBV of TWD(tg) mice compared to STD(tg) 
mice in the cortex (mean STD(tg) 91% ± 3.6, mean TWD(tg) 78% ± 5.6) could be observed 
and transgenic animals on DHA diet, (DHA(tg)), showed a significantly higher delta R2* 
(rCBV) in the entire brain (ANOVA p=0.001 ) and especially in the neocortex (ANOVA; p= 
0.003) compared to TWD(tg) (both p<0.007) and STD(tg) mice (both p<0.002) (Fig.2c). 
Together, these data indicate that the increase in the entire brain blood volume in DHA(tg) 
mice is probably caused by an increase in cortical blood volume. 
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Typical western diet increases parenchymal plaque burden in the dentate gyrus of the 
hippocampus 
We quantified the Aß plaque load (total Aß) of the transgenic mice in frontal cortex (pre-
limbic area (PL) and anterior cingulate gyrus (ACg)) and hippocampus (CAI, CA3 and 
dentate gyrus (DG)) in three serial sections per region. The Aß plaque load showed sig-
nificant regional variation, such that an overall higher Aß plaque load was demonstrated 
in the DG compared to all other hippocampal and cortical regions (ANOVA p<0.001). Aß 
plaques covered 21% of the DG, while corresponding ratio was 12% in CAI, 8% in CA3, 
7% in PL and 13% in ACg. 
SId(lg) TWDftg) DHA<tg| 
Fig 4. Parenchymal ß-amyloidpathology in the brains ofAPP/PSl mice. 
Photomicrographs demonstrate the differences in ß-amyloid load in the dentate gyrus of the hip-
pocampus stained with WO-2 antibody (mouse anti-human Aß5-8 ) . Bar = 250pm A: STDfwt) 
B: STD(tg). C: TWD(tg). D: DHA(tg). E: diet affect on plaque burden in STD(tg). TWD(tg) and 
DHA(tg). Values represent mean ± SEM. a=different from STD(tg) (p=0.0l2). Figure F shows the 
location of the dentate gyrus of the hippocampus. 
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These results indicate that in these mice the dentate gyrus is most vulnerable to Aß depo-
sition. In addition, the ANOVA revealed an overall diet effect in the DG (p=0.013); i.e., 
significantly more plaques were detected in the DG (Fig.4) of TWD(tg) animals compared 
to STD(tg) (p=0.011), and a similar trend was observed between TWD(tg) and DHA(tg) 
groups (p=().10). The DHA(tg) mice did not differ from STD(tg) mice. No significant dif-
ferences between the diet groups were observed in other brain areas. 
a DHA-enriched diet decreases Aß deposition in the vasculature of the cinguiate 
gyrus 
Apart from parenchymal Aß plaque load, we also determined the Aß deposition in the vas-
culature of the PL, ACg and hippocampus, respectively containing the middle prefrontal 
branches of the anterior cerebral artery, the anterior cerebral artery and the vessels in the 
hippocampal fissure. No dietary effects were found in the amount of vascular Aß in the 
hippocampus and PL area. However, in the anterior cerebral artery of the cinguiate gyrus, 
the amount of vascular amyloid-ß was decreased in DHA(tg) mice compared to STD(tg) 
(p=0.003) and TWD(tg) mice (p=0.002) (Fig.5). 
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Fig 5. Vascular ß-amyloid pathology in the brains ofAPP/PSl mice. 
Photomicrographs demonstrate the differences in vascular ß-amyloid pathology in the cinguiate gv-
rus stained with WO-2 antibody (mouse anti-human Aß5-8 ) . Bar = 250pm. 
A: STD(tg) B: TWD(tg), C: DHA(tg). D: diet affect on vascular ß-amyloid pathology in STD(tg). 
TWD(tg) and DHA(tg). Values represent mean ± SEM. a=different from STD(lg) (p=0.003) and 
b=differentfrom TWD(tg) (p=0.002). 
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High dietary cholesterol does not influence the cholesterol content in the brain of 
APP/PS1 mice but does increase serum cholesterol levels 
Table 3 summarizes the serum and brain sterol levels in different diet groups. No diffe-
rences were observed in serum sterol levels between wildtype and STD(tg) mice. Howe-
ver, Serum cholesterol levels were significantly increased in TWD(tg) mice compared to 
STD(tg) and DHA(tg) mice (both p<0.001). Further, lathosterol levels, a main cholesterol 
precursor in the de novo synthesis pathway, was significantly decreased in TWD(tg) mice 
compared to STD(tg) (p=0 009) and in addition, the cholesterol elimination rate from the 
brain measured by 24S-OH-cholesterol levels, was increased in TWD(tg) mice compa-
red to STD(tg) (pO.001) and DHA(tg) mice (p=0.001). The diets did not directly affect 
brain cholesterol levels, which was not surprising as most cholesterol in the brain is me-
tabolically quite inert in the myelin sheath and serum cholesterol crosses the blood brain 
barrier in minimal amounts. Further, neither absolute nor relative levels of lathosterol dif-
fered between the groups. In addition, the diets did not affect cholesterol elimination rate 
from the brain (24S-OH-cholesterol levels). In contrast, transgenic mice compared to wild 
type mice did show increased brain cholesterol levels (ANOVA p=0 01 ) However the "de 
novo" synthesis or cholesterol elimination rate did not differ between the genotypes (no 
changes in lathosterol or 24s-OH-cholesterol levels). 
Dietary manipulation shifts the balance between n3 and n6 fatty acids in the brain of 
APP/PS1 transgenic mice 
The relative concentrations of different fatty acids in the brain of 18-month-old APP/PS1 
mice are shown in Table 4 Notably, animals fed with the diet containing DHA show a 
general increase in n3 fatty acids (1.2%) and a decrease (1.5%) in n6 fatty acids in brain 
tissue compared to STD(tg) and TWD(tg). This means a pronounced shift in the n6/n3 ratio 
in favour of n3. The change in n6 content was mainly caused by the decrease in arachidomc 
acid (20 4«6, (p<0,001), while the change in n3 content stemmed from an increase in DHA 
(22 6n3, pO.001) content. The brains of TWD(tg) mice had significantly higher n6 FA 
content than STD(tg) mice. This increase was mainly caused by an increase in arachidomc 
acid (p<0.03) in TWD(tg) as compared with the other two transgenic groups. These chan-
ges clearly indicate that dietary manipulations lasting 12 months are able to influence the 
composition of fatty acids in the phospholipid fraction of the mouse brain. 
^0 
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Different sterols were determined in serum (STD(wt) n=12, STD(tg) n=8, TWD(tg) n=9, DHA(tg) n = 8) and brains (STD(wt) n=3, STD(tg) n=6, 
TWD(tg) n=3, DHA{tg) /i=3) of wild type and APP/PSl mice. Values represent mean±SEM. "Different from standard(tg), bdifferent from TWDitg), 'different 
from DHA(tg). 
Table 4 








































































Brain fatty acids were determined in STD(wt) η = 3, STD(tg) η=6, TWD(tg) η=3 and DHA(tg) η=3. Values represent mean±SEM. "Different from standard(tg), 
bdiflferent from TWD(tg) and different from DHA(tg). 
Discussion 
In this study we investigated the long-term effects of dietary cholesterol and docosahexae-
noic acid (DHA) in the development of AD-like pathology and brain circulation in trans-
genic APP/PS1 mice. Both cholesterol and DHA may affect the degenerative processes in 
AD by influencing the Aß metabolism of via indirect effects on vasculature. High serum 
cholesterol may contribute to the development of AD via hypoperfusion of the brain lea-
ding to the elevated production of Aß [33,34,54] followed by cerebrovascular degeneration 
and cerebral amyloid angiopathy (CAA), whereas DHA may have a protective effect by 
maintaining vascular health [55-57]. We demonstrated that the typical western diet (TWD), 
containing 1% cholesterol, increased plaque burden in the dentate gyrus of the hippocam-
pus of 18-month-old APP/PS1 double transgenic Alzheimer mice, but did not significantly 
affect rCBV or CBF. In contrast, the DHA enriched diet significantly increased the relative 
cerebral blood volume (rCBV), indicating a larger circulation in the brain compared to 
STD(tg) and TWD(tg), without changing the cerebral blood flow (CBF) and decreased the 
vascular amyloid deposition in the anterior cingulate gyrus. 
Several studies show that AD patients and elderly people in general have a diminished 
CBF [58-60] and CBV [37,38]. However, our 18-month-old mice did not show significant 
differences in rCBV and CBF between transgenic and wild type mice on a standard diet. 
This observation may be explained by a large age-related decrease of rCBV and CBF in 
both genotypes, which may mask a smaller genotype difterence or by the fact that our 18-
month-old experimental groups were to small to notice small differences in rCBV. Namely, 
the additional results from the much larger group of 15-iTionth-old mice, show a significant 
decrease in rCBV in STD(tg) mice compared to STD(wt). These data confirm that our 
APP/PS1 mouse model is a good model to represent AD related hypoperfusion. Further-
more, it could be hypothesized that dietary changes influence haemodynamics and thereby 
affect the cognitive state and AD development. For example our transgenic animals that 
were fed a DHA enriched diet displayed an increase in rCBV compared to both the STD(tg) 
and TWD(tg) groups. Theoretically, this increase of rCBV may be caused by vasodilatation 
or genesis of new capillaries. Vasculogenesis is an unlikely explanation for the finding, 
because anti-angiogenic effects of DHA have been reported [61,62]. Vasodilatation is in 
our view a more likely explanation, since CBF did not change, and a mismatch between 
CBF and CBV has been interpreted as compensatory vasodilatation [63]. In support of this 
notion, intake of n3 PUFAs (to which family DHA belongs) in human subjects has been 
shown to affect endothelial function and improve flow-mediated dilatation of the brachial 
artery [57] and enhance nitric oxide mediated vasodilatation in the microcirculation of the 
forearm [64]. Furthermore, transgenic mice overexpressing APP have an impairment in 
cerebrovascular responses mediated by the release of vasoactive factors from brain endo-
thelial cells, such as nitric oxide (NO), while simultaneous overexpression of superoxide 
dismutase restores their responses, implicating reactive oxygen species in the mechanisms 
of the endothelial dysfunction [65]. It is of interest in this context that DHA has been re-
ported to increase glutathione peroxidase levels in aortic endothelial cells and cerebrum of 
aged rats, although it is generally known to enhance susceptibility of membranes to lipid 
peroxidation due to its several double bonds [66,67]. Apart from an increased rCBV, pro-
bably due to vasodilatation in these aged APP/PSl transgenic mice fed a DHA containing 
diet, we also expected less hypometabolic and degenerating neurons [68] resulting in a bet-
ter cognitive status [29,30]. Oksman et al. have already shown in the same APP/PSl mice 
that a diet supplemented with DHA increased exploratory behaviour [29] and indirectly 
consolidates the influence of rCBV on behaviour, since Aß deposition did not change in 
DHA(tg) mice. 
The TWD diet, however, did not significantly decrease the rCBV in aged APP/PSl trans-
genic mice compared to STD(tg) and DHA(tg) groups. We did find a decrease in the rCBV 
of TWD(tg) mice compared to STD(tg) mice in the cortex, although not significant. This 
finding is rather surprising since it could be expected that chronic high cholesterol intake 
causes the development of atherosclerosis, as shown in studies in C57BL/6J and transge-
nic Alzheimer mice models [69,70], resulting in a decreased CBV, and high cholesterol in 
combination with aging is known to further decrease CBF [71]. Accordingly, our latest re-
sults with 15-month-old APP/PSl and wild type littermates fed the same TWD diet show a 
significant decrease in rCBV compared to STD mice (not shown). The experimental groups 
used in that experiment are larger which could explain why significant difference could be 
found in the 15 and not in the 18-month-old APP/PSl mice. 
In accordance with Refolo, who reported that high dietary cholesterol increases Abeta ac-
cumulation and accelerates AD-related pathology [12], the brains of our TWD(tg) mice 
also did show increased Aß levels in the DG of the hippocampus, indicating that Aß de-
position can be modulated by diet-induced hypercholesterolemia. Altogether, the results 
showing a decrease in rCBV in combination with the increased amount of Aß deposition 
in the DG in mice fed a cholesterol enriched diet, do support the hypoperfusion theory, in 
which high serum cholesterol may contribute to the development of AD via hypoperfusion 
of the brain leading to the elevated production of Aß [33,34,54]. 
It is possible that there is an increase of cholesterol in the cerebral vasculature which cau-
ses vascular damage or mild atherosclerosis leading to increased Aß deposition. Although 
we did not find significant increases in total brain cholesterol level in TWD(tg) animals, 
an increased vascular cholesterol level is still possible. However, the intravascular com-
partment, representing just a small volume fraction of the total brain (3-5%), could not be 
measured separately. Increased amyloid plaque load with no significant changes in cere-
bral circulation may also suggest that high dietary intake of cholesterol directly influences 
Aß processing in the brain. This finding is consistent with the recent report of Oksman et 
al. (2006), showing that addition of SFA and cholesterol containing oils (as opposed to 
fish-oil) increased Aß production in transfected cells. Notably, the effect of high SFA and 
cholesterol containing oils on Aß deposition in the brain was regionally specific. This is 
consistent with the fact that the DG, which responded significantly to TWD, was also more 
vulnerable for Aß depositions than other areas in these APP/PS1 mice. In addition, our Aß 
analysis also showed the systematic finding that the DG is, in all transgenic mice more vul-
nerable for Aß depositions compared to all other brain areas. This is in accordance with the 
AD syndrome in which Aß depositions are first present in the hippocampus and especially 
the DG [72-74]. The DG is the first area that is affected in AD [74,75], even before the ac-
cumulation of Aß plaques [75] and this may explain why a TWD diet influences the amount 
of Aß only in the DG, and not other brain regions. Another explanation for this finding that 
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only the hippocampus shows differences in abeta load, is that we may face the interesting 
possibility that abeta load in the cortex has already reached the ceiling and is therefore 
more insensitive to small manipulations, whereas hippocampal Aß is in a more dynamic 
state since this brain area maintains neurogenesis throughout the lifespan of rodents. 
In mice fed a DHA-enriched diet we expected, besides of an increased rCBV, a decreased 
Aß load. Firstly, it has been hypothesized that hypoperfusion of the brain per se leads to 
increased Aß load [76,77]. Therefore, a more healthy circulation is expected to lead to 
decreased Aß load levels. Secondly, it has been suggested that increased incorporation 
of DHA in neuronal membranes increases membrane fluidity, resulting in increased APP 
processing via the non-amyloidogenic a-secretase pathway instead of the amyloidogenic 
pathway [13,15]. Indeed, Lim et al. (2005) reported lower Aß levels as measured by ELISA 
and reduced amyloid pathology in the hippocampus and parietal cortex of APPswe mice, 
which had been fed a DHA diet from 18 until 23 months [28]. This is partially consistent 
with the study by Oksman et al. [29], who also reported lower Aß levels in ELISA assays 
in APP/PS1 mice receiving a DHA enriched diet. However, DHA supplementation did not 
affect the immunohistochemically measured amyloid plaque burden either at the age of 
10 months [29] or at 18 months (present study) in the parenchyma. The DHA effects in 
Lim's study [28] may be due to the fact that their control group received a DHA depleting 
diet and our mice a control diet containing a small amount of linolenic acid which may be 
converted to DHA. In our study we therefore investigated effects of supplementation with 
DHA instead of replenishment of depleted DHA as in the Lim study. The results of our 
phospholipid and fatty acid analysis of the brain homogenates show no difference in DHA 
content nor n6 and n3 LCPUFA content in the brains of the transgenic mice compared to 
wildtype mice, showing that transgenicity does not cause DHA depletion. The animals 
used in the Oksman study [29] were 10 months of age and plaque burden is much less in 
this mouse compared to the 18-month-old animals in our study; it therefore may be difficult 
to bring about effects on that age. 
Nevertheless, we did find a significant decrease in the amount of vascular Aß in the cingu-
late gyrus tissue surrounding the longitudinal fissure and in leptomeningeal arteries (main-
ly anterior cerebral artery), suggesting that not only replenishment of a DHA deficit (Lim et 
al., 2005) but also DHA supplementation may be warranted in aged people at risk for AD. 
This result in combination with the increased rCBV fortifies the hypothesis that high intake 
of DHA may have a protective effect by improving vascular health and thus the perfusion 
of the brain ultimately leading to a decreased amount of Aß. Another beneficial effect of 
DHA supplementation may be a reduced microglia activation as found by Oksman (Oks-
man et al., 2005) in the same APP/PS1 mice receiving exactly the same DHA enriched diet 
as used in our study which may indicate dampening of the neuroinflammatory response 
resulting in neuroprotection. 
According to the changes in Aß load and rCBV due to different diets, alterations in the fatty 
acid and sterol profile of cholesterol, its precursor lathosterol or its main metabolite 24S-
OH-cholesterol in brain tissue, were also expected. However, no differences in SFA and 
cholesterol levels in the brain were found. Liitjohann et al. (2002) has also shown no signi-
ficant changes in brain cholesterol levels in APP transgenic animals of different age groups 
(3, 6, 9, 12 and 18 months) on cholesterol diets compared to wild types, indicating two 
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separate cholesterol mechanisms for brain and body [78]. In addition, the observation that 
cholesterol levels do not change in brain homogenates due to dietary cholesterol supple-
mentation in mice may indicate that membrane fluidity is not influenced by administration 
of dietary cholesterol. This statement questions Wolozin's theory in which he hypothesizes 
that high cholesterol in neuronal membranes increases amyloid-ß (Aß) production [15], 
and is furthermore an indirect ratification for the hypoperfusion theory [33-35]. 
Fatty acid analysis did show differences in brain tissue composition of TWD(tg) and 
DHA(tg) animals. TWD(tg) mice showed a small increase in brain levels of the n6 LCPU-
FA arachidonic acid (AA) compared to STD(tg) mice, and the ratio of n6/n3 PUFAs in 
DHA(tg) animals was shifted in favour of n3, which is in line with the DHA diet containing 
more n3 PUFAthan the other diets (Table 1). This indicates a direct influence of dietary FA 
on brain, demonstrating exchange of LCPUFA across the blood brain barrier [79]. More-
over, the relative increase of n3 FAs over n6 FAs may imply increased membrane fluidity 
[80]. Gray matter is composed of of approximately 30-40% of DHA, which is almost 17% 
of the total weight of fatty acids in the brain. Because of this huge abundance of DHA in 
the brain, it can be expected that a significant increase or decrease of DHA in the brain, will 
greatly influence membrane fluidity. In previous studies, increased DHA concentrations in 
neuronal membranes have lead to changes in the physical properties of membranes, en-
zyme activities, receptors, transport and cellular interactions [81-83]. These physiological 
changes are also accompanied by improved learning in behavioural studies [84,85]. More 
specifically, an optimal n6/n3 ratio can also influence the level of performance in learning 
and memory tasks, and has been shown to improve spatial learning in rats after a 4-week 
treatment with oils low in n6/n3 ratio [85]. Another study on fish-oil-depleted young rats 
demonstrated improved maze learning after 10-week DHA supplementation, which further 
correlated positively with the hippocampal and cortical DHA/AA ratio [84]. 
Consequently, one should expect an improved cognitive state in DHA(tg) mice compared 
to, for example, TWD(tg) and STD(tg) animals. Our parallel study in Finland [29] perfor-
med the behavioural studies with our mice when they were 10 months of age, and showed 
that a diet supplemented with DHA increased exploratory behaviour. This increased ex-
plorative behaviour suggests more active and less anxious mice, whearas in AD patients, 
anxiety, agitation and restlessness often occur [86]. Therefore an increase in explorative 
behaviour may suggest less AD related problems. Altogether, it could be hypothesized that 
a DHA containing diet fed to aged APP/PS1 mice may influence cognition via increased 
membrane fluidity, but as stated above, also has effects via the circulation, since the DHA 
diet increased rCBV. 
In conclusion, our results show that that long-term intake of dietary lipids can impact brain 
circulation, neuronal membrane composition and the deposition of Aß plaques in the brain. 
This study adds to the accumulating evidence that the classic dietary risk factors for cardio-
vascular disease, high amounts of saturated fatty acids and cholesterol, promote amyloid 
deposition in the brain. Whereas DHA supplementation has effects on brain circulation, it 
increased cerebral blood volume probably due to vasodilatation, and decreases the amount 
of vascular Aß, fortifing the hypothesis that high intake of DHA may have a protective ef-
fect by improving vascular health and thus the perfusion of the brain ultimately leading to 
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a decreased amount of Aß. The present study also demonstrates that the recent advances 
in MR imaging methods can be applied to genetically manipulated mice modelling AD. 
Future studies should utilize even more challenging imaging techniques such as arterial 
spin labelling to explore the exact contribution and regional differences of the cerebral 
circulation in the pathogenesis of AD. 
Acknowledgments 
We would like to thank David Borchelt and Janina Jankowsky (Johns Hopkins University, 
Baltimore) for providing us with the mice and Henk Arnts for his excellent care giving 
of our animals. The laboratory work on sterol analysis of Anja Kerksiek and Sylvia Frie-
drichs from the Department of Clinical Pharmacology, University of Bonn, Germany, is 
also gratefully acknowledged. Martin Balvers at Numico Research, Wageningen, skillfully 
performed all PL and FA analyses. This study is partly supported by an EU 5th framework 
project (no:QLRT-2002-172), a travel grant from the Academy of Finland (#209716) and a 
Research visit grant from Zon-MW the Netherlands organization for Health Research and 
Development (910-31-704 ). 
References 
111 de la Torre JC. Vascular basis oFAIzheimer's pathogenesis. Ann Ν Y Acad Sci 
2002;977:196-215. 
[2] Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflamma­
tion, cholesterol, and misfoldcd proteins. Lancet 2004;363 (9415):l 139-46. 
[3] Luchsinger JA, Rcitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular 
risk factors and risk of incident Alzheimer disease. Neurology 2005;65 (4):545-51. 
[4J Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen 
H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later 
life: longitudinal, population based study. Bmj 2001 ;322 (7300): 1447-51. 
[5] Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. 
Neurobiol Aging 2000;21 (2): 153-60. 
[6] Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. 
Lancet 2000;356 (9242): 1627-31. 
[7] Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-
Traver S, Lochhead J, Ziolwolski C. Atorvastatin for the treatment of mild to moderate 
Alzheimer disease: preliminary results. Arch Neurol 2005;62 (5):753-7. 
[8] Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand Ρ, Gauthier S. Apolipoprotein E 
polymorphism and Alzheimer's disease. Lancet 1993;342 (8873):697-9. 
[9] Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, 
Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased fre­
quency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 
1993;90(5):1977-81. 
[ 10] Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr., 
Rimmler JB, Locke PA, Conneally PM, Schmader RE, et al. Protective effect of apoli-
poprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7 (2): 180-4. 
[11] Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons Κ. Cholesterol de 
pletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci 
U S A 1998;95 (I l):6460-4. 
[12] Refolo LM, Malester Β, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, 
DufTK, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer's amyloid patho­
logy in a transgenic mouse model. Neurobiol Dis 2000;7 (4):321-31. 
[13] Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F. Low cholesterol stimulates the 
nonamyloidogenic pathway by its effect on the alpha -secrelase ADAM 10. Proc Natl Acad 
SciUSA2001;98(10):5815-20. 
[14] Yeagle PL. Modulation of membrane function by cholesterol. Biochimie 1991;73(I0): 
1303-10. 
[15] Wolozin B. A (luid connection: cholesterol and Abeta. Proc Natl Acad Sci U S A 2001 ;98 
(10):5371-3. 
[16] Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol micro-domains in brain 
plasma membranes. Biochem Pharmacol 2003;65 (5):843-56. 
[17] Oner P, Bekpinar S, Cinar F, Argun A. Relationship of some endogenous sex steroid hor 
mones to leukocyte arylsulphatase A activities in pre- and postmenopausal healthy women. 
Horm Metab Res 1994;26 (6):301-4. 
[18] Sinha AK, Shattil SJ, Colman RW. Cyclic AMP metabolism in cholesterol-rich platelets. J 
Biol Chem 1977;252 (10):3310-4. 
[19] Mitchell DC, Straume M, Miller JL, Lilman BJ. Modulation of metarhodopsin formation 
by cholesterol-induced ordering of bilayer lipids. Biochemistry I990;29 (39):9143-9. 
[20] Criado M, Eibl H, Barrantes FJ. Effects of lipids on acetylcholine receptor. Essential need 
of cholesterol for maintenance of agonist-induced state transitions in lipid vesicles. Bioche-
mistry 1982;21 (15):3622-9. 
[21] Fassbender Κ, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, 
Berlsch T, von Bergmann K, Hennenci M, Beyreuther K, Hartmann T. Simvastatin strongly 
reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in 
vitro and in vivo. Proc Natl Acad Sci U S A 2001 ;98 ( 10):5856-61. 
[22] Wahrlc S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, 
Younkin SG, Golde TE. Cholesterol-dependent gamma-secretase activity in buoyant cho­
lesterol-rich membrane microdomains. Neurobiol Dis 2002;9 (1):11-23. 
[23] Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004;41 (1):7-I0. 
[24] Hashimoto M, Hossain S, Shimada T, Shido O. Docosahexaenoic acid-induced protective 
effect against impaired learning in amyloid beta-infused rats is associated with increased 
synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 2006;33 (10):934-9. 
[25] Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, 
Schneider J. Consumption offish and n-3 fatty acids and risk of incident Alzheimer disease. 
Arch Neurol 2003;60 (7):940-6. 
[26] Barberger-Gateau P, Lelenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, 
meat, and risk of dementia: cohort study. Bmj 2002;325 (7370):932-3. 
[27] Kalmijn S, Launer LJ, Oll A, Witleman JC, Hofman A, Breteler MM. Dietary fat intake and 
the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42 (5):776-82. 
[28] Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N, Jr., Frautschy SA, Cole 
GM. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid 
burden in an aged Alzheimer mouse model. J Neurosci 2005;25 (12):3032-40. 
[29] Oksman M, livonen H, Hogyes E, Amtul Z, Penke B, Leenders 1, Broersen L, Lutjohann 
D, Hartmann Τ, Tanila Η. Impact of different saturated fatty acid, polyunsaturated fatty 
acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic 
mice. Neurobiol Dis 2006;23 (3):563-72. 
[30] de Wilde MC, Parkas E, Gerrits M, Kiliaan AJ, Luiten PG. The effect of n-3 polyunsatura­
ted fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral 
hypoperfusion. Brain Res 2002;947 (2): 166-73. 
[31] de Wilde MC, Hogyes E, Kiliaan AJ, Parkas Τ, Luiten PG, Parkas E. Dietary fatty acids 
alter blood pressure, behavior and brain membrane composition of hypertensive rats. Brain 
Res2003;988(l-2):9-l9. 
[32] Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006;83 
(6Suppl):1477S-82S. 
[33] Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin Τ, Chen J. Cleavage of 
amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 
2000;21 (2):207-14. 
[34] Lin B, Schmidt-Kästner R, Busto R, Ginsberg MD. Progressive parenchymal deposition of 
beta-amyloid precursor protein in rat brain following global cerebral ischemia. Acta Neuro-
pathol (Beri) 1999;97 (4):359-68. 
[35] van Groen Τ, Puurunen Κ, Maki HM, Sivenius J, Jolkkonen J. Transformation of diffuse 
beta-amyloid precursor protein and beta-amyloid deposits to plaques in the thalamus after 
transient occlusion of the middle cerebral artery in rats. Stroke 2005;36 (7):155l-6. 
[36] ladecola C. Cerebrovascular effects of amyloid-beta peptides: mechanisms and implicati 
ons for Alzheimer's dementia. Cell Mol Neurobiol 2003;23 (4-5):681-9. 
[37] Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA. Renshaw PP. 
Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alz­
heimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol 
1998; 19 (9): 1727-32. 
[38] Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M, Hatano K, Sasaki T. Cerebral 
blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular 
dementia with deep white matter changes. Neuroradiology 1998;40 (3): 131-7. 
[39] Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-ex 
pression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 
2001;17(6):157-65. 
[40] Perthen JE, Calamante P, Gadian DG, Connelly A. Is quantification of bolus tracking MRI 
reliable without deconvolution? Magn Reson Med 2002;47 (l):6l-7. 
[41] Trivedi RA, Green HA, J UK-I, Graves M, Black R, Kirkpatrick PJ, Griffiths PD, Gillard 
JH. Cerebral haemodynamic disturbances in patients with moderate carotid artery stenosis. 
Eur J Vase Endovasc Surg 2005;29 (l):52-7. 
[42] Ackerman JJ, Ewy CS, Becker NN, Shalwitz RA. Deuterium nuclear magnetic resonance 
measurements of blood flow and tissue perfusion employing 2H20 as a freely diffusible 
tracer. Proc Natl Acad Sci U S A 1987;84 (12):4099-102. 
5*) 
[43] Zierler KL. Equations for Measuring Blood Flow by External Monitoring of Radioisotopes. 
CircRes 1965;16:309-21. 
[44] Roberts GW, Larson KB, Spaeth EE. The interpretation of mean transit lime measurements 
for multiphase tissue systems. J Theor Biol 1973;39 (2):447-75. 
[45] Dctrc JA, Subramanian VH, Mitchell MD, Smith DS, Kobayashi A, Zaman A, Leigh JS, 
Jr. Measurement of regional cerebral blood flow in cat brain using intracarolid 2H20 and 
2H NMR imaging. Magn Reson Med 1990;14 (2):389-95. 
[46] Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR 
imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 
1998;40(6):793-9. 
[47] Kennan RP, Zhong J, Gore JC. Intravascular susceptibility contrast mechanisms in tissues. 
Magn Reson Med 1994;31 (1):9-2I. 
[48] Franklin K, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: academic 
press, 1997. 
[49] Luljohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal Β, Thelen Κ, Andersson U, Bjork 
hem I, Bergmann Kv K, Fassbender Κ. High doses of simvastatin, pravastatin, and choles­
terol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004;69 (6):431-8. 
[50] Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Abeta 
deposition is associated with neuropil changes, but not with overt neuronal loss in the 
human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997; 17 
(18):7053-9. 
[51] Shukla C, Bridges LR. Regional distribution of tau, beta-amyloid and beta-amyloid precur 
sor protein in the Alzheimer's brain: a quantitative immunolabelling study. Neuroreport 
1999;10(18):3785-9. 
[52] Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann Κ, Bey 
reuther Κ, Multhaup G, Bayer TA. Profile of cholesterol-related sterols in aged amyloid 
precursor protein transgenic mouse brain. J Lipid Res 2002;43 (7): 1078-85. 
[53] Thelen KM, Rentsch KM, Gutteck U, Hevenn M, Olm M, Andersson U, von Eckardstein 
A, Bjorkhem I, Lutjohann D. Brain cholesterol synthesis in mice is affected by high dose of 
simvastatin but not of pravastatin. J Pharmacol Exp Ther 2005. 
[54] de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence 
Stroke2002;33(4):ll52-62. 
[55] Nestel PJ, Pomeroy SE, Sasahara T, Yamashita T, Liang YL, Dart AM, Jennings GL, Abbey 
M, Cameron JD. Arterial compliance in obese subjects is improved with dietary plant n-3 
fatty acid from flaxseed oil despite increased LDL oxidizability. Artenoscler Thromb Vase 
Biol 1997; 17 (6): 1163-70. 
[56] Nestel Ρ, Shige Η, Pomeroy S, Cehun M, Abbey M, Raederstorff D. The n-3 fatty acids 
eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in 
humans. Am J Clin Nutr 2002;76 (2):326-30. 
[57] Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation 
with marine omega-3 fatty acids improve systemic large artery endothelial function in 
subjects with hypercholesterolemia. J Am Coll Cardiol 2000;35 (2):265-70. 
[58] Ries F, Horn R, Hillekamp J, Honisch C, König M, Solymosi L. Differentiation of multi-mf 
arct and Alzheimer dementia by intracranial hemodynamic parameters. Stroke 1993 ;24 
60 
(2):228-35. 
[59] Franceschi M, Alberoni M, Bressi S, Canal N, Comi G, Fazio F, Grassi F, Perani D, Volonte 
MA. Correlations between cognitive impairment, middle cerebral artery flow velocity and 
cortical glucose metabolism in the early phase of Alzheimer's disease. 
Dementia 1995;6(l):32-8. 
[60] Reed BR, Jagust WJ, Seab JP, Ober BA. Memory and regional cerebral blood flow in 
mildly symptomatic Alzheimer's disease. Neurology 1989;39 (11):1537-9. 
[61] Rose DP, Connolly JM. Antiangiogenicity of docosahexaenoic acid and its role in the sup 
pression of breast cancer cell growth in nude mice. Int J Oncol 1999; 15 (5): 1011-5. 
[62] Mukutmoni-Norris M, Hubbard NE, Erickson KL. Modulation of murine mammary tumor 
vasculature by dietary n-3 fatty acids in fish oil. Cancer Lett 2000; 150 (1): 101-9. 
[63] Dijkhuizen RM, Nicolay Κ. Magnetic resonance imaging in experimental models of brain 
disorders. J Cereb Blood Flow Metab 2003;23 (12):l383-402. 
[64] Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. 
Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and 
non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with 
coronary artery disease. J Cardiovasc Pharmacol 1999;33 (4):633-40. 
[65] ladecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, 
Hsiao KK, Carlson GA. SODI rescues cerebral endothelial dysfunction in mice overex 
pressing amyloid precursor protein. Nat Neurosci 1999;2 (2): 157-61. 
[66] llossain MS, Hashimoto M, Gamoh S, Masumura S. Antioxidative efTects of docosahexae 
noie acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic 
rats. J Neurochem 1999;72 (3):1133-8. 
[67] Delton-Vandenbroucke I, Vericel E, Janucl C, Carreras M, Lecomle M, Lagarde M. Dual 
regulation of glutathione peroxidase by docosahexaenoic acid in endothelial cells depen­
ding on concentration and vascular bed origin. Free Radie Biol Med 2001;30 (8):895-904. 
[68] Parkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. 
Prog Neurobiol 2001 ;64 (6):575-611. 
[69] Li L, Cao D, Garber DW, Kim H, Fukuchi K. Association of aortic atherosclerosis with ce­
rebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am 
J Pathol 2003; 163 (6):2155-64. 
[70] Nishina PM, Lowe S, Verstuyft J, Naggert JK, Kuypers FA, Paigen B. Effects of dietary 
fats from animal and plant sources on diet-induced fatty streak lesions in C57BL/6J mice. 
J Lipid Res 1993;34 (8): 1413-22. 
[71] de la Torre JC. Cerebral hypoperfusion, capillary degeneration, and development of Alzhei­
mer disease. Alzheimer Dis Assoc Disord 2000; 14 Suppl I :S72-81. 
[72] Braak E, Griffing Κ, Arai Κ, Bohl J, Bratzke Η, Braak Η. Neuropathology of Alzheimer's 
disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 1999;249 
Suppl 3:14-22. 
[73] Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific 
pathology isolates the hippocampal formation. Science 1984;225 (4667): 1168-70. 
[74] Reilly JF, Games D, Rydel RE, Freedman S, Schenk D, Young WG, Morrison JH, Bloom 
FE. Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of 




DHA and cholesterol containing diets influence 
Alzheimer-like pathology, cognition and 
cerebral vasculature in APPswe/PSldE9 mice 
Hooijmans CR ", Van der Zee CEEM b, Dederen PJ *, Brouwer KM ", Reijmer YD · 
van Groen Τ ', Broersen LM d, Lütjohann D °, Heerschap A ', Kiliaan AJ m 
' Radboud University Nijmegen Medical Centre, Department of Anatomy 
and s Department of Cognitive Neuroscience, Donders Centre for Neuroscience, 
Geert Grooteplein noord 21, 6500 HB, Nijmegen, The Netherlands.b Radboud University 
Nijmegen Medical Centre, Department of Cell Biology, NCMLS, 
Geert Grooteplein zuid 26, 6525 GA, Nijmegen, The Netherlands;c University of 
Alabama at Birmingham, Department of Cell Biology, AL 35294-0006, 
Birmingham, USA.d Danone Research, PO Box 7005, 6700 CA, Wageningen, 
The Netherlands ' University of Bonn, Institute of Clinical Chemistry and Pharmacology, 
Sigmund-Freud-Strasse 25, 53105 Bonn, Germany. ' Radboud University Nijmegen 
Medical Centre, Department of Radiology, Geert Grooteplein zuid 10, 6500 HB, 
Nijmegen, The Netherlands. 
Submitted to Neurobiol. aging 
Abstract 
Both cholesterol and docosahexanoic acid (DHA) may affect degenerative processes in 
Alzheimer's Disease (AD) by influencing Aß metabolism indirectly via the vasculature. 
We investigated whether a DHA-ennched diet or cholesterol-containing Typical Western 
Diet (TWD) alter behavior and cognition, cerebral hemodynamics (relative cerebral blood 
volume (rCBV)) and Aß deposition in 8 and 15-month-old APPswe/PSldE9 mice. In ad-
dition we investigated whether changes in rCBV precede changes in Aß deposition or vice 
versa. Mice were fed either a regular rodent chow, a TWD diet, or a DHA-containing diet 
until 8 and 15 months of age. Behavior, learning and memory were investigated, and rCBV 
was measured using contrast-enhanced MRI. The Aß load was visualized immunohisto-
chemically. We demonstrate that a DHA-ennched diet altered rCBV in 8-month-old APP/ 
PS1 and wild type mice In 15-month-old APP/PS1 mice DHA supplementation improved 
spatial memory, decreased the amount of Aß and slightly increased rCBV, indicating that a 
DHA-ennched diet can diminish AD-hke pathology. In contrast, a TWD diet decreased the 
rCBV in 15-month-old mice. The present data indicate that long-term dietary interventions 
can change AD-hke pathology in APP/PS1 mice In addition, the effects of the tested diets 
on vascular parameters were observed before effects on Aß load were noted. These data un-
derline the importance of vascular factors in the APP/PS1 mouse model of AD pathology. 
64 
Introduction 
The cause of Alzheimer's disease (AD) is still largely unknown despite many years of ex-
tensive research. Since AD is characterized by the presence of neurofibrillary tangles and 
amyioid-ß (Aß) containing aggregates in neuritic plaques and cerebral blood vessel walls, 
it has been suggested accumulation of Aß in the brain is the primary influence driving 
AD pathogenesis (the amyloid-ß hypothesis) [1]. However, gene mutations in presenilin 
1 (PS1), presenilin 2 (PS2), or amyloid precursor protein (APP) responsible for increased 
production of Aß [2], are only responsible for approximately 5% of all cases of AD world-
wide. Therefore, it could be suggested that beside Aß, other AD risk factors such as car-
diovascular-, lifestyle- or environmental factors, play an important role in the development 
of AD [3-5]. 
There are indications that modification of lifestyle factors, such as nutrition, alter the risk 
of developing AD later in life [4,6]. For example, high serum cholesterol, which can be 
caused by dietary intake, is an important risk factor in AD [7,8]. The role of cholesterol 
in AD is also strengthened by epidemiological studies that associate cholesterol lowering 
statins with diminished prevalence of AD [9] and with less deterioration of cognitive func-
tions [10]. Identification of the cholesterol transporter apolipoprotein E4 as a major genetic 
risk factor for hypercholesterolemia, vascular dementia and sporadic AD [11-13], has rein-
forced the relationship between cholesterol and AD. Further support for the link between 
high cholesterol intake and AD pathology comes from cell culture and experimental animal 
studies. For example, reduction of cellular cholesterol levels in rat hippocampal neurons 
reduce the formation of Aß [14], whereas high dietary cholesterol intake in double transge-
nic AD mice increases Aß accumulation [15,16]. In addition, a study in guinea pigs showed 
that lowering whole body cholesterol with statins decreases Aß formation [17]. 
Another lipid diet factor influencing the risk of AD is the omega-3 long chain poly-unsatu-
rated fatty acid (n3 LCPUFA) docosahexaenoic acid (DHA). The Framingham Heart study 
showed that people with high plasma DHA levels have a decreased risk of developing 
dementia, and AD in particular [18]. Also other epidemiological studies have indicated 
that sufficient DHA intake reduces the risk of developing AD [19-21]. Several studies have 
shown that dietary intake of n3 PUFA may reduce cognitive decline [22,23], and a recent 
trial by Freund-Levi et al showed positive effects of DHA supplementation on cognition 
in patients with very mild AD [24]. Recent experimental studies in APP transgenic mice 
reported decreased brain Aß levels after dietary DHA supplementation [25,26]. Ithasbeen 
proposed that DHA supplementation increases the amount of the neuronal sorting protein 
LR11 which regulates APP processing together with a subsequent decrease in Aß produc-
tion [27]. In addition, Calon et al showed that DHA supplementation to DHA depleted 
tg2576 AD mice improved memory acquisition [28] Taken together, the above-mentioned 
data show that high cholesterol levels or low plasma DHA levels are risk factors for AD. 
Moreover, cholesterol and DHA are also involved in cardiovascular diseases such as hyper-
tension and atherosclerosis [29]. It could therefore be suggested that cholesterol and DHA 
may also exert their effects on the development of AD by influencing the peripheral and ce-
rebral vasculature. A recent study performed in our lab, showed that a cholesterol enriched 
Typical Western Diet (TWD) and a DHA diet, indeed, influenced cerebral hemodynamics 
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such as the cerebral blood volume (CBV) in 18-month-old double transgenic APP/PS1 
mice [15] This is in line with studies showing that CBV is affected in AD [30] In addition 
a study from Niwa et al showed that in Tg2576 Alzheimer mice cerebral blood flow (CBF) 
was reduced throughout the brain prior to Aß deposition, suggesting that cerebrovascular 
abnormalities are early events in the pathogenesis of Alzheimer's disease [31] 
Our study also showed that the cholesterol enriched TWD diet increased plaque burden in 
the hippocampus, whereas the DHA enriched diet decreased the amount of Aß deposits in 
cerebral blood vessel walls in the 18-month-old double transgenic APP/PS1 mice [15] 
In the current study we investigate whether changes in relative cerebral blood volume 
(rCBV), determined using susceptibility enhanced MRI, precede changes in Aß deposition 
in these APP/PS 1 mice or vice versa We also tested the effects of DHA and TWD diets 
on cognition, rCBV, the amount ot Aß depositions and the sterol and fatty acid profiles of 
the brain, from 8 and 15-month-old APP/PS 1 mice We used similar diets as in our former 
study [15] Explorative behavior was determined with an open field test, and spatial lear-
ning and memory with both the Morris water maze (MWM), and the 12 circular hole board 
in 8 and 15-month-old wild type and double transgenic APPswe/PSldE9 mice 
Materials and methods 
Animals and diets 
The APPswe/PSldE9 founders were obtained from Johns Hopkins University, Baltimore, 
MD, USA (D Borchelt and J Jankowsky, Dept of Pathology) and a colony was establis-
hed at the Radboud University Nijmegen Medical Centre, The Netherlands In short, mice 
were created by co-injection of chimeric mouse/human APPswe (mouse APP695 harbo-
ring a human Aß domain and mutations K.595N and M596L linked to Swedish familial 
AD pedigrees) and human PSl-dE9 (deletion of exon 9) vectors controlled by independent 
mouse prion protein promoter elements The two transfected genes co-integrate and co-se-
gregate as a single locus [32] This line was originally maintained on a hybrid background 
by backcrossing to C3HeJ χ C57BL6/J Fl mice (so-called pseudo F2 stage) For the pre­
sent work, the breeder mice were backcrossed to C57BL6/J for 7 generations to obtain 
mice tor the current study 
Male APP/PS 1 transgenic mice and their wild type littermates were assigned to different 
diet groups, which varied only with respect to the composition of the 5% fat in the diets 
(table 1) 
Apart from that, the remaining components in all diet groups are the same as used in 
standard rodent chow, with for example, wheypowder, barley, wheat etcetera and a vita-
min/mineral mix containing vitamin E in a concentration of 30 mg/kg in each diet group 
Feeding the diets started when the mice reached the age of 2 months and was maintained 
until 8 and 15 months of age 
Transgenic mice and their wild type littermates were fed either a Typical Western Diet 
(TWD), containing 1% cholesterol, a high percentage of saturated fatty acids (SFA), a low 
percentage of long chain poly unsaturated fatty acids (LCPUFAs) and a high n6/n3 LCPU-
FA ratio, or a DHA diet containing 0 4% DHA, a low percentage SFA, a high percentage 
LCPUFA and a low n6/n3 LCPUFA ratio, or a standard control diet (STD), with interme­
d i 
Table 1. Sources and contents of fatty acids in the experimental diets 
Source 
% soya oil 
% coconut oil 
% com oil 
% fish oil 
% sunflower oil 
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SFA= saturated fatty acids, 1VIUFA= Mono unsaturated fatty acids, 
PUFA= poly unsaturated fatty acids 



























































































rCBV= relative cerebral blood volume, IHC= immunohistochemistry, 
FA= fatty acids 
diate values for SFA and LCPUFA content and the n6/n3 LCPUFA ratio. 
In total 165 mice were used, table 2 describes the number of mice used in each experiment. 
The majority of the mice were used for behavioral analyses, and subsequently for relative 
cerebral blood volume measurements. Mice from MRI experiments during which techni-
cal errors occurred were excluded from further analyses of rCBV (Table 2). The largest 
part of the mice used for rCBV measurements were subsequently sacrificed (transcardially 
perfused) and their brains processed for immunohistochemistry. The remaining mice were 
sacrificed to determine brain sterol and fatty acid levels. 
Throughout the experiments the animals were housed individually in a controlled environ-
ment, with room temperature at 2TC, and an artificial 12:12h light:dark cycle (lights on at 
07:00 a.m.) Food and water were available ad libitum. The experiments were performed 
according to Dutch federal regulations for animal protection and were approved by the 
Veterinary Authority of the Radboud University Nijmegen Medical Centre. All testing was 
performed on mice of 8 and 15 months of age between 8:00 a.m. and 17:00 p.m. 
Body and brain weight 
The body weights of the mice were determined one week before the start of the behavioral 
tests. The entire brain without the spinal cord was dissected and weighed directly after 
completing all experiments, respectively at 8 and 15 months of age. Brain weights are 
expressed as a percentage of the total body weight. 
Behavioral analysis 
Behavioral testing was performed in 8 and 15 months-old mice in the following order: First 
open field, then Moms water maze (MWM), followed by reversal MWM and finally the 
12 circular hole board. 
Open field 
To analyze explorative behaviour mice were placed individually in a square open field (L: 
50 cm, W: 50 cm, H: 40 cm) with white Plexiglas walls, and were videotaped for 30 min. 
The durations (s) of walking, wall leaning, rearing, sitting and grooming were scored and 
later analyzed in three blocks of 10 min.These open field parameters were defined as fol-
low: walking, movement of its hind paws and forepaws with a minimal distance of 1 cm, 
wall leaning, standing on its hind legs, the mouse places one or two forepaws against the 
wall, rearing, the mouse stands upright on the hind legs, while the forepaws are not tou-
ching any surface, sitting, no movements of the hind paws and forepaws for a duration of 
2 s, and grooming, washing (parts of) its body. In addition, moving latency, the time before 
starting to move after being placed in the open field, and the total number of faeces during 
the 30 min were recorded. 
By applying a computer-assisted walking pattern analysis [33] the videotaped sessions 
were further used to calculate the total walking distance during the 30 min observation, the 
walking pattern and the time mice spent in the border respectively the centre of the open 
field. 
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Morris water maze (MWM) 
To investigate spatial learning abilities, mice were tested in the Morris MWM. In short, 
mice were placed in a pool (120 cm diameter) filled with water (21-22 °C; made opaque 
by the addition of milk powder) at different starting positions and trained to find the sub­
merged platform by using distant visual cues in the room. On the four walls in the test room 
spatial cues were present at a distance of 0.5 m. To facilitate video camera tracing of the 
mouse, a strip of white tape (width 15 cm) was taped along the top/inside perimeter of the 
pool to prevent dark reflection. The 8 cm diameter round platform was submerged 1 cm 
below the water surface and placed in the middle of the NE quadrant. The latency (sec) to 
find the platform and the time spent (sec) in the training quadrant and the number of cros­
sings of the former platform location (platform crossings) were measured. During all trials 
the researcher was present and always located at the same location in the room. 
Acquisition. 8 and 15 months-old mice performed four acquisition trials (maximal swim­
ming time 120 s; 30 s on the platform; inter-trial interval 60 min) per day during 4 con­
secutive days. Starting positions were: S, N, E, W. After the 2 min swim the mice were 
placed back in their home cage. A paper towel was available inside the cage for additional 
drying. 
Probe. All mice performed a single probe trial at 60 min following the last trial on day 4, in 
which the platform was removed from the swimming pool. Mice were allowed to swim for 
120 s and the time spent swimming and searching in the NE quadrant (where the platform 
had been located) was recorded using a video-tracking computer analysis program made 
by D. Heeren (Radboud University Nijmegen). 
Reverse Morris water maze 
On the day after the standard MWM probe trial, a simplified reversal MWM session was 
performed in which the platform location was changed to SW [34]. In this procedure, ear­
lier locations need to be encoded in the long-term memory. Memory retrieval needs to be 
selective for the most recently learned location, introducing an episodic like component in 
the spatial memory task [34]. Acquisition and probe sessions were performed similar to the 
standard MWM sessions, except that starting positions were: E, W, S, Ν for acquisition and 
the target quadrant was SW. 
Circular hole board 
Spatial learning ability of the mice was also tested in the circular hole board (dry maze) 
similar to a previously described method [35,36] with some minor changes, in short, mice 
were placed in the middle of the 12-circular hole board and were trained to find the escape 
tunnel to their home cage, at a fixed location, by using distant visual cues in the room. The 
spatial cues were present on the four walls in the test room at a distance of 0.5 m. The 
circular hole board consists of a large, white circular board (110 cm diameter) containing 
12 equally spaced holes (4 cm diameter) at a distance of 9 cm from the rim. The maze was 
affixed at 90 cm above the floor by a tripod. The holes can be open (an open escape tunnel 
(s-shaped)) or closed (a closed tube (5 cm depth)). Only in close proximity to the hole, the 
mouse can recognize whether the hole is open or closed. The open escape tunnel ends in 
the home cage of the animal, which is placed underneath the circular hole board. To cor-
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reet for possible odor cues, two additional cages with used bedding material were placed 
underneath the board. 
Habituation and handling During the pre-training, an s-shaped tube is placed inside the 
home cage for the mice to explore (similar tubes are used during the acquisition) The mice 
were handled and habituated to the testing procedure by placing them individually inside 
an open cylinder positioned around a hole with an escape tunnel, allowing the mice to enter 
the escape tunnel freely (within 120 s) during two handling sessions per day for 3 days. 
When animals did not enter freely, they were gently guided into the tunnel. Also, before 
starting the acquisition trials all mice were individually placed once on the board for 5 mm 
with all holes closed 
Acquisition The mouse was placed in an open cylinder in the center of the board with 11 
holes closed and one hole connected to an escape tunnel, at a fixed position in respect to 
the spatial cues, leading to the home cage. After 30 s the cylinder was lifted and the mouse 
could start to search the escape tunnel for maximally 2 mm. During the acquisition trials 
(two trials per day for 7 days) a hole visit was scored when the animal was in contact with 
the hole (closed or open) Two successive visits to the same hole were counted separately 
if the animal visited another hole in between, or moved away over a distance of at least his 
own body length The time to find the escape tunnel in the NW quadrant was registered 
as the escape latency (s), a visit to a closed hole was registered as an error The return to 
the home cage via the escape tunnel is the reward, which serves as a positive motivation 
to learn about the location of the open escape hole. After each trial the board and escape 
tunnel were cleaned and turned in such a way that another hole became the escape hole at 
the fixed NW position 
Probe Each mouse was allowed to explore the hole board, now with all holes closed Du-
ring the 2 mm probe trial the number of holes visited in the NW, NE, SE, SW quadrants 
(each containing three holes) was scored using a video-tracking computer analysis pro-
gram made by D. Heeren (Radboud University Nijmegen). In addition, the percentage of 
hole visits was calculated for each quadrant 
Relative cerebral blood volume measurements 
To assess differences in brain vasculature, relative cerebral blood volume (rCBV) was de-
termined in 8 and 15-month-old mice with a susceptibility-induced contrast MRI technique 
using Ultra Small Particles of Iron Oxide (USPIO) as blood-pooled contrast agent. 
Before starting with the MR measurements, the mice were weighed Following anesthesia, 
all mice received an intravenous tail vein catheter for bolus injections of USPIO During 
the MR experiments mice were anesthetized with 1 9% isoflurane (Abott, Cham, Swit-
zerland) in a mixture of oxygen and N20 (1:2) through a nose cone The composition of 
the mixture was monitored continuously using a gas analyzer (Datascope, Multinex) The 
body temperature was maintained at 37.2 ± 1 2 0C using a heated water pad and monitored 
with a rectal fluoroptic temperature probe. Breathing of the animal was monitored using 
an optical respiratory gating apparatus (Sirecust 401, Siemens) MR measurements were 
performed on a 7 Tesla/200 mm horizontal bore MR spectrometer (Magnex Scientific, 
Abingdon, England) interfaced to a S M I.S. console (Surrey Medical Imaging Systems, 
Surrey, England) The MR acquisition parameters were optimized in normal wild-type 
"0 
mice matched in weight and age to the animals participating in the present study. 
The USPIO contrast agent provides a valuable tool to characterize tissue vascularity since 
it remains intravascular for a prolonged period of time and highly enhances the transverse 
water proton MR relaxation rate (R2*). Previous studies have shown that magnetic sus­
ceptibility effects caused by USPIO can be used to assess relative blood volume within 
tissues [37,38]. In particular, the enhancement in the transverse relaxation rate (AR2*) after 
administration of USPIO, is proportional to the tissue blood volume. 
An elliptical shaped ( 15 χ 11 mm) surface coil was used for excitation and signal reception. 
The image acquisition protocol started with three gradient-echo scout images for slice posi­
tioning. Thereafter, multislice gradient-echo imaging was performed prior to and 1 minute 
after administration of a bolus injection with USPIO (AMI-277, Sinerem®, Guerbet Labo­
ratories, France, 170 μg Fe/mouse). Imaging parameters were: field of view (FOV) of 25 
mm χ 25 mm, matrix size of 256 χ 256, slice thickness of 1 mm, echo time (TE) of 7 ms, 
repetition time (TR) of 2000 ms and 2 averages per image, resulting in a total scan time of 
17 minutes per multislice gradient-echo series. For each animal, pixel-by-pixel AR2* maps 
were obtained from the formula: AR2* =(l/TE)log(S0
bcl/5'„aft), where TE is the echo time, 
and S0 the signal amplitude pre-USPIO {S„
be') and post-USPIO (S^), in the gradient echo 
images. The mean AR2* were calculated by drawing a Region of Interest (ROl) on the 
AR2* maps and averaging the values of all pixels within the ROl. To assess blood volume, 
regions of interest (ROls) that included the entire hippocampus, prefrontal cortex, cerebral 
cortex (all cortical areas above the corpus callosum), diencephalon and the entire brain, 
were drawn on the images. These ROIs are based on the mouse brain atlas of Franklin and 
Paxinos 1997 [39]. The change in AR2* in the hippocampus, cerebral cortex and entire 
brain is proportional to the rCBV in these regions. In some regions, AR2* was not different 
from image noise and therefore assumed to be zero. All algorithms were implemented in 
Matlab (Mathworks, Natick, MA, USA). 
Immunohistochemistry 
Mice (Table 2) were transcardially perfused (after blood sampling via heart puncture) star­
ting with a 0.1 M phosphate buffered saline (PBS) followed by Somogyi's fixative (4% 
paraformaldehyde, 0.05% glutaraldehyde and 0.2 % picric acid in 0.1 M phosphate buffer, 
PB, pH=7.2). Following transcardial perfusion fixation, mice were decapitated and brains 
were removed from the skull. The entire brain, without the spinal cord, was weighed, the­
reafter postfixed for 15 hours at 4 0C in Somogi's fixative and subsequently stored in PB 
at 4° C. Before cutting, the brain tissue was cryoprotected by immersion in 30% sucrose 
in PB at 4 0C. Series of 40 μηι coronal sections were cut through the brain using a sliding 
microtome (Microm HM 440, Walldorf, Germany) equipped with a object table for freeze 
sectioning at -60° C. The Aß load was visualized using WO-2 antibody (mouse anti-hu-
man Αβ4-10, Τ Hartmann, Heidelberg, Germany). Immunohistochemistry was performed 
using standard free-floating labeling procedures. Briefly, after blocking the brain sections 
against endogenous peroxidase with 0.3% H202 in PB the sections were pretreated with 
0.05M sodium citrate solution at 85 0C for 30 minutes. The following steps are carried out 
in Tris buffered saline with 0.5% Triton-X-100 (TBS-T) Monoclonal mouse anti-Aß4-10 
( 1:20.000) was used as primary antibody. The sections were incubated overnight at room 
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temperature on a shaker table Sections were then rinsed thoroughly with TBS-T and trans-
ferred to the solution containing the secondary antibody; donkey-anti-mouse biotin 1 1500 
(Jackson Immuno research). After 90 minutes of incubation the section were rinsed three 
times and transferred to a solution containing Vector ABC-elite 1 800 (Vector laboratories, 
Burlingame) for another 90 minutes After rinsing with TBS-T, visualization of Aß was 
achieved by incubation with 3-3'diaminobenzidine tetra hydrochloride with Ammonium 
nickel sulphate as an intensifier (DAB-Ni solution) After subsequent washing with PB, all 
stained sections were mounted on gelatin-coated slides, dried overnight in a stove at 370C, 
dehydrated in alcohol series, cleared with xylol and mounted in Entellan 
Quantification 
To determine the amount of Aß in the parenchyma of the frontal cortex (prehmbic area 
(PLA)), anterior cingulate gyrus (ACg) and in the hippocampus (CAI, CA3 and dentate 
gyrus (DG)), appropriate sections were digitized and quantified, using a Zeiss Axioskop 
microscope equipped with hardware and software of Microbnghtfield, (Wilhston, USA). 
These cortical regions were chosen because of their large amyloid load in humans and 
transgenic mice and their importance in learning and memory [40,41]. Quantitative ana-
lyses were done with a computer-assisted analysis system (Stereo Investigator) using Ca-
valieri 's probe A contour was drawn along the borders of the hippocampal subregions. In 
the ACg and PLA a square box was placed, within the borders of intended brain areas To 
determine the amount of Aß in the vasculature, a contour was PLA, ACg and in the hip-
pocampus, respectively containing the middle prefrontal branches of the anterior cerebral 
artery, the anterior cerebral artery and the vessels in the hippocampal fissure. Brain regions 
were based on the mouse brain atlas of Franklin and Paxinos 1997 [39] and quantified in 
three sections, with 200 μπι distance between the sections The ACg was quantified at level 
+1.10 up to +0.86 anterior to bregma, PLA was quantified at +1.98 upto +1.78 anterior to 
bregma. The hippocampus was quantified at -2 18 up to -2.46 posterior to bregma 
All measurements were performed double blind by two investigators. Aß load was defined 
as the percentage of area covered by Aß 
Hippocampal atrophy 
In the mice used for immunohistochemistry (Table 2), hippocampal atrophy was measured. 
As a measure for hippocampal atrophy, the thickness of the outer molecular layer of the 
dentate gyrus (DG) was measured in two sections, with 200 μπι distance in between using 
a Zeiss Axioskop microscope, equipped with hardware and software of Microbnghtfield 
(Wilhston, USA). The width of the outer molecular layer of the DG has been measured 
since this layer is subject of age related loss of synapses [42,43] partly originating from 
perforant path afférents from the entorhinal cortex which are affected in AD. 
Serum sterol analysis 
Directly after completion of the behavioral experiments, mice were anaesthetized with 
Nembutal (60 mg/kg, ι ρ ) (Ceva Santa Animals BV, Maassluis) and blood samples were 
collected via heart puncture Serum cholesterol levels and the cholesterol precursor lathos-
terol and its oxidative brain specific metabolite 24S-hydroxycholesterol were measured by 
gas-chromatography-mass spectrometry-selected ionmonitoring (GC-MS-SIM) as descri­
bed in detail previously [44-46]. 
Preparation of brain sterol extracts GC-MS analysis. A subgroup of mice was sacrificed 
to determine brain sterol levels (Table 2). The brains were snap frozen in liquid nitrogen 
and were kept frozen at -80oC. Sterols were extracted overnight by chloroform/methanol 
trimethylsilylated prior to GC-MS-SIM analysis [44,46]. 
Brain fatty acid analysis 
Fatty acid analyses were performed with a part of the homogenate (described above). Total 
lipid was extracted from brain homogenates by methanol and chloroform. Subsequently, 
samples were centrifuged at 3000 rpm for 10 min and the lower phase (chloroform and 
lipids) was removed. Chloroform was added to the upper phase, samples were centrifuged 
again at 3000 rpm for 10 min and the lower phase was combined with the first one. The 
chloroform fractions were dried in a SpeedVac® and 2 ml methanol and 40 μΙ concentrated 
sulfuric acid were added to the dried extract. The samples were heated at 100 "C for 60 min, 
and 2 ml hexane and 0.5 ml 2.5 M sodium hydroxide solution were added. After vortexing 
and centrifuging the samples for 5 min at 3000 rpm, the upper layer was collected and eva­
porated in a SpeedVac®. The fatty acids were dissolved in 125 μΙ iso-octane and analyzed 
on a GC-FID with a CP-S1L88 column (50 m χ 0.25 mm id. 0.22 μπι film thicknesses). The 
n6/n3 ratio was calculated as a sum of analyzed n6 FAs divided by the sum of n3 FA. 
Statistical analyses 
Data are expressed as mean ± SEM and were analyzed with SPSS for windows 12.0 soft­
ware (SPSS Inc. Chicago, IL, USA). The repeated measures ANOVA was used for the open 
field parameters (with the repeated measure: time) and the acquisition phases of the MWM, 
reversal MWM and circular hole board (with the repeated measure: trial block). Multiva­
riate ANOVA's were conducted to analyze possible differences between the two genotypes 
and the different diet groups in the probe trials of the MWM, the reversal MWM and the 
circular hole board. MANOVA's were also applied to body and brain weights and serum 
cholesterol levels. The between group factors were Genotype and Diet. If interactions bet­
ween genotype and diet (between-group-factors) were present, the data were splitted for 
the concerning factor and thereafter analyzed with the MANOVA. To evaluate regional dif­
ferences in Aß load, a one-way ANOVA was used. If no interactions between the genotype 
and diet were present and overall analysis revealed a significant difference, the separate 
groups were analyzed post hoc by using Tukey's HSD test. For clarity reasons, F-values are 
only displayed for the behavioral studies. Statistical significance was set at p< 0.05. 
Results 
Body and brain weight 
All mice were weighed one week before starting the behavioral test battery. Body weight 
was not affected by genotype or diet at either 8-months or 15-months. Overall mean body 
weight was 32.4 ± 0.4 g in the 8-month-old mice and 44.0 ± 0.6 g in the 15-month-old 
group. Relative brain weight was not affected by genotype or diet in both 8- and 15-month-
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old mice. Overall mean brain weight was 1.60 ± 0.03 % of total body weight in the 8-
month-old mice and 1.17 ± 0.03 % in the 15-month-old group. Absolute brain weights did 
not differ between the age groups either. 
Behavioral Testing 
Open field 
In the open field locomotion activity and active exploration parameters (walking, sitting, 
wall leaning, rearing) and grooming are scored for 30 minutes divided in three blocks of 
10 minutes. 
8-month-old mice 
During the 30 min of observation, both in wild type and APP/PS1 mice the time spent wal-
king (F(2,120)=66.70, pO.OO 1 ) and wall leaning (F(2,120)=26.48, p<0.05) decreased (Fig. 
1 A,D), whereas sitting (F(2,120)=44.53, pO.OOl), rearing (F(2,120)=26.48, pO.001) and 
grooming (F(2,120)=6.83, pO.01) increased (Fig. 1B,C and E). 
8-month-old APP/PSl mice were more active in the open field than wild type mice (Fig 1): 
APP/PSl mice walked more (Fig. 1A: F(l,60)=23.61, pO.OOl), traveleda longer distance 
(F(l,60)=29.66, pO.OOl) and sat less (Fig. IB: F( 1,60)= 18.71, pO.OOl) than wild type 
mice. APP/PSl mice spent less time rearing (Fig. 1C: F(l,60)=14.30, pO.OOl), and more 
time leaning (Fig. ID: F(l,60)=6.36, pO.05) than wild type mice. No differences were 
observed in the time spent grooming (Fig. IE) or the frequency of defecation (Fig. IF) 
between the genotypes. Dietary intervention for 6 months, with either the DHA enriched or 
the Typical Western Diet (TWD) did not alter any of the open field parameters. 
15-month-old mice 
Like at 8 months, the time spent walking (Fig. 2A: F(2,118)=60.86; pO.OOl) decre-
ased whereas the time spent sitting (Fig. 2B: F(2,118)=15.61; pO.OOl), rearing (Fig.2C: 
F(2,l 18)=42.56; pO.OOl) and grooming (Fig. 2E F(2,118)=7.06; pO.OOl) increased over 
time in both wild type and APP/PSl mice. However, the increase in rearing over time was 
significantly less in APP/PSl mice compared to wild type mice (F(2,l 18)=1.76; p=0.05), 
indicating less habituation to the new situation. 
Compared to wild type mice, APP/PSl mice spent less time sitting (Fig 2B; F(l,59)=5.48; 
pO.05), more time walking (F(l,59)=7.11; pO.01), and they traveled a longer distance 
(F(l,57)=25.72; pO.OOl ) and spent less time in the centre of the open field (F(l,57)=4.73; 
p<0.05). Furthermore, APP/PSl mice showed less rearing (Fig 2C; F(l,59)=9.90; pO.01) 
and more wall leaning behavior (Fig 2D; F(l,59)=25.13; pO.OOl). Grooming was not 
affected by genotype. Finally, APP/PSl mice showed increased frequency of defecation 
during the testing phase (Fig 2F, F(l,57)=6.33; pO.01), indicating a higher anxiety level. 
Altogether, these data show increased activity and anxiety in transgenic APP/PSl mice 
compared to wild type mice. No behavioral differences regarding all open field parameters 
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Fig.l. Open Field behaviour in 8-month-old APP/PSl and wild type mice. 
Different open field parameters were measured within a 30 min period, and scored in three IO min 
trial blocks. A) duration of walking, B) duration of sitting, C) duration of rearing; i.e. standing on 
the hind paws, and exploring the environment, D) duration of wall leaning, E) duration of grooming 
and F) frequency of defecating. APP/PSl mice spent more time walking (p<0.00l) and wall leaning 
(p<0.05), and spent less time sitting (p<0.001) and rearing (p<0.001) compared to wild type mice. 
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Fig. 2. Open Field behaviour in 15-month-old APP/PSl and wild type mice. 
Different open field parameters were measured within a 30 min period, and scored in three 10 min 
trial blocks. A) duration of walking, B) duration of sitting, C) duration of rearing; i.e. standing on 
the hind paws, and exploring the environment, D) duration of wall leaning, E) duration of grooming 
and F) frequency of defecating. APP/PSl mice spent more time walking (p<0.01) and wall leaning 
(p<0.001) and defecated more (p<0.02), and spent less time sitting (p<0.02) and rearing (p<0.003) 
compared to wild type mice. Values represent the mean and SEM. * p<0.05. 
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Morris waler maze (MWM) 
The Morris water maze is designed to test spatial learning by training the mice to find a hid-
den platform (acquisition phase). Spatial memory is tested in a trial in which the platform is 
removed from the maze (probe trial) directly following the acquisition phase. 
8-month-old mice 
Both APP/PSl and wild type mice showed a decrease in escape latency during training 
(Fig. 3A: F(7,420)=39.00, pO.001). Escape latencies did not differ between the wild type 
and the APP/PSl mice (Fig. 3A), indicating that spatial learning was not affected by geno-
type in 8-month-old mice. No effects of diets were found. 
Wild type mice tended to spend more time in the platform quadrant (NE) during the probe 
trial than APP/PS1 mice (Fig 38: F( 1,60)=3.73, p=0.058), but neither group deviated from 
25% chance performance (wild type 26.7 ± 1.4%, APP/PSl 23.1 ± 1.2%) indicating no 
memorization of the platform location . No effects of diets on probe test performance were 
noted. 
15-month-old mice 
Both wild type and APP/PS 1 animals learned to find the platform during acquisition, as in-
dicated by a decrease in latency over trials (Fig. 3C: F(7,385)=23.31; p<0.001). However, 
APP/PSl mice needed more time to find the platform than the wild types (F(l,55)=6.2; 
p<0.05). Diet did not change MWM acquisition. 
During the probe trial, APP/PSl mice spent less time in the NE target quadrant compa-
red to their wild type littermates (Fig. 3D: F(l,50)=22.45; pO.001) irrespectively of diet. 
Since APP/PSl mice spent only 20.9 ± 1.1% in the target quadrant, which is less than the 
25%) chance level, these results indicate that APP/PS 1 mice did not remember the location 
of the platform at all. The number of platform crossings was also lower in APP/PSl mice 
compared to wild types (Wild type 5.2 ± 0.4, APP/PSl 3.6 ± 0.5; F(l,50)=4.53; p<0.05), 
reflecting impaired spatial memory as well. 
Interestingly, transgenic animals fed a DHA diet, spent more time in the target quadrant 
during the probe trial compared to transgenic mice fed STD diet (F(2,24)=4.27; p<0.05; fig 
3F) indicating improved memory due to DHA. This dietary effect was not found in wild 
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Fig. 3. Spatial learning and memory in the Morris water maze. 
Spatial learning was measured in a 4 day acquisition phase (A, C and E) by determine the latency 
to find a hidden platform. The spatial memory was tested in the probe phase (B, D and F) in which 
the % of time spent in the north east (NE) quadrant (i.e. where formerly the platform had been lo­
cated), was measured. A) acquisition phase of 8-month-old wild type and APP/PSl mice, B) probe 
trial of 8-month-old wild type and APP/PSl mice. C) acquisition phase of 15-month-old wild type 
and APP/PSl mice, D) probe trial of 15-month-old wild type and APP/PSl mice. E) DHA effects 
in the acquisition phase of 15-month-old wild type and APP/PSl, F) DHA effects in the probe trial 
of 15-month-old APP/PSl mice. Values represent the mean and SEM. # trendp=0.058, * p<0.05, 
a=different from STDftg). 
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Reverse Morris water maze 
In the reverse Morris water maze, mice have to learn to find a novel position for the hidden 
platform. This task is considered to be a test for new learning abilities, in which a previous 
successful strategy must be inhibited and a new strategy should be developed. 
8-month-old mice 
The wild type animals showed a significant decrease in escape latency over the time in 
the acquisition phase (Fig. 4A: F(3,90)=7.46; pO.001), indicating spatial learning (Fig. 
4A). The APP/PSl mice in contrast, did not show a significant decrease in escape latencies 
(Fig.4A), 
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Fig. 4. Spatial learning and memory with an extra episodic memory component in the reversal Mor­
ris water maze. 
Spatial learning and memory with an extra episodic memory component in the reversal Morris wa­
ter maze. Spatial learning was measured in a 2 day acquisition phase in 8-month-old mice (A) and 
15-month-old mice (C), by determine the latency to find a hidden platform in the south-west (SW) 
quadrant. The spatial memory was tested in the probe phase in both 8-month-old mice (B) and 15-
month-old mice (D), in which the % of time spent in the quadrant where the platform formerly was 
located and the other quadrants was measured. Values represent the mean and SEM. * p<0.05, 
2=differenl form north-west (NW) quadrant, 3= different form north-east (NE) quadrant, 4= dif­
ferent from south-east (SE) quadrant. 
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indicating that these mice had problems learning to find the new SW platform location, 
and showed indeed longer escape latencies compared to wild type mice (F(l,60)=3.90; 
p<0.05). Analyses of the probe test revealed that wild type mice spent significantly more 
time swimming and searching in the "right" SW quadrant compared to APP/PS1 mice 
(F(l,60)=16.43; p<0.001), indicating a better new learning ability. Although both groups 
of mice spent more than 25% of their time in the SW quadrant, indicating that both groups 
remembered the new platform location, the wild type mice performed better. No dietary 
effects were found in the probe test. 
15-month-old mice 
In the acquisition phase, wild type mice showed decreased latencies over time 
(F(3,108)=7.53; pOOOl (Fig 4C). In contrast, escape latencies tended to increase in APP/ 
PS1 mice (Fig. 4C; F(3.57)=2.74 p=0.05), due to unexpected low latencies at the initial 
trials. In spite of that, there was no difference in average escape latencies between the 
APP/PS1 and wild type animals. In addition, like in the 8-month old mice, no significant 
dietary effects were found. 
The probe trial (Fig. 4D) revealed that both wild types and APP/PS1 mice learnt to locate 
the platform, since they spent more time than the 25% chance level in the SW target qua-
drant. There was no significant difference in spatial memory between wild type and APP/ 
PS1 mice in time spent in the SW quadrant. Nevertheless, APP/PS1 mice did perform a bit 
worse, since they showed a preference for both SW and SE, indicating that they did not 
learn the new task as good as the wild types. Similar to the 8-month old mice, no significant 
dietary effects were found. 
The 12 circular hole board 
In order to confirm spatial learning and memory ability without swimming related stress 
factors, the 12 circular hole board was performed. 
8-month-old mice 
Latencies to find the escape hole decreased during the acquisition trials irrespective of 
genotype (Fig. 5A; F(6,35)=15.81; p<0.001). Spatial learning acquisition did not reveal 
differences between the genotypes. In the probe test wild type mice spent 36.4 ± 2.0 % of 
their time in the target quadrant, which is significantly more compared to the other three 
quadrants (NW-SE pO.001, NW-SW pO.001, NW-NE pO.001), indicating that wild 
type mice memorized the location of the platform. In contrast, APP/PS1 mice spent only 
29.4 ± 2.3 % of their time the NW quadrant, which was not significantly different from the 
25% chance level (Fig. 5B). 
More importantly, compared to wild type mice, the APP/PS1 mice spent significantly less 
time in the target quadrant (F(l,59)=5.09; p<0.05). This result was fortified by the number 
of visits (F(l,59)=3.96, p<0.05) with wild type mice visiting 33.8 ± 1.6% holes in the NW 
quadrant, compared to the 28.7 ± 1.9% of the visits to holes in the NW quadrant made by 
APP/PS1 mice. Both findings point to impaired spatial memory in APP/PS1 mice. Diets 
did not affect 12CHB performance in either the acquisition or the probe phase. 
15-month-old mice 
Both transgenic and wild type animals showed decreasing escape latencies during the ac-
quisition of the task (Fig. 5C: F(6,120)=9.03 pO.001 and F(6,120)= 15.48 pO.001), but 
NO 
the mean latency was higher in APP/PSl mice (F(l,56)=12.61 pO.OOl), indicating im-
paired spatial learning in APP/PSl mice. In the probe test (Fig. 5D) wild type mice spent 
significant more time in the NW-quadrant compared to the three remaining quadrants (all 
p<0.001) showing good spatial memory. This was in contrast to APP/PSl mice which 
did not spent significantly more time in the NW-quadrant, indicating that APP/PSl mice 
did not memorize the location of the escape hole. More importantly, APP/PSl mice spent 
significantly less time in the correct quadrant compared to the wild types (F(l,56)=4.69 
p<0.05). No diet effects were detected in the acquisition or probe trial in the 15-month-old 
mice. 
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Fig. 5. Spatial learning and memory in the 12 circular hole board test. Spatial learning was measu­
red in a 7 day acquisition phase in 8-month-old mice (A) and 15-month-old mice (C) by determining 
the latency to find a hidden platform in the north-west (NW) quadrant. The spatial memory or memo­
ry retention was tested in the probe phase in both 8-month-old mice (B) and 15-month-old mice (D), 
in which the % of time spent in the quadrant where the platform formerly was located and the other 
quadrants was measured. Values represent the mean and SEM. *p<0.05. 1 =differentform south west 
(SW), 3= different form north-east (NE) quadrant, 4= different from south-east (SE) quadrant. 
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Relative cerebral blood volume (rCBV) 
To explore regional differences in rCBV in the brain, a susceptibility-induced contrast MR 
imaging technique was used. 
8-month-old mice 
In 8-month-old mice no significant differences were found in rCBV in either the diencep-
halon, prefrontal cortex or the hippocampus between wild type and APP/PSl mice. In the 
cerebral cortex no differences were observed in rCBV between STD(wt) and STD(tg) mice 
(Fig. 6A). 
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Fig. 6. Relative cerebral blood volume (rCBV) in the brains of wild type and APP/PSl mice. 
Changes in AR2 * relaxation after injection of ultra small particles of iron oxide (USPIO) was measu-
red in A) 8-month-old mice, and B) 15-month-old mice. The change inAR2* is proportional to rCBV. 
Values represent the mean and SEM. * p<0.05, a= different from STD fed mice, p<0.05. 
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However, diet effects were observed in the cerebral cortex. Wild type mice fed the DHA 
diet showed an increased rCBV compared to mice fed the STD diet (mean DHA(wt) 127,3 
± 3.5%, mean STD(wt) 100.0 ± 7.2%, pO.01). APP/PSl mice fed the DHA diet in con-
trast, showed a significant decreased rCBV compared to APP/PSl mice fed the STD diet 
(mean DHA(tg) 88.3 ± 2.3%, mean STD(tg) 119.6 ± 5.8%, p<0.05). Dietary intervention 
with either the DHA enriched or the TWD did not alter rCBV in any of the other brain 
regions. 
15-month-old mice 
15-month-old APP/PSl mice fed the STD diet showed a significant decrease in rCBV 
compared to their wild type littermates in the cerebral cortex (Fig. 6B; p<0.05). The hippo-
campus showed a comparable decrease in rCBV as found in the cortex (29%), although not 
significant. Furthermore, some diet effects were observed. Mice fed the TWD diet showed 
a significant decreased rCBV compared to mice fed the STD diet (p<0.05). This effect was 
most pronounced in the wild type mice (p<0.01). Also a small DHA diet effect was seen 
in APP/PSl mice. DHA(tg) mice showed a 14% bigger rCBV compared to TWD(tg) mice 
(p=0.058). No dietary effects were found in any of the other brain regions (hippocampus, 
diencephalon and prefrontal cortex). 
Amyloid-ß load 
In cortical regions (prelimbic area (PLA), anterior cingulate gyrus (ACg)) and in hippo-
campal regions (CAI, CA3 and dentate gyrus (DG)) both the parenchymal and vascular 
Amyloid-ß (Aß) load was determined. The brains of all mice were immunohistochemically 
stained with WO-2 antibody (mouse anti-human Aß4-10). Wild type mice showed no im-
munoreactivity with this antibody, while Aß deposits in transgenic mice were intensively 
stained. 
8-month-old mice 
8-month-old APP/PSl mice showed some regional variation (Fig. 7A; p<0.001) in the 
Aß plaque burden in the parenchyma, such that the DG showed a significantly higher Aß 
plaque load (p<0.001) compared to all other regions, directly followed by the cingulate gy-
rus. (p<0.002). In the DG approximately 4.7% of the total area was covered with plaques, 
compared to 2.3% in the ACg, 0.77% in the CAI, 0.5% in the CA3 and 1.22% in the PLA. 
No diet effects could be observed on vascular or parenchymal Aß. 
15-month-old mice 
In 15-month-old APP/PSl mice regional variation in Aß plaque load was observed as well 
(Fig 7 A; pO.001). Again, the DG showed the highest amount of Aß plaques compared to 
the GC (p<0.01), the CA3 (pO.001), CAI (pO.001) and PLA area (pO.001). 
Aß depositions covered 21.3% of the DG compared to 18.0 % in the ACg, 10.5% in the 
CAI, 9.3% in the PLA and 3.7% in the CA3. These results indicate that the DG, directly 
followed by ACg, is most vulnerable to Aß dposition. In addition an overall main diet ef-
fect was observed in the ACg (Fig. 7B; p<0.05); where DHA decreased the Aß load com-
pared to STD (Fig 7D,E and F; p<0.05). The TWD diet seemed to decrease the amount of 
parenchymal Aß as well, but this effect was not significant. 
The DHA diet also diminished the amount of vascular Aß in the PLA compared to mice fed 
the TWD diet (Fig. 7C, G and H and I; p<0.05). All together, these results indicate that the 
DHA diet diminished the amount of Aß. 
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Fig. 7. ß-amyloid pathology in the brains of APP/PSl mice. 
A) regional distribution of Aß in the cerebral parenchyma in 8 and 15-month old APPPS1 mice. 
The dentate gyrus (DC) exposes the highest Aß load compared to all other areas (CAI, CA3, cin-
gulate gyrus (ACg). prelimbic area (PLA)) in both the 8 and 15-month old mice. B) the DHA con-
taining diet decreases the amount of parenchymal Aß load in the cingtilate gyrus of 15-month-old 
APP/PSl mice. C) the DHA containing diet decreases the amount of vascular Aß in the prelimbic 
area (PLA) of 15-month-old APP/PSl. Values represent the mean and SEM. a= different from STD 
fed mice, c=different from TWD fed mice, p<0.05.D,E,F) Representative examples of parenchymal 
amyloid load in the cingulate gyrus of 15-month-old mice (D= Overview, 2.5x; E=STD(tg), Wx 
and F=DHA(tg), Wx) G.H,1) Representative examples of the vascular amyloid load in the PLA 
(G=overview, 2.5x; H=STD(tg), 40x andI=DHA(tg), 40x). 
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Atrophy 
To determine whether atrophy of the hippocampus occurs in APP/PSl mice the width of 
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Fig. 8. Width of the outer molecular layer of the DG, as a measure of hippocampal atrophy. Values 
represent the mean and SEM. *p<0.05. 
8-month-old mice 
In 8-month-old mice we did not observe differences in the width of the outer molecular 
layer of the DG between wild type and APP/PSl mice (Fig. 8). Also no effects of either a 
TWD or DHA diet were observed. 
15-month-old mice 
15-month-old APP/PSl mice however, showed a 15% thinner outer molecular layer of 
the DG compared to their age matched wild type littermates (Fig. 8). No diet effects were 
observed. 
Serum and brain sterols 
8-month-old mice 
As shown in Table 3, brain and serum sterol levels did not change due to genotype. Howe­
ver, serum cholesterol levels did increase due to the cholesterol containing TWD diet in 
both wild type and APP/PSl mice (pO.Ol). 
In addition, serum lathosterol, a main cholesterol precursor in the "de novo" synthesis pa­
thway, significantly decreased in TWD fed mice (p<0.001), and the cholesterol elimination 
rate from the brain, measured by serum 24S-OH-cholesterol levels decreased in mice fed 
the TWD diet (pO.001). Further, the TWD diet did not alter brain lathosterol, 24S-OH-
cholesterol or cholesterol levels. 
The finding that brain cholesterol did not change, indicates that there is not much trans­
port of cholesterol across the blood brain barrier. The DHA diet also did not alter brain 
cholesterol levels, but did reduce brain lathosterol levels (p<0.05), indicating diminished 






In 15-month-old mice no genotype effects were found in serum lathosterol nor 24S-OH-
cholesterol levels (Table 3). Serum cholesterol levels did not differ between the genotypes 
as well, except for mice fed a TWD diet. Mice fed a TWD diet showed an interaction bet­
ween diet and genotype for serum cholesterol levels (p=0.05) and a split file test revealed 
that this interaction is present because of a genotype effect (p=0.05). Like at 8 months the 
TWD diet, increases the serum cholesterol in both wild type and APP/PS1 mice (p<0.001). 
Thus, a TWD diet increases serum cholesterol, but the effect is significant larger in APP/ 
PS1 mice compared to wild types. Also serum 24S-OH-cholesterol levels increase due to a 
TWD diet (p<0.001), but no interaction between genotype and diet could be observed. The 
cholesterol synthesis precursor lathosterol, decreased as a result of a TWD diet in serum of 
both wild types and APP/PS1 mice (pO.001). 
The brain cholesterol concentration decreased in 15-month-old APP/PS1 mice compared 
to wild type mice (p<0.005). No changes in brain sterol levels due to the TWD or DH A diet 
were observed in 15-month-old mice. 
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a=dilTercnt from STD(wt), h=dirrerent from DHA(»t), d=dilTerenl from STD(lg), e=dilTerent from DHA(tg). ). * 
indicates (he presence of an interaction between genotype and diet ( p=0.05). This interaction is present because 
of a genotype effect (p=0.()5) in mice fed the TWO diet. 
Ν 6 
Brain fatty acids 
8-month-old mice 
The relative concentrations of different fatty acids (FA) in brain tissue of 8 and 15-month-
old mice are shown in Table 4. APP/PSl and wild type mice fed the DHA containing diet 
showed a shift in the balance between n3 and n6 fatty. The relative amount of n3 FA in 
DHA fed mice increased compared to the STD and TWD groups (pO.001), whereas the 
relative amount of n6 decreased (p<0.001) resulting in a pronounced shift in the n3/n6 ratio 
in DHA fed mice in favor of the n3 (p<0.001). The reduction in the relative n6 content was 
mainly caused by the decrease in arachidonic acid (20:4n6, (pO.001), while the higher n3 
content originated from an increase in relative DHA (22:6n3, p<0.001) content. 
1 S-month-old mice 
In 15-month-old mice (Table 4), a similar shift in the balance between n3 and n6 fatty 
acids in DHA fed mice was observed. Again, the amount of n3 fatty acids in DHA fed mice 
increased compared to the STD and TWD groups (p<0.001), whereas the amount of n6 
decreased (p<0.001). 
In contrast to the 8-month-old group, 15-month-old APP/PSl mice showed a significant 
increase in n6 fatty acids (p<0.05) irrespective of diet, and consequently a decreased n3/n6 
ratio (p<0.05). 
Table 4. Relative fatty acid composition % of the lipid fraction of brain homogenates of Sand 15/moiith-old 
wild type and APP/PSl mice on various diets 
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a=different form STD(wt), c=different from TWD(wt), d=different from STD{tg), Indiffèrent from TWD(tg). 
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Discussion 
The present data show that the DHA-enriched diet altered rCBV in 8-month-old APP/PS1 
and wild type mice. In addition, 15-month-old APP/PS1 mice fed DHA-enriched diet for 
more than a year showed improved spatial memory, decreased parenchymal and vascular 
Aß in the brain and a slightly increased relative cerebral blood volume (rCBV), indicating 
that a DHA-enriched diet may diminish aggravation of Alzheimer-like pathology. In con-
trast, a TWD diet may increase AD development by decreasing the rCBV in 15-month-old 
mice, and increasing the amount of Aß depositions at a later stage as shown in our previous 
study [15]. Furthermore, the effects of the tested diets on vascular parameters were ob-
served before effects on Aß load were noted, indicating that the DHA and TWD diets may 
influence AD-like pathology by initially changing the cerebral circulation. 
Genotype 
The most obvious and first appearing clinical sign of late onset AD is memory impair-
ment. A mouse model featuring this characteristic early in the disease development would 
be very useful in AD research. In this study APP/PS1 mice already show cognitive im-
pairment at the age of 8 months in combination with amyloid-ß deposition and increased 
activity and decreased explorative behavior compared to their wild type littermates. The 
increased activity is a specific characteristic of many APP transgenic mice [47-49] and may 
be explained as either a results of elevated anxiety levels [49,50] or impaired habituation 
learning [47,48],[51]. In our view increased anxiety is most likely, since the 8-month-old 
APP/PS1 mice showed also less rearing (exploring the environment), but more impor-
tantly, at the age of 15 months the APP/PS1 mice spend less time in the centre of the open 
field accompanied by increased defecating (i.e. anxious mice prefer the border of the field 
and defecate more [52,53]). Increased anxiety and restlessness, as noticed as hyperactivity 
in mice, also occur in AD patients [54,55]. 
At the age of 8 months, APP/PS1 mice also showed impaired spatial reversal learning. 
The reversal task requires selective memory retrieval of the newly learned location of the 
platform, and contains therefore a extra episodic component [56]. Since episodic memory 
impairment is a major characteristic in early AD [57-59] our results in APP/PS1 mice re-
semble the problems that are present in early AD patients. 
Initial spatial memory (i.e. without the extra episodic component) in contrast, is diminished 
in both 8 and 15-month-old mice. However, at 15 months of age, differences in cognition 
are more aggravated; i.e. compared to the 8-month-old mice, spatial learning is impaired in 
both the MWM and the 12 circular hole board, and in the probe of the MWM a significant 
decrease in spatial memory in 15-month-old APP/PS1 mice is present as well. Further, we 
noticed that transgenic mice do not show learning in the reverse MWM acquisition phase 
but did perform better in the first 2 acquisition trials compared to their wild type litterma-
tes. Because the MWM results show that APP/PS1 mice have a preference for both the SE 
and SW quadrants, and the platform was moved to the SW quadrant in the reversal task, 
the better performance of the APP/PS1 mice in the first 2 trials might be a coincidence. 
This preference probably does not interfere with our MWM results, since despite the prefe-
rences to the SE and SW quadrants, the mice still learned to locate the platform in the NE 
SX 
quadrant. The preferences for the above mentioned quadrants will likely only have made 
the spatial learning task a bit harder. 
Besides cognitive impairment, we also found a relative increase in cerebral omega-6 fatty 
acid content, which is thought to increase the risk for AD in man [60,61], and decreased 
brain cholesterol levels in the 15-month-old APP/PS1 mice compared to their wild type 
littermates. It could be suggested that the decrease in cholesterol levels are a consequence 
of increased brain export as indicated by a trend toward a increase in serum 24s oxysterol 
levels in 15-month-old AFP/PS 1 mice. Either way, these observations and literature in AD 
raises questions about the use of cholesterol lowering statins. There are studies showing 
that brain cholesterol levels are also decreased in AD patients [62,63] and reviewed in 
[64]), and serum cholesterol levels might thus not reflect the cholesterol status of the brain. 
Further lowering of brain cholesterol with lipophilic statins, which cross the blood-brain 
barrier, might even accelerate disease development, despite helping some aspects of AD 
pathogenesis (APP processing, famosylation, etc.). The decrease in cholesterol levels may 
also be caused by Aß related oxidation [65,66]. Oxidation of cholesterol plays an important 
role in atherogenesis and is indicated as a pathogenic event in AD [65,66]. Thus, increased 
cholesterol oxidation can cause increased atherosclerosis, which in turn may induce hypo-
perfusion in the brain, aggravating AD development. Indeed the rCBV in the 15-month-old 
AFP/PS I mice decreased compared to the wild type mice. 
Various studies in elderly and AD patients have shown that both cerebral blood flow (CBF) 
and CBV are diminished [15]. It has been shown that CBF diminishes with age [67,68] 
and that the effects are even more pronounced in AD patients, especially in the parietal and 
temporal cortices [69]. In our 15-month-old mice, the rCBV did alter in these regions as 
well, but in addition shows a slight decrease in the hippocampus. Together, these results 
indicate that the AFP/PS I mouse model is a good model to study cognitive impairment but 
also AD related hypoperfusion of the brain. 
A reduction in rCBV may be caused by a reduction in capillaries, however, previous re-
search with 18-month-old AFP/PS 1 mice has shown no changes in capillary density [70]. 
Another study has shown a reduction in capillary segments, in the white matter of AFP/PS I 
mice [71] and we in contrast have found differences in CBV only in the gray matter. 
A second possibility is that a reduction in rCBV in AFP/PS 1 mice is caused by enhanced 
vasoconstriction, possibly mediated by Aß deposition in the vasculature [72,73]. Vascular 
Aß has previously been suggested to have a vasoactive role through the production of free 
radicals [72,74]. The effect of Aß on vasoregulation was also strengthened by the observa-
tion that Aß interacts with endothelial cells in the rat aorta causing increased production of 
superoxide radicals leading to enhanced contraction [75]. Enhanced vasoconstriction may 
cause hypoperfusion of specific brain regions [76] leading to cerebrovascular dysfunction 
and subsequent neuronal loss and degeneration [76-78]. Hence, these vasoactive mecha-
nisms can be an important factor in the pathogenesis of AD. 
We have also determined the Aß load and the amount of hippocampal atrophy in AFP/PS 1 
mice. From 8 up to 15 months of age the amount of Aß increased fivefold in the DG. The 
DG contains the highest amount of Aß in both the Sand 15-month-old AFP/PS 1 mice com-
pared to all other brain regions. This sensitivity of the DG is similar to human AD patho-
logy where Aß depositions appear first in the hippocampus and especially the DG [79-81]. 
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The DG is also the area first affected with neuronal dysfunction [81,82] It is therefore not 
surprising that we also find hippocampal atrophy in the brains of 15-month-old APP/PS1 
transgenic mice The sensitivity of the DG for AD pathology is also fortified by the obser-
vation that between 8 and 15 months of age, the width of the outer molecular layer of the 
DG increases in wild type mice (i e probably due to growth), whereas APP/PS1 mice do 
not show this increase, which may indicate atrophy in this area or less growth 
Taken together, we observe the highest amount of Aß levels in the DG of the hippocampus 
in both 8 and 15-month old mice, a decreased rCBV in the cortex and hippocampus, and 
hippocampal atrophy in 15 month-old mice These results indicate that in the APP/PS1 
mice the hippocampus is heavily affected, which support our finding that spatial learning 
and memory are also impaired since they are both dependent on hippocampal functio-
ning 
It is however unclear, which parameter (i e rCBV, Aß or hippocampal atrophy) is responsi-
ble for the cognitive impairment and it is likely that all contribute to cognitive impairment 
together Many researchers have indeed shown that AD should not be seen as a single no-
sological entity [83] However, Aß deposition must be involved, since at 8 months of age 
both Aß deposition and cognitive impairment are already present at the same time, without 
changes in rCBV or atrophy 
This conclusion indirectly reinforces the amyloid hypothesis in which accumulation of Aß 
in the brain is suggested to be the primary influence driving AD pathogenesis [1] However, 
it has also been shown that cerebral hypoperfusion, due to for example occlusion of the 
carotid arteries of rats, impairs spatial learning and memory as well [84-87] All together, 
it could be hypothesized that aggravation of the disease only happens when changes in the 
brain circulation develop which are followed by cell death and hippocampal atrophy 
Diet effects 
Both wild type and APP/PS1 mice received a TWD diet containing 1% of cholesterol, a 
DHA enriched diet, or a control/ STD diet Besides these obvious components such as 
cholesterol and DHA, the experimental diets slightly differ from each other in the amount 
of SFA and n6/n3 ratio 
However, a study from Oksman (Oksman et al, 2006), performed with the same mice 
showed that a diet with comparable high concentrations of SFA and increased n6/n3 ratio 
did not influence behavior, cognition or the amount of Aß deposition compared to their 
standard diet which has exactly the same composition as our STD diet In addition, conver-
sion of hnolenic acid from soy oil into DHA, and the natural occurrence of cholesterol in 
the different oils is minimal Our DHA-ennched diet also contains a small amount of the 
omega-3 fatty acid Eicosapentaenoic acid (EPA) 
DHA is the most important omega-3 fatty acid in brain tissue, whereas both DHA and 
EPA are known for their effects on the vasculature Because of the large amount of DHA 
compared to EPA (almost 5 1) it is most likely that the effects are due to DHA instead of 
EPA Thus, the largest differences between the t experimental diets lay in the cholesterol 
and DHA content, which suggests that these dietary ingredients are responsible for the 
observed differences due to the experimental diets in our mice 
% 
TWD Diet 
The hypothesis that the rCBV is important in aggravating or declining symptoms of AD 
is strengthened by the effects of diets found in this study. During the use of a cholesterol 
containing diet, the rCBV is the first parameter changing, and this seems also to be the case 
in mice fed the DHA diet (Table 5). 
15-month-old mice fed the cholesterol containing TWD diet, show increased serum cho-
lesterol levels, and decreased rCBV. This decrease in rCBV, likely causing hypoperfusion 
of the brain, may be the result of by an aggravation of the vasoconstriction induced by Aß 
depositions [72,73,75]. Nevertheless, it can also be caused by atherosclerosis. It has been 
shown that AD patients show atherosclerosis in both intracranial and extracranial ves-
sels [88,89]. Atherosclerosis is suggested to be a primary event in the development of AD 
[88,89], and can therefore be the trigger for aggravation of AD symptoms. However, it is 
also possible that atherosclerosis and Alzheimer's disease are independent but convergent 
disease processes [90]. 
In addition, our previous research in 18-month-old mice fed similar TWD diets for a year 
[13] shows that rCBV decreased alongside an increased Aß deposition in the DG. These 
results together with the decrease in rCBV in 15-month-old mice fed TWD as found in this 
study, indicate that a TWD diet first changed the cerebral circulation before altering the 
histologically detectable Aß load. Theoretically it is still possible that small oligomeric Aß 
aggregates are involved in initiating AD pathogenesis. 
However, a study from Bennett et al [91], showed that also smaller biochemical detected 
Aß fragments increase as a consequence of an impaired circulation, and indirectly streng-
thens our conclusion that vascular abnormalities precede Aß deposition. 
A relation between high serum cholesterol levels and cognition, is found by Cao et al. 
[92] who have shown that hypercholesterolemic Tg2576 mice show more spatial learning 
deficits than normal transgenic Tg2576 mice after the manifestation of Aß deposition [92]. 
This finding in combination with our results indicates that a TWD diet possibly aggravates 
AD pathology already at 15 months, but may alter cognition at a later age (Table 5). 
Besides this major conclusion , we also noticed a larger effect of a TWD diet on plasma 
cholesterol levels in 15-month-old APP/PS1 micecompared to the age matched wild types. 
We did not find larger effects of a TWD diet on lathosterol and 24-OH cholesterol levels 
in transgenic animals which could have explained the difference found in serum choles-
terol levels via an affected brain cholesterol metabolism. Also literature [64,93] does not 
report increased serum cholesterol levels in AD patients compared to healthy subjects. We 
therefore have no other explanation further than that it might be an epiphenomenon of the 
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DHA Diet 
The effect of DHA supplementation upon the order of events in the currently used model 
is a bit less clear since spatial memory was improved, the amount of vascular and paren-
chymal Aß decreased, and the rCBV slightly increased in APP/PSl mice at 15 months of 
age. The sequence of events is therefore not clear. However, in 8-month-old mice, there are 
some changes in rCBV present. Although it is unclear why the rCBV reacts oppositely on 
DHA diet in the 2 different genotypes, it is clear that DHA may affect the rCBV at a very 
early age, at which diet-induced changes in Aß load were not yet detected. 
Our finding that a DHA containing diet improves spatial memory in APP/PS1 mice, is con-
firmed by others in both mice [28,94] and rats [95]. However, there are also some reports 
showing no effects of DHA on behavior or cognition [26,96]. Both research groups did not 
find any differences in spatial learning and memory, but this could be explained in the Oks-
man case by the fact that they studied the mice at a much younger age, i.e. 10 months, and it 
could be suggested that DHA benefits take a longer supplementation time to establish their 
effects, than the 4 months used in Oksman's study. In addition, studies in which a DHA-
enriched diet was supplemented might have suffered from oxidation of DHA in the food 
aliquots, which may have accounted for a reported lack of efficacy. In order to minimize 
oxidation of DHA in our study, the experimental diets were stored at -20 0C in 2-day sup-
ply aliquots to make sure that all mice received fresh food without oxidated DHA. 
In addition, several studies in AD patients have already shown that DHA intake may im-
prove cognition. A study from Kotani et al showed an improvement in immediate memory 
and attention scores after 90 days of supplementation of DHA in subjects with mild cog-
nitive dysfunction [22]. Furthermore a dose response relation was noted between intake of 
n3 fatty acids and cognitive decline, showing less cognitive decline with a higher n3 FA 
intake [19,23]. Also a recent study by Freund-Levi et al has shown some positive effects on 
cognition in patients with very mild AD [24]. 
The fact that the improvement in spatial memory due to DHA intake was most pronounced 
in the APP/PSl animals indicates that a diseased brain profits more from a DHA containing 
diet than a normal healthy brain. It could be suggested that the replenishment of DHA, to 
DHA poor neuronal membranes such as in AD [97,98], are the cause for this improvement. 
Indeed there is a study which shows that DHA supplementation protects from Ν M DA re­
ceptor subunit loss [99]. In addition, a few other reports show that DHA, and some other 
n3 PUFA's, in neuronal membranes increase membrane fluidity and thereby improve neu­
rotransmission and signaling via increased receptor binding and the affinity of receptors 
and function of ion channels [100-102]. 
It has also been suggested that DHA improves cognition by influencing the neuronal mem­
brane fluidity thereby shifting APP processing to the non-amyloidogenic pathway [103]. 
Indeed, both 8 and 15-month-old mice fed a DHA diet showed a pronounced shift of the 
ratio n3/n6 in favor of the n3 FA. This indicates an exchange of LCPUFAs across the blood 
brain barrier [104], incorporation in neuronal membranes and possibly a subsequent incre­
ase in neuronal membrane fluidity. However it has also been shown in other studies that 
DHA is able to improve vascular conditions via lowering plasma triaglycerol [105,106], 
vascular reactivity [105,107], and decreasing atherosclerosis [108,109]). These positive 
effects on the circulation may improve age, and AD related hypoperfusion in the brain and 
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in this way may contribute to improvement of cognition 
Indeed in our study rCBV is slightly increased in 15-month-old DHA(tg) mice, and these 
effects are even more pronounced in 18-month-old mice [15]. Theoretically, this increase 
of rCBV may be caused by vasodilatation or genesis of new capillaries Vasculogenesis 
may be an unlikely explanation for the finding, because anti-angiogenic effects of DHA 
in for example tumors have been reported [110,111]. In addition, unpublished results from 
our lab showed no changes in capillary density in 15 and 18-month-old mice fed the DHA 
diet Vasodilatation is in our view a more likely explanation, since CBF did not change, and 
a mismatch between CBF and CBV has been interpreted as compensatory vasodilatation 
[112]. In support of this notion, intake of n3 PUFAs in human subjects has been shown 
to affect endothelial function and improve flow-mediated dilatation of the brachial artery 
[107] and enhance nitric oxide mediated vasodilatation in the microcirculation of the fo-
rearm [113] 
In line with the hypothesis that DHA will be beneficial to prevent AD via improving vas-
cular conditions, is the decreased amount of vascular Aß due to DHA. This decrease in 
vascular Aß load is not a surprise, since hypoperfusion induces increased amounts of Aß 
[69,91,114,115], and thus theoretically, an improved perfusion could decrease the amount 
of Aß Furthermore, there is also research showing the vasoactive role of Aß [72-75], cau-
sing vasoconstriction, and this again underscores the involvement of DHA in improving 
vascular conditions 
In addition, another experimental study also reported lower Aß levels as measured by 
ELISA and reduced amyloid pathology in the hippocampus and parietal cortex of single 
transgenic APPswe mice which had been fed a DHA diet from 18 until 23 months [25] The 
difference with our study is that in Lim's study [25] most of the DHA effects result from a 
comparison between a 0 6% DHA diet with a DHA depleting diet (<0 01% DHA), and our 
control group received a standard diet containing a small amount ot alpha-lmolenic acid 
from soy oil which may be converted to DHA Thus, in our study we investigated effects 
of supplementation with DHA instead of replenishment of depleted DHA as in the Lim et 
al. study Nevertheless, both supplementation and replenishment of depleted DHA seem to 
have diminishing effects on Aß plaque load 
The results of our phospholipid and fatty acid analysis of the brain homogenates show no 
difference in DHA content nor n6 and n3 LCPUFA content in the brains of the transgenic 
mice compared to wild-type mice, showing that transgemcity does not cause DHA deple-
tion In conclusion, our results show that the APP/PS1 mouse model is a valid model to 
study Alzheimer's Disease, because behavior and cognition become impaired at early age 
and Aß deposition increases fast, especially in the hippocampal region, during ageing. The 
changes in the cerebral hemodynamics and the observed hippocampal atrophy observed in 
this mice provides in a good model to study AD and related hypoperfusion. 
In addition, a cholesterol containing Typical Western diet aggravates AD-like pathology 
by impairing the cerebral circulation (i e rCBV) at 15 months and subsequently increasing 
Aß deposition at 18 months [13]. A DHA containing diet seems to inhibit development of 
AD-like pathology, improving vascular health and decreasing parenchymal Aß load The-
refore, the present data indicate that dietary lipids cause alterations in cerebral brain hemo-
dynamics before changing the histologically detectable Aß load in the brain, and we have 
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shown that these changes influence the course of the disease. These data further underline 
the importance of vascular factors in the APP/PS1 mouse model of AD pathology. 
Acknowledgements 
We would like to thank Henk Amts for his excellent care giving of our animals, Erna Bas­
ten en Coen Graven for their laboratory work, and Giulio Gambarota and Andor Veltien 
for their support with the MR! measurements. The laboratory work on sterol analyses of 
Sylvia Friedrichs from the Institute of Clinical Chemistry and Pharmacology, University 
of Bonn, Germany, is also gratefully acknowledged. Martin Balvers at Numico Research, 
Wageningen, skillfully performed all FA analyses. This study is partly supported by an EU 
5th framework project (no:QLRT-2002-l 72), and a Research visit grant from Zon-MW the 
Netherlands organization for Health Research and Development (910-31-704 ). 
References 
11 | Seikoe DJ, Alzheimer's disease is a synaptic failure. Science 2002;298 (5594):789-91. 
[2] Seikoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-
based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-84. 
[3] Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. 
Neurobiol Aging 2000;21 (2): 153-60. 
[4] Dosunmu R, Wu J, Basha MR, Zawia NH. Environmental and dietary risk factors in Alz­
heimer's disease. Expert Rev Neurother 2007;7 (7):887-900. 
[5] Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Mortel KR Risk factors for 
cerebral degenerative changes and dementia. Eur Neurol I998;39 Suppl 1:7-16. 
[6] Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, Barberger Gateau P, Berr C, Bonnefoy 
M, Dartigues JF, de Groot L, Ferry M, Galan P, Hercbcrg S, Jeandel C, Morris MC, Nour-
hashemi F, Payette H, Poulain JP, Portet F, Roussel AM, Ritz Ρ, Rolland Y, Vellas Β. ΙΑΝΑ 
task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007; 11 
(2): 132-52. 
[7] Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, livonen 
S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen II. Apolipoprotein E epsilon4 allele, 
elevated midlife total cholesterol level, and high midlife systolic blood pressure are inde­
pendent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137 (3): 149-55. 
[8] Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen 
H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later 
life: longitudinal, population based study. Bmj 2001;322 (7300): 1447-51. 
[9] Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. 
Lancet 2000;356 (9242): 1627-31. 
[10] Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-
Traver S, Lochhead J, Ziolwolski C. Atorvastatin for the treatment of mild to moderate 
Alzheimer disease: preliminary results. Arch Neurol 2005;62 (5):753-7. 
[H] Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E 
polymorphism and Alzheimer's disease. Lancet 1993;342 (8873):697-9. 
95 
[12] Strittmatter WJ, Saunders AM, Schmechel D, Pcricak-Vance M, Enghild J, Salvesen GS, 
Roses AD. Apolipoprolein E: high-avidity binding to beta-amyloid and increased fre­
quency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sei U S A 
I993;90(5):1977-81. 
[ 13] Corder EH, Saunders AM, Risch Ν J, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr., 
Rimmler JB, Locke PA, Conneally PM, Schmader KE, el al. Protective effect of apoli 
poprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7 (2): 180-4. 
[14] Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons Κ. Cholesterol de 
plelion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci 
USA1998;95(ll):6460-4. 
[15] Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen Τ, Broersen 
LM, Lutjohann D, Heerschap A, Tamia Η, Kiliaan AJ. Changes in cerebral blood volume 
and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid 
(DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 2007;28 
(1): 16-29. 
[16] Refolo LM, Malesler B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, 
DuffK, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer's amyloid patho­
logy in a transgenic mouse model. Neurobiol Dis 2000;7 (4):321-31. 
[17] Fassbender Κ, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller Ρ, Runz H, Kuhl S, 
Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly 
reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in 
vitro and in vivo. Proc Natl Acad Sci U S A 2001 ;98 ( 10):5856-61. 
[ 18] Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle 
DJ, Wilson PW, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content 
and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 
2006;63(ll):l545-50. 
[19] Moms MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, 
Schneider J. Consumption offish and n-3 fatly acids and risk of incident Alzheimer disease. 
Arch Neurol 2003;60 (7):940-6. 
[20] Barbcrger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, 
meat, and risk of dementia: cohort study. Bmj 2002;325 (7370):932-3. 
[21] Kalmijn S, Launcr LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and 
the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42 (5):776-82. 
[22] Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, 
Yoshimoto T, Guo J, Yamashima T. Dietary supplementation of arachidonic and doco­
sahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006;56 (2): 159-64. 
[23] van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, 
and subsequent 5-y cognitive decline in elderly men: the Zulphen Elderly Study. Am J Clin 
Nulr2007;85(4):ll42-7. 
[24] Freund-Levi Y, Enksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind 
A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 
patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-
blind trial. Arch Neurol 2006;63 ( 10): 1402-8. 
[25] Lim GP, Calon F, Monhara T, Yang F, Teter B, Ubeda O, Salem N, Jr., Frautschy SA, Cole 
96 
GM. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid 
burden in an aged Alzheimer mouse model. J Neurosci 2005;25 (12):3032-40. 
[26] Oksman M, livonen H, Hogyes E, Amtul Z, Penke B, Leenders 1, Broersen L, Lutjohann 
D, Hartmann Τ, Tanila Η. Impact of different saturated fatty acid, polyunsaturated fatty 
acid and cholesterol containing diets on beta-amyloid accumulation in APP/PSI transgenic 
mice. Neurobiol Dis 2006;23 (3):563-72. 
[27] Ma QL, Tetcr B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, Tuck ML, Frautschy SA, 
Cole GM. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LRI I, a sorting 
protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD 
prevention. J Neurosci 2007;27 (52): 14299-307. 
[28] Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Jr., 
Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic patho­
logy in an Alzheimer's disease mouse model. Neuron 2004;43 (5):633-45. 
[29] Skoog 1, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 
2006;28(6):605-ll. 
[30] Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, Renshaw PF. 
Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alz­
heimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol 
1998; 19 (9): 1727-32. 
[31] Niwa K, Kazama K, Younkin SG, Carlson GA, ladecola C. Alterations in cerebral blood 
flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neuro­
biol Dis 2002;9 ( 1 ):61-8. 
[32J Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-ex 
pression of multiple transgenes in mouse CNS: a comparison of strategics. Biomol Eng 
2001;17(6):Ι57-65. 
[33] Heeren DJ, Cools AR. Classifying postures of freely moving rodents with the help of 
Fourier descriptors and a neural network. Behav Res Methods lustrum Comput 2()()();32 
(l):56-62. 
[34] de Bruin JP, Sanchez-Santed F, Heinsbroek RP, Donker A, Postmes P. A behavioural ana 
lysis of rats with damage to the medial prefrontal cortex using the Morris water maze: 
evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res 
1994;652(2):323-33. 
[35] Grootendorst J, de Kloet ER, Vossen C, Daim S, Oitzl MS. Repeated exposure to rats has 
persistent genotype-dependent effects on learning and locomotor activity of apolipoprotcin 
E knockout and C57BI/6 mice. Behav Brain Res 2001; 125 (l-2):249-59. 
[36] Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, Van der Zee CE. Structural 
and behavioural consequences of double deficiency for creatine kinases BCK and UbCK-
mit. Behav Brain Res 2005; 157 (2):2l9-34. 
[37] Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR 
imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 
l998;40(6):793-9. 
[38] Kennan RP, Zhong J, Gore JC. Intravascular susceptibility contrast mechanisms in tissues. 
Magn Reson Med 1994;31 (1):9-21. 
[39] Franklin K, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: academic 
press, 1997 
[40] Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT Abeta 
deposition is associated with neuropil changes, but not with overt neuronal loss in the hu­
man amyloid precursor protein V717F (PDAPP) transgenic mouse J Neurosci 1997,17 
(18)7053-9 
[41] Shukia C, Bridges LR Regional distribution of tau, beta-amyloid and beta-amyloid precur 
sor protein in the Alzheimer's brain a quantitative immunolabelling study Neuroreport 
1999,10(18)3785-9 
[42] Gemisman Y, de Toledo-Morrell L, Morrell F, Persina IS, Rossi M Age-related loss of 
axospinous synapses formed by two afferent systems in the rat dentate gyrus as revealed by 
the unbiased stereological dissector technique Hippocampus 1992,2 (4) 437-44 
[43] Scheff SW, Sparks DL, Price DA Quantitative assessment of synaptic density in the 
outer molecular layer ol the hippocampal dentate gyrus in Alzheimer's disease Dementia 
1996,7(4)226-32 
[44] Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann Κ, Bey-
reuther K, Multhaup G, Bayer TA Profile ol cholesterol-related sterols in aged amyloid 
precursor protein transgenic mouse brain J Lipid Res 2002,43 (7) 1078-85 
[45] Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K, Andersson U, Bjork-
hem I, Bergmann Kv K, Fassbender Κ High doses ol simvastatin, pravastatin, and choies 
tcrol reduce brain cholesterol synthesis in guinea pigs Steroids 2004,69 (6) 431-8 
[46] Thelen KM, Rentsch KM, Gutteck U, Heverm M, Olin M, Andersson U, von Eckardslem 
A, Bjorkhem I, Lutjohann D Brain cholesterol synthesis in mice is affected by high dose ol 
simvastatin but not of pravastatin J Pharmacol Exp Ther 2006,316(3) 1146-52 
[47] Lalonde R, Kim HD, Fukuchi Κ Exploratory activity, anxiety, and motor coordination in 
bigemc APPswe + PS 1 /DeltaE9 mice Neurosci Lett 2004,369 (2)156-61 
[48] Lalonde R, Kim HD, Maxwell JA, Fukuchi Κ Exploratory activity and spatial learning in 
12-month-old APP(695)SWE/co+PSl/DeltdE9 mice with amyloid plaques Neurosci Lett 
2005,390 (2) 87-92 
[49] Puohvah J, Wang J, Heikkmen T, Heikkila M, Tapiola T, van Groen Τ, Tamia Η Hippo 
campal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double trans­
genic mice Neurobiol Dis 2002,9 (3) 339-47 
[50] Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D Non-cognitive behaviours in an 
APP/PS1 transgenic model ol Alzheimer's disease Behav Brain Res 2007,178 (1) 18-28 
[51] Leussis MP, Bolivar VJ Habituation in rodents a review of behavior, neurobiology, and 
genetics Neurosci Biobehav Rev 2006,30 (7) 1045-64 
[52] Roesler R, Walz R, Quevedo J, de-Pans F, Zanata SM, Graner E, Izquierdo 1, Martins VR, 
Brentani RR Normal inhibitory avoidance learning and anxiety, but increased locomotor 
activity in mice devoid of PrP(C) Brain Res Mol Brain Res 1999,71 (2) 349-53 
[53] Simon P, Dupuis R, Costentin J Thigmotaxis as an index ol anxiety in mice Influence of 
dopaminergic transmissions Behav Brain Res 1994,61 (1) 59-64 
[54] Grossberg GT Diagnosis and treatment of Alzheimer's disease J Clin Psychiatry 2003,64 
Suppl 9 3-6 
[55] Patterson MB, Schnell AH, Martin RJ, Mendez MF, Smyth KA, Whitehouse PJ Assess­
ment of behavioral and affective symptoms in Alzheimer's disease J Gcnatr Psychiatry 
% 
Neurol 1990;3 (l):2l-30. 
[56] Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, 
Games D, Freedman SB, Morris RG. A learning deficit related to age and beta-amyloid 
plaques in a mouse model of Alzheimer's disease. Nature 2000;408 (6815):975-9. 
[57] Locaselo JJ, Growdon JH, Corkin S. Cognitive test performance in detecting, staging, and 
tracking Alzheimer's disease. Arch Neurol I995;52 (11): 1087-99. 
[58] Small BJ, Mobly JL, Laukka EJ, Jones S, Backman L. Cognitive deficits in preclinical 
Alzheimer's disease. Acta Neurol Scand Suppl 2003;179:29-33. 
[59] Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline 
in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch 
Neuroll 991;48(3):278-81. 
[60] Cooper JL. Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy. 
Drugs Aging 2003;20 (6):399-418. 
[61] Kalmijn S, Feskens EJ, Launcr LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, 
and cognitive function in very old men. Am J Epidemiol 1997;145 (1):33-41. 
[62] Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE. Cholesterol modulates the mem 
brane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in 
Alzheimer's disease. Dement Geriatr Cogn Disord 2000;ll (4):181-6. 
[63] Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG. Evidence for changes 
in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neu-
robiol Aging 1992; 13 (3):413-9. 
[64] Wood WG, Igbavboa U, Eckert GP, Johnson-Anuna LN, Muller WE. Is hypercholesterole­
mia a risk factor for Alzheimer's disease? Mol Neurobiol 2005;31 (l-3):185-92. 
[65] Liu KZ, Cuddy TE, Pierce GN. Oxidative status of lipoproteins in coronary disease pa­
tients. Am Heart J 1992; 123 (2):285-90. 
[66] Pappolla MA, Smith MA, Bryant-Thomas T, Bazan N, Petanceska S, Perry G, Thai LJ, 
Sano M, Refolo LM. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the 
horizons of pathogenesis. Free Radie Biol Med 2002;33 (2): 173-81. 
[67] Kawamura J, Terayama Y, Takashima S, Obara K, Pavol MA, Meyer JS, Mortel KF, 
Weathers S. Leuko-araiosis and cerebral perfusion in normal aging. Exp Aging Res 
l993;19(3):225-40. 
[68] Reich T, Rusinek H. Cerebral cortical and white matter reactivity to carbon dioxide. Stroke 
1989;20(4):453-7. 
[69] Parkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. 
Prog Neurobiol 2001 ;64 (6):575-611. 
[70] Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen Τ, Kiliaan AJ. Amyloid beta 
deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in 
brains of aged APP/PS1 mice. Brain Res 2007;1181:93-103. 
[71] Lee GD, Aruna JH, Barrett PM, Lei DL, Ingram DK, Mouton PR. Stereological analysis 
of microvascular parameters in a double transgenic model of Alzheimer's disease. Brain 
Res Bull 2005;65(4):317-22. 
[72] Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, ladecola C. A beta-peptides 
enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Cire Physiol 2001 ;281 
(6):H2417-24. 
[73] Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, 
Hyman BT, Moskowitz MA, Ayata C Age-dependent cerebrovascular dysfunction in a 
transgenic mouse model of cerebral amyloid angiopathy Brain 2007,130 (Pt 9) 2310-9 
[74] Crawford F, Suo Ζ, Fang C, Mullan M Characteristics of the in vitro vasoactivity of beta-
amyloid peptides Exp Neurol 1998,150(1) 159-68 
[75] Thomas T, Thomas G, McLendon C, Sutton T, Mullan M beta-Amyloid-mediated vaso­
activity and vascular endothelial damage Nature 1996,380(6570) 168-71 
[76] de la Torre JC Critically attained threshold of cerebral hypoperlusion can it cause Alzhei­
mer's disease'' Ann Ν Y Acad Sci 2000,903 424-36 
[77] Crawford F, Soto C, Suo Ζ, Fang C, Parker T, Sawar A, Frangione B, Mullan M Alzhei­
mer's beta-amyloid vasoactivity identification of a novel beta-amyloid tonformational 
intermediate FEBS Lett 1998,436(3)445-8 
[78] Thomas T, Sutton ET, Hellermann A, Price JM Beta-amyloid-induccd coronary artery 
vasoactivity and endothelial damage J Cardiovasc Pharmacol 1997,30 (4) 517-22 
[79] Braak E, Gnffing Κ, Arai Κ, Bohl J, Bratzke Η, Braak Η Neuropathology of Alzheimer's 
disease what is new since A Alzheimer''Eur Arch Psychiatry Clin Neurosci 1999,249 
Suppl 3 14-22 
[80] Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL Alzheimer's disease cell-specific 
pathology isolates the hippocampal lormalion Science 1984,225 (4667) 1168-70 
[81] Reilly JF, Games D, Rydel RE, Freedman S, Schenk D, Young WG, Morrison JH, Bloom 
FE Amyloid deposition in the hippocampus and entorhinal cortex quantitative analysis ol 
a transgenic mouse model Proc Natl Acad Sci U S A 2003,100 (8) 4837-42 
[82] Jacobsen JS, Wu CC, Redwine JM, Comery TA, Anas R, Bowlby M, Marione R, Morrison 
JH, Pangalos MN, Reinhart PH, Bloom FE Early-onset behavioral and synaptic deficits in 
a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 2006,103 ( 13) 5161 -6 
[83] Ritchie K, Lovestone S The dementias Lancet 2002,360 (9347) 1759-66 
[84] De Jong GI, De Vos RA, Steur EN, Luiten PG Cerebrovascular hypoperfusion a risk 
factor for Alzheimer's disease9 Animal model and postmortem human studies Ann Ν Y 
Acad Sci 1997,826 56-74 
[85] De Jong Gl, Parkas E, Stienstra CM, Plass JR, Keijser JN, de la Torre JC, Luiten PG 
Cerebral hypoperfusion yields capillary damage m the hippocampal CAI area that cor 
relates with spatial memory impairment Neuroscience 1999,91 (1) 203-10 
[86] de Wilde MC, Parkas E, Gerrits M, Kiliaan AJ, Luiten PG The effect of n-3 polyunsatura­
ted fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral 
hypoperfusion Brain Res 2002,947 (2) 166-73 
[87] Ni J, Ohla H, Matsumoto K, Watanabe H Progressive cognitive impairment following 
chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries 
in rats Brain Res 1994,653 ( I -2) 231 -6 
[88] Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van 
Broeckhoven C, Grobbee DE Atherosclerosis, apolipoprotein E, and prevalence of demen­
tia and Alzheimer's disease in the Rotterdam Study Lancet 1997,349 (9046) 151-4 
[89] Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG 
Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease Artenoscler 
Thromb Vase Biol 2003,23 (11) 2055-62 
100 
[90] Casserly I, Topoi E. Convergence of atheroscierosis and Alzheimer's disease: inflamma­
tion, cholesterol, and misfolded proteins. Lancet 2004;363 (9415):l 139-46. 
[91] Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin Τ, Chen J. Cleavage of 
amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 
2000;21 (2):207-14. 
[92] Cao D, Fukuchi Kl, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning defi­
cits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 2005. 
[93] Knittweis JW, McMullen WA. The effect of apoE on dementia is not through atherosclero­
sis: the Rotterdam study. Neurology 2000;54 (12):2356-8. 
[94] Cole GM, Frautschy SA. Docosahexaenoïc acid protects from amyloid and dendritic patho-
logy in an Alzheimer's disease mouse model. Nutr Health 2006; 18 (3):249-59. 
[95] Tanabe Y, Hashimoto M, Sugioka K, Maruyama M, Fujii Y, Hagiwara R, Hara T, Hossain 
SM, Shido O. Improvement of spatial cognition with dietary docosahexaenoïc acid is as-
sociated with an increase in Fos expression in rat CAI hippocampus. Clin Exp Pharmacol 
Physiol 2004;31 (10):700-3. 
[96] Arendash GW, Jensen MT, Salem N, Jr., Hussein N, Cracchiolo J, Dickson A, Lcighty R, 
Potter H. A diet high in oiTicga-3 fatty acids does not improve or protect cognitive perfor-
mance in Alzheimer's transgenic mice. Neuroscience 2007; 149 (2):286-302. 
[97] Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phosp-
holipid alterations in Alzheimer's disease. Neurochem Res I998;23 (l):8l-8. 
[98] Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phosp-
holipids in aging and in Alzheimer's disease. Lipids I99l;26 (6):42l-5. 
[99] Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N, Jr., Frautschy SA, Cole GM. 
Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA 
receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 
2005;22(3):6l7-26. 
[100] Bourre JM, Dumont O, Piciotti M, Clement M, Chaudière J, Bonneil M, Naibone G, Lafont 
H, Pascal G, Durand G. Essentiality of omega 3 fatty acids for brain structure and function. 
World Rev Nutr Diet 1991;66:103-17. 
[101] Bourre JM, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G, Durand G. The effects 
of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, 
amplitude of electrophysiological parameters, resistance to poisons and performance of 
learning tasks in rats. J Nutr 1989;119 (12): 1880-92. 
[102] Parkas E, de Wilde MC, Kiliaan AJ, Meijer J, Keijser JN, Luiten PG. Dietary long chain 
PUFAs differentially affect hippocampal muscarinic I and serotonergic 1A receptors in 
experimental cerebral hypoperfusion. Brain Res 2002;954 (1):32-4I. 
[103] Sahlin C, Pettersson FE, Nilsson LN, Lannfelt L, Johansson AS. Docosahexaenoïc acid 
stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular 
models of Alzheimer's disease. Eur J Neurosci 2007;26 (4);882-9. 
[104] Tsukada H, Kakiuchi T, Fukumoto D, Nishiyama S, Koga K. Docosahexaenoïc acid (DHA) 
improves the age-related impairment of the coupling mechanism between neuronal acti-
vation and functional cerebral blood flow response: a PET study in conscious monkeys. 
Brain Res 2000;862 ( 1 -2): 180-6. 
[105] Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr I997;65 
101 
(5Suppl):l645S-54S. 
[106] Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohy­
drate on plasma lipoproteins and cardiovascular disease. Am J Med 2002; 113 Suppl 
9B:13S-24S. 
[107] Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation 
with marine omega-3 fatty acids improve systemic large artery endothelial function in 
subjects with hypercholesterolemia. J Am Coll Cardiol 2000;35 (2):265-70. 
[ 108] Okuda N, Ueshima H, Okayama A, Saitoh S, Nakagawa H, Rodriguez BL, Sakata K, 
Choudhury SR, Curb JD, Stamler J Relation of long chain n-3 polyunsaturated fatty acid 
intake to serum high density lipoprotein cholesterol among Japanese men in Japan and 
Japanese-American men in Hawaii: the INTERLIPID study. Atherosclerosis 2005;178 
(2):371-9. 
[109] von Schacky C, Harris WS Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 
2007;73(2):310-5. 
[110] Rose DP, Connolly JM. Antiangiogenicity of docosahexaenoic acid and its role in the sup 
pression of breast cancer cell growth in nude mice. Int J Oncol 1999;15 (5):1011-5. 
[I l l ] Mukutmoni-Noms M, Hubbard NE, Erickson KL. Modulation of murine mammary tumor 
vasculature by dietary n-3 fatty acids in fish oil. Cancer Lett 2000; 150 (I):101-9. 
[112] Dijkhuizen RM, Nicolay Κ. Magnetic resonance imaging in experimental models of brain 
disorders. J Cereb Blood Flow Metab 2003;23 (12): 1383-402. 
[113] Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. 
Long-term treatment with cicosapentaenoic acid augments both nitric oxide-mediated and 
non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with 
coronary artery disease. J Cardiovasc Pharmacol 1999;33 (4):633-40. 
[114] de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypo­
thesis of Alzheimer's pathogenesis. Neurobiol Aging 2000;2I (2):331-42. 




Amyloid beta deposition is related to decreased 
glucose transporter-1 levels and hippocampal 
atrophy in brains of aged APP/PS1 mice 
Hooijmans CR ', Graven C ', Dederen PJ ", Tanila Hh, van Groen Τ ', Kiliaan AJ •,. 
a Radboud University Nijmegen Medical Centre, Department of Anatomy, 
Geert Grooteplein noord 21 6500 HB Nijmegen, The Netherlands. 
b A.I. Virtanen Institute, University of Kuopio, and Department of Neurology, 
Kuopio University Hospital, Kuopio, Finland.c University of Alabama at Birmingham, 
department of Cell Biology, AL 35294-0006, Birmingham, USA. 
Brain Res. 2007 Nov 21; 1181:93-103 
Abstract 
The amount of the glucose transporter type-1 (GLUT-1) is decreased in the hippocam-
pus and cerebral cortex of AD patients In this study we therefore wanted to investigate 
the causal relationship between amyloid-ß (Aß), GLUT-1 and hippocampal atrophy in the 
brains of young (8-months) and old (18-months) APP/PS1 mice Methods: Aß and GLUT-
1 were visualized immunohistochemically. Aß load, GLUT-1 amount, capillary density 
and GLUT-1 amount per capillary density were determined in cortical and hippocampal 
areas using computer-assisted analysis systems Hippocampal atrophy was determined by 
calculating the width of the outer molecular layer of the dentate gyrus (DG) Results Inl8-
month-old APP/PS1 mice we found a reduced GLUT-1 amount in the hippocampus but no 
differences in capillary density. The DG of these mice contained the highest level of Aß in 
combination with hippocampal atrophy, and a reduced GLUT-1 amount per capillary den-
sity. At 8-months no differences were observed. The highest Aß deposition was found in 
the DG, although fourfold less compared to 18-month-old mice. Conclusions: We conclude 
that the GLUT-1 amount and capillary density in both wild type and transgenic mice decre-
ase due to ageing Further, a decreased amount of GLUT-1 is caused by decreased GLUT-1 
amount/capillary density and not due to a reduced capillary density. We suggest that Aß 
load in the hippocampus precedes the reduction of GLUT-1 A certain level of Aß must be 
reached in the hippocampus, before it affects GLUT-1 amount/capillary density leading to 
further impairment of energy metabolism and hippocampal atrophy 
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Introduction 
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease characterized by 
the presence of amyloid-ß (Aß) peptide containing plaques, and neurofibrillary tangles 
(NFT). Aß accumulates in the brain either as neuritic plaques or as vascular deposits that 
cause cerebral amyloid angiopathy (CAA). Aß is derived through the proteolytic cleavage 
of the amyloid precursor protein (APP) by β- and γ secretases (see ref [1] for review). Aß 
has been suggested to be a major contributor to the neurodegenerative processes in AD in 
which the entorhinal cortex, hippocampus and neocortex of AD patients are predominantly 
affected [2-5]. 
However, accumulated evidence suggests that vascular risk factors play an important role 
in AD. For example, AD and vascular dementia share the same risk factors [6,7], and phar-
macotherapy improving cerebrovascular insufficiency decreases AD symptoms [8]. There 
is also evidence showing that cerebral perfusion is decreased in AD patients [9]. Cerebral 
blood flow diminishes with age [10,11]; however, in AD these perfusion/haemodynamic 
effects are even more pronounced and especially the parietal and temporal cortices are 
consistently shown to be affected [9]. 
Besides haemodynamic changes, various microvascular pathologies have been observed in 
AD patients, such as basement membrane thickening, pericyte degeneration, endothelial 
cell shape changes and luminal buckling (see ref [12] for review). Furthermore, a decrease 
in vascular density is also frequently observed [13]. Capillary degeneration in ageing rats 
can be induced by mild chronic cerebral hypoperfusion [14], and this in turn may trigger 
cognitive and degenerative changes [15,16]. These findings support the CATCH hypo-
thesis of de la Torre [17], positing that advanced age, in combination with a vascular risk 
factor converges to create a critical attained threshold of cerebral hypoperfusion (CATCH). 
This further triggers brain microcirculatory disturbances and hypoperfusion. These chan-
ges may generate a chain of events leading to the progressive evolution of brain metabolic, 
cognitive and tissue pathology that characterize Alzheimer's disease [17]. 
The CATCH hypothesis is in line with findings of reduced glucose metabolism in AD, 
which is most pronounced in the temporal and parietal cortex [18,19]. Glucose transporter 
type 1 (GLUT-1 ) is selectively expressed at high levels in the capillary endothelium of the 
brain and is responsible for the transfer of glucose across the blood brain barrier [20]. 1m-
munolabeling and binding experiments using GLUT-l as a marker for vascular endothelial 
cells have revealed decreased amount of GLUT-1 transporter in the hippocampus and ce-
rebral cortex of AD patients [21-23]. This finding indicates diminished glucose transport, 
reflecting decreased glucose metabolism and probably a hypometabolic state. 
Hypoperfusion may cause endothelial degeneration in cerebral small vessels leading to 
Aß deposition [9,24] and ultimately to loss of GLUT-1 transporters. Several studies have 
shown that cerebral ischemia results in progressive accumulation of Aß [25,26]. In addi-
tion, a recent study from Kouznetsova et al. reported a diminished capillary density in areas 
with high Aß depositions [27]. In that study, capillary density was determined by using the 
percentage of brain area covered by GLUT-1 immunoreactivity as a measure. However, in 
our view, a decreased percentage of the area covered by GLUT-1 immunoreactivity could 
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also mean that GLUT-1 transporter amount/capillary density is decreased in the vicinity 
of Aß deposits rather than capillary density per se. This view has been supported by some 
other studies as well [28,29]. 
The present study set out to determine Aß deposition, capillary density, the amount of 
GLUT-1 in total and in relation to capillary surface area (GLUT-1 amount/capillary densi-
ty) in different brain regions in young (8-month-old) and old (18-month-old) double trans-
genic AD mice expressing the human mutated APPswe and PSldE9 genes [30]. In addition 
the degree of tissue atrophy in the hippocampus was determined. 
We hypothesize that an increased amount of Aß reduces the GLUT-1 amount/capillary 
density in the hippocampus of AD mice, and as a consequence contributes to hippocampal 
atrophy via decreased glucose availability. 
Materials and Methods 
Animals 
The APPswe/PSldE9 breeder mice were obtained from Johns Hopkins University, Balti-
more, MD, USA (D. Borchelt and J. Jankowsky, Dept. Pathology), and a colony was esta-
blished at the University of Kuopio Finland (experiment 1). Mice from the colony of the 
University of Kuopio were used to set-up our own colony at the Radboud University Nij-
megen Medical Centre. For experiment 2 mice were used from the latter colony. In short, 
mice were created by co-injection of chimeric mouse/human APPswe (mouse APP695 har-
boring a human Aß domain and mutations K.595N and M596L linked to Swedish familial 
AD pedigrees) and human PSl-dE9 (deletion of exon 9) vectors controlled by independent 
mouse prion protein promoter elements. The two transvected genes co-integrated and co-
segregate as a single locus [30]. This line was originally maintained in a hybrid background 
by backcrossing to C3HeJ χ C57BL6/J Fl mice (so-called pseudo F2 stage). For the pre­
sent work, the breeder mice were backcrossed to C57BL6/J for 5-6 generations to obtain 
mice for the current study. Age matched non transgenic littermates served as controls. 
Throughout the experiments the animals (experiment 1 : wild type n= 10 and APP/PS1 n=8, 
experiment 2: wild type n=7 and APP/PS 1 n=7) were housed individually in a controlled 
environment, food and water were available ad libitum. Experiments were performed ac­
cording to Dutch and Finnish federal regulations for animal protection and were approved 
by the Veterinary Authority Radboud University Nijmegen. At 16 months the mice used 
in experiment 1 were transported to Radboud University Nijmegen, the Netherlands. At 8 
respectively 18 months of age the experiments were performed. 
Immunohistochemical procedures 
All mice were weighed directly before starting the immunohistochemical procedures at 
8 respectively 18 months of age. Subsequently, mice were anesthetized with Nembutal 
(60mg/kg i.p.) (Ceva Santa Animals BV, Maassluis, the Netherlands) and transcardially 
perfused with a 0.1 M phosphate buffered saline (PBS) followed by Somogyi's fixative (4% 
paraformaldehyde, 0.05% glutaraldehyde and 0.2 % picric acid in 0.1 M phosphate buffer, 
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PB). Following transcardial perfusion fixation mice were decapitated and brains were dis­
sected from the skull. The entire brain without spinal cord was weighed and thereafter post 
fixated for 15 hours at 40C in Somogi's fixative. The brain tissue was then cryoprotected 
by immersion in 30% sucrose in PB at 4aC. Six series of 40 μιτι coronal sections were cut 
through the brain using a sliding microtome (Microm HM 440, Walldorf, Germany). 1m-
munohistochemistry was performed using standard free-floating labeling procedures on 
series 1 and 2. All sections were stained in one session to minimize differences in staining 
intensity. 
Amyloid-ß 
The Aß load was visualized using WO-2 antibody (mouse anti-human Aß4-10, kind gift of 
K. Beyreuther, Centre for Molecular Biology, University of Heidelberg, Germany). Briefly, 
the sections were pretreated with sodium citrate solution at 850C for 30 minutes. Mono-
clonal mouse anti-human Aß4-10 (1:20.000) was used as primary antibody. The sections 
were incubated overnight at room temperature on a shaker table. Following incubation the 
sections were rinsed thoroughly with PBS and transferred to the solution containing the 
secondary antibody; donkey-anti-mouse biotin 1:1500 (Jackson Immuno research). After 
90 minutes of incubation the section were rinsed three times and transferred to a solution 
containing Vector ABC-elite 1:800 (Vector laboratories, Burlingame, CA, USA) for again 
90 minutes. Visualization of Aß plaques was achieved by incubation with DAB-Ni solu-
tion. All stained sections were mounted on gelatin-coated slides and dehydrated in alcohol 
series, cleared with xylol and mounted in Entellan. 
GLUT-1 
The GLUT-1 amount was visualized using GLUT-1 antibody (rabbit anti GLUT-1 trans-
porter, Chemicon AB 1340, Chemicon International, Inc., Temecula, CA, USA). In short, 
the sections were pretreated for 30 minutes with 0.3% H202 in 0.1 M PBS. Thereafter, the 
sections were rinsed in PBS and pre-incubated in 0.1 M PBS containing 1% bovine serum 
albumin (BSA) and 0.3% triton-X-100 (PBS-BT) followed by a 18h incubation with rabbit 
anti-GLUT-1 AB 1340 (1:10,000, Chemicon International, Inc., Temecula, CA). Following 
incubation the sections were rinsed thoroughly with PBS and transferred to the solution 
containing the secondary antibody; donkey anti rabbit biotin 1:1500 (Jackson Immuno 
research). After 90 minutes of incubation the sections were rinsed three times and transfer-
red to a solution containing Vector ABC-elite 1:800 (Vector laboratories, Burlingame, CA, 
USA) for another 90 minutes. Visualization of the GLUT-1 amount was achieved by incu-
bation with DAB-Ni solution. All stained sections were mounted on gelatin-coated slides 
and dehydrated in alcohol series, cleared with xylol and mounted in Entellan. 
Quantification 
To determine the amount of Aß, GLUT-1 and capillary density in the hippocampus, CAI, 
CA3 and dentate gyrus (DG) (exp 1 and 2), in the frontal cortex (prelimbic area (PLA)) and 
anterior cingulate gyrus (ACg 1 and 2) (exp 1 ), the appropriate slices were digitized using 
a Zeiss Axioskop microscope, equipped with hardware and software of Microbrightfield, 
(Williston, VT, USA). Brain regions were based on the mouse brain atlas of Franklin and 
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Paxinos 1997 [55] and quantified in three sections (with 200 μπι distance between the 
sections) for each region. ACgl and 2 were quantified at level +1.10 up to +0.86 anterior 
to bregma, PLA was quantified at +1.98 upto +1.78 anterior to bregma. The hippocampus 
was quantified at -2.18 up to -2.46 posterior to bregma. The cortical regions were chosen 
because of their large amyloid load in humans and transgenic mice and their importance 
in memory [56,57]. 
Amyloid-ß 
Quantitative analyses were performed with a computer-assisted analysis system (Stereo 
Investigator, Microbrightfield (Wilhston, USA).) using Cavalieri's probe. A contour was 
drawn along the borders of the hippocampal subregions (CAI, CA3 and DG). In the ACg 
and PLA a contour was placed, largely within the borders of the particular cortical areas. 
Aß load was defined as the percentage of area covered by Aß. All measurements were 
performed double blind by two investigators, in three sections with 200-μιη distance in 
between. 
GLUT-1 
Capillary density was determined with a computer-assisted analysis system (Stereo In­
vestigator) using Cavalierfs probe and was defined as percentage of the area covered by 
GLUT-1 immunoreactivity as compared to the total area of the region measured. The capil­
lary density was determined within a square contour, touching the anatomical borders of 
respectively the CAI, CA3, DG, ACg and PLA. 
The total amount of GLUT-1 was estimated exactly in the same area as the capillary den­
sity, with stereo investigator collecting luminance information. The amount of GLUT-1 
was measured as the luminance intensity of an entire region and was corrected for the 
background luminance in areas with no GLUT-1 expression. To avoid changes in exposure, 
which might affects measurements, intensity measurements of all sections were performed 
in one session. 
The ratio between the GLUT-1 amount and the capillary density was measured by dividing 
the total GLUT-1 amount by capillary density. 
Hippocampal atrophy 
As a measure for hippocampal atrophy, the thickness of the outer molecular layer of the 
dentate gyrus (DG) was measured in two sections, with 200 μιτι distance in between (Fig2) 
using a Zeiss Axioskop microscope, equipped with hardware and software of Microbright­
field (Williston, USA). The width of the outer molecular layer of the DG was measured 
since this layer is subject of age-related loss of LTP and synapses in both animals models 
and humans [45,46], partly originating from primary perforant path afférents from the en-
torhinal cortex which are affected in AD. 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed with an independent t-test, except 
for regional differences in amyloid-ß load, which was quantified by using the one-way 
ANOVA. If the overall analysis revealed a significant difference, the separate groups were 
analyzed post hoc by using Tukey HSD. Correlation analyses were done with the bivariate 
Pearson's correlation method. Statistical significance was established at p< 0.05. 
lOS 
Results 
Experiment 1: 18-month-old mice 
Body and brain weight 
Mice were weighed at two different time points during the follow-up. The body weight did 
not differ between the groups at 6 months of age (p=0.42, wild type 32.1 ±1.0, APP/PS1 
31.9 ±1.0) nor at 18 months of age (p=0.36, wild type 40.7 ± 1.7, APP/PS1 43.5 ±2.5). 
Brain weight was determined only at the end of the experiment (18 months of age). Brain 
weight did not differ (p=0.39) between the genotypes (wild type 0.46 ±0.01, APP/PS1 0.47 
±0.01). Thus, body and brain weight were not affected by genotype. 
The dentate gyrus of the hippocampus demonstrates the highest amount ofamyloid-ß 
The brains of all mice were immunohistochemically stained with WO-2 antibody (mouse 
anti-human ΛΡ410). Wild type mice showed no immunoreactivity with this antibody, while 
Aß deposits in transgenic mice were intensively stained. 
Fig 1. Amyloid beta (Aß) deposition in the brains of 18-month-old APP/PS1 mice. 
Representative examples of the amyloid load in prelim bic area (FLA. photo A. 2.5x -and Β I Ox), 
anterior cingulatedgyrus (ACg. photo C 2.5x -and D Wx) and hippocampus (photo E 5x) stained 
with WO-2 antibody (mouse anti human Aß 4-10). F: dentate gyrus (DC) exposes the highest amount 
of Aß compared to all other areas. Values represent mean ± SEM. * p<0.05. 
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There was a significant regional variation in Aß plaque burden, such that cortical and hip-
pocampal areas showed many plaques (Fig 1) while the cerebellum, thalamic nuclei, hy-
pothalamic nuclei and other diencephalon structures were relatively free of plaques. We 
measured % of section area covered with Aß depositions in the hippocampus (DG, CAI 
and CA3 regions), frontal cortex (prelimbic area (PL) and anterior cingulate gyrus (ACgl 
and 2) and showed that the dentate gyrus expressed the highest amount of Aß compared 
to all other areas (ANOVA pO.001) (Fig If). Aß depositions covered 17.5% of the DG, 
which is significantly more than the 10.6% load in the CAI (p=0.006), 6.91% in the CA3 
(pO.001), 7.99% in the PLA (pO.001) and 11.34% in the ACg (p=0.014). These results 
indicate that in 18-month-old mice the dentate gyrus is most vulnerable to Aß depositi-
ons. 
Total amount of GLUT-1 is decreased in the hippocampus of APP/PSl mice 
GLUT-1 is an active glucose transporter and is primarily localized in brain vascular en-
dothelial cells. Quantification of the immunohistochemical staining (Fig 2) revealed that 
in APP/PSl mice, and especially in the DG and CA3 regions, the GLUT-1 amount was 
significantly decreased in comparison to wild type mice (DG: p=0.023, CA3: p=0.006). 
Additionally, a trend towards decreased GLUT-1 amount was observed in the CAI region 
(p=0.064). In contrast, no difference in the amount of GLUT-1 transporter was found in the 
cortical areas PLA (p=0.55) and ACg (p=0.16). 
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Pig 2. Total amount of GLUT-1 is decreased in the hippocampus of 18-month-old APP/PSl mice. 
Characteristic photomicrographs of labeled glucose transporter type 1 (GLUT-1) in the hippocam-
pus of wild type (photo A) or APP/PSl (photo Β J mice showing a decreased GLUT-1 amount in 
the entire hippocampus (C) and especially in the DG and CAS region (D). DG dentale gyrus, PLA 
prelimbic area, ACg anterior cingulated gyrus. Values represent mean ± SEM. * p<0.05. a.u. = 
arbitrary units. 
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Capillary density is not changed in APP/PS1 mice 
In order to reveal the underlying cause for the decrease in total GLUT-1 amount, the dis­
tribution of brain capillaries in the mouse brain (capillary density) was measured in hip­
pocampal (DG, CAI and CA3) and cortical (ACg and PLA) areas. Although the capillary 
density appeared slightly lower in CAI and CA3 areas in APP/PS1 mice, the statistical 
analysis a showed no significant differences in capillary density between transgenic and 
wild type mice in any of the observed regions (p>0.14 Fig 3a). Nonetheless, a 4-fold higher 
capillary density was observed in cortical areas (approximately 20%) compared to hippo­
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Fig 3. Decreased GLUT-1 amount/capillary density, and no changes in capillary density in the DG 
of 18-month-old APP/PS1 mice. 
A: Capillary density in hippocampal (DG, CA I, CA3) and cortical (PLA, A Cg) areas in wild type and 
APP/PS1 transgenic mice. B: GLUT-1 expression, calculated as the ratio between GLUT-1 amount 
and capillary density, in hippocampal and cortical areas. DG dentate gyrus, PLA prelimbic area, 
ACg anterior cingulatedgyrus. Values represent mean ± SEM. * p<0.05. 
GLUT-1 amount/capillary density is decreased in the dentate gyrus ofAPP/PSl mice 
To further assess the decrease in the GLUT-1 amount, we also measured the amount of 
GLUT-1 per capillary density by dividing the total GLUT-1 immunoreactivity by the ca­
pillary density. This parameter was 56 % lower in the DG ofAPP/PSl mice compared to 
wild type controls (p=0.()42. Fig 3b). The GLUT-1 amount/capillary density did not differ 
in other areas (p>0.18), indicating a major vulnerability of the DG 18-month-old APP/PS1 
mice. 
Atrophy in the dentate gyms ofagedAPP/PSl mice 
A reduced width of the outer molecular layer in the dentate gyrus was used as a measure for 
hippocampus atrophy. At the age of 18 months, APP/PS1 transgenic mice had significantly 
thinner molecular layer than the wild type mice (Fig 4 p=0.015). The reduction in the width 













Fig 4. Decreased width of the dentate gyrus in 18-month-old APP/PSI mice. 
A: Width of the outer molecular layer of the DG, as a measure of hippocampal atrophy, in wild 
type and APP/PSI transgenic mice. B: Figure showing the location of the DG and the outer mole­
cular layer within the DG of the hippocampus. DG dentate gyrus. Values represent mean ± SEM. * 
p<0.05. 
Correlation between GLUT-l amount/capillary density and hippocampal atrophy 
A bivariate Pearson correlation between hippocampal atrophy and GLUT-1 amount/capil­
lary density (Fig 5) showed a moderate to good relation between GLUT-1 amount/capillary 
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Fig 5. Correlation between GLUT-1 amount per capillary and hippocampal atrophy in IH-month-
oldmice The line depicts the linear regression (r=0.61, p=0.013). 
Experiment 2: 8-month-old mice 
In order to examine whether Aß precedes the observed differences in GLUT-1 amount/ca-
pillary density and hippocampal atrophy in 18-month-old mice, we performed an additio-
nal experiment in which we measured Aß deposits, GLUT-1 amount/capillary density and 
hippocampal atrophy in the hippocampus of 8-month-old APP/PS1 and wild type mice. 
Body and brain weight 
Body and brain weighed were determined at the end of the experiments. The body weight 
and brain weight did not difter between the groups (p=0.12, wild type 30.54 ±0.75, APP/ 
PS1 32.46 ±1.20 respectively p=0.16 wild type 0.49 ± 0.02, APP/PS1 0.52 ±0.01) 
Thus, body and brain weight were not affected by genotype in 8-month-old mice. 
The dentale gyrus of the hippocampus demonstrates the highest amount ofamyloid-ß 
There was a significant regional variation in Aß plaque burden, such that cortical and hip-
pocampal areas showed many plaques (Fig 1) while the cerebellum, thalamic nuclei, hy-
pothalamic nuclei and other diencephalon structures were relatively free of plaques. The 
dentate gyrus expressed the highest amount of Aß compared to the other hippocampal areas 
(ANOVA pO.001) (Fig 6a). Aß depositions covered 4.1% of the DG, which is less than 
one fourth of the amount observed in 18-month-old mice, which was 17.5%. However, the 
amount of Aß depositions in the DG was significantly higher compared to the Aß load in 
the CAI (0.77%, pO.001) and the CA3 (0.66%, pO.001). These results indicate that also 
in 8-month-old mice the dentate gyrus is most vulnerable to Aß depositions. 
Total amount of GLUT-1, capillary density and GLUT-1 amount/capillary density are not 
changed in 8-month-old mice. 
Analysis of the GLUT-1 staining in the hippocampus revealed no differences in any of 
the regions in the amount of GLUT-1 (Fig 6b; DG p=0.37, CAI p=0.68 and CA3 p=0.26), 
capillary density (Fig 6c; DG p=0.96, CAI p=0.69 and CA3 p=0.95) or GLUT-1 amount/ 
capillary density (Fig 6d; DG p=0.30, CAI p=0.95 and CA3 p=0.09). 
No atrophy in the dentate gyrus of young APP/PSI mice 
At the age of 8 months, APP/PSI transgenic mice did not have a significantly thinner mo-
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Fig 6. 8->nonth-old mice 
A: The dentate gyrus (DG) exposes the highest amount of Aß compared to other hippocampal areas. 
Values represent mean ± SEM. *p<0.05.B: Total amount ofGLUT-I in hippocampal (DG, CAI and 
CAS) areas. C: Capillary density in hippocampal (DG. CAI, CAS) areas. D: GLUT-1 expression, 
calculated as the ratio between GLUT-1 amount and capillary density, in hippocampal (DG, CAI 
and CAS) areas. E: Width of the outer molecular layer of the DG. as a measure of hippocampal 
atrophy, in wild type and APP/PS1 transgenic mice. 
Effects of ageing 
Ageing causes a decrease in GLUT-1 and capillary density 
In order to investigate the effects of ageing, differences between 8 and 18-month-old mice 
were determined for both the wild type and transgenic group. As mentioned earlier, the Aß 
load significantly increased during ageing in APP/PS1 mice in all hippocampal areas 
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(Table 1; p<0.01). The width of the outer molecular layer in the dentate gyrus was in-
creased in both groups, however, this increase was only significant in the wild type mice 
(p=0.02), indicating a diminished growth of the hippocampus in transgenic mice probably 
due to neurodegeneration. Both wild type and transgenic mice showed a significant de-
crease in GLUT-1 amount and capillary density in the DG, CAI and CA3 region during 
ageing (Table 1 ). No differences were observed in the ratio GLUT-1 amount/capillary den-
sity due to ageing. 
Discussion 
In this study we investigated the relation between Aß deposition, amount of GLUT-1 trans-
porter and capillaries, hippocampal atrophy and the effect of ageing on these parameters 
in 8 and 18-month-old double transgenic APPswe PSldE9 (APP/PS1) mice GLUT-1 is a 
marker for vascular endothelial cells in the brain and has been shown to be reduced in AD 
patients [21-23]. Our results show a reduced amount of the GLUT-1 immunoreactivity 
in the hippocampus of 18-month-old APP/PS1 but no decrease in the capillary density 
compared to age matched wild type mice. Therefore, these findings point towards a decre-
ased GLUT-1 amount/capillary density in this transgenic AD mouse model. Furthermore, 
amyloid deposition (Aß), atrophy and a reduced GLUT-1 amount/capillary density are all 
concentrated in the dentate gyrus (DG) of 18-month-old mice. 8-inonth-old mice also show 
an increased amount of amyloid deposition in the DG, although much less compared to 
18-month-old mice but do not show any differences in GLUT-1 immunoreactivity nor hip-
pocampal atrophy. Therefore, we suggest that Aß deposition in the hippocampus precedes 
the reduction of GLUT-1 but the amount of Aß must be high enough to affect GLUT-1 
immunoreactivity. Further, ageing causes a decrease in GLUT-1 amount and in capillary 
density in both wild type and APP/PS1 mice. However, the decrease in GLUT-1 amount is 
more pronounced in transgenic mice. 
Nowadays AD is generally considered to have mixed underlying pathology, in which 
vascular risk factors combined with amyloid accumulation and age-related degenerative 
changes cause cognitive impairment. Several studies in recent years have shown haemo-
dynamic and microvascular pathologies in AD [9,10,12], combined with impaired glucose 
utilization. A consistent finding in positron emission tomography (PET) studies has been 
regional decreases in glucose utilization, which are most pronounced in the parietal and 
temporal cortex [21,23,31]. Our findings of a decreased GLUT-1 amount in the hippo-
campus of 18-month-old APP/PS1 mice compared to wild type mice is in accord with 
these PET studies, as well as with studies reporting reductions of hippocampal GLUT-1 in 
AD patients [21,22,27]. Several other studies had also reported reductions in hippocampal 
GLUT-1 in AD [21,22,27], however it is also reported that during normal ageing glucose 
utilization diminishes [32,33]. This finding is strengthened by our findings in which both 
wild type and APP/PS1 mice showed a significant decrease in GLUT-1 amount in time. The 
decrease in GLUT-1 amount is larger in transgenic mice, causing a significant difference 
between wild types and transgenic mice at 18 months of age. Nevertheless, investigators 
disagree about the cause of this decline. A decreased GLUT-1 amount may be caused by a 
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reduced capillary density or may result from decreased GLUT-1 amount/capillary density. 
In our study the capillary density remained unchanged, so the results point to a decrease in 
GLUT-1 amount/capillary. 
Since the GLUT-1 antibody was used to measure capillary density and the amount of 
GLUT-1, it could theoretically have been the case that because of a decreased amount of 
GLUT-1 a decreased number of vessels could be observed. However, since we found a 
decreased amount of GLUT-1 in the hippocampus but no changes in these areas occupied 
with blood vessels (capillary density), these data confirm the reliability of the use of the 
GLUT-1 antibody to determine capillary density. 
Although capillary density did not differ between wild type and APP/PS1 mice at 8 and 
18 month of age, ageing did cause a decrease in the density of the capillaries in both wild 
type and transgenic mice. It could therefore be suggested that ageing on its own triggers the 
development of a hypoperfused state causing an energy crisis, which could be devastating 
in transgenic mice since they also showed a larger decrease in GLUT-1 amount, ultimately 
causing cognitive impairment and other AD pathology. 
In 18-month-old mice we found the highest Aß plaque load in the DG of the hippocampus 
compared to all measured brain regions. This was also the only brain region with a decre-
ased GLUT-1 amount per capillary density, suggesting that Aß plaque load and GLUT-1 
amount/capillary density may be causally related. In our 8-month-old-transgenic mice we 
also observed the highest amount of amyloid deposition in the DG, however a fourfold 
less compared to 18-month-old mice, but we did not find any differences in GLUT-1 im-
munoreactivity. This indicates that the amount of Aß in the DG of 8-month-old mice was 
not sufficient to cause damage to GLUT-1 (i.e. Aß load needs to reach a threshold before 
causing damage to endothelial cells and GLUT-1 expression). In the CA3 region another 
process may be involved, since the amount of GLUT-1 in theCA3 of 18-month-old mice is 
decreased, while the capillary density and GLUT-1 amount/capillary density are not signi-
ficantly altered, the, although very weak, trend towards a decreased capillary density in the 
CA3 region may explain the cause of the decreased GLUT-1 amount. Since parenchymal 
Aß could not be the cause of the decreased GLUT-1 amount in the CA3 of these 18-month-
old mice, it will be interesting to measure the amount of soluble Aß and examine whether 
there is a causal role for soluble Aß in reducing the GLUT-1 amount in this area. 
The notion that Aß has harmful effects on the cerebral vasculature is also supported by 
previous studies showing a relation between Aß plaque load and GLUT-1 in a Tg2576 AD 
mouse [27,34]. This is also consistent with other studies describing the toxicity of Aß for 
vascular endothelial cells and GLUT-1 transporters [35-38]. The exact mechanism where-
by Aß reduced GLUT-1 amounts is unknown but it likely involve inhibition of its synthesis 
or possibly even increase of its degradation. 
A decreased amount of GLUT-1 may also affect cognitive deficits associated with AD. For 
instance, the levels of acetyl-CoA, a product of the glycolytic pathway required for the syn-
thesis of acetylcholine, a neurotransmitter involved in learning and memory will be decre-
ased when glucose supply is diminished. Further, impaired cholinergic neurotransmission 
can contribute to Aß deposition since it increases amyloid precursor protein expression and 
reduces its non-amyloidogenic cleavage by the a-secretase pathway [39-41]. 
Besides the huge amount of Aß and the decrease in GLUT-1 in the capillaries in the DG in 
llf! 
these 18-month-old APP/PSl mice, we also observed atrophy in this brain area, indicating 
a specific sensitivity of the DG for AD pathology. This observation is also fortified by the 
finding that between 8 and 18 months of age the width of the outer molecular layer of the 
DG increases in wild type mice, probably due to growing, whereas transgenic mice do not 
show a significant increase, indicating atrophy in this area. This sensitivity of the DG is in 
accordance with human AD pathology in which Aß depositions appear first in the hippo-
campus and especially in the DG [42-44]. The DG is also the area first affected in AD with 
neuronal dysfunction [44,45], even before the accumulation of Aß plaques [45]. The width 
of the outer molecular layer of the DG was measured since this layer is subject of age-re-
lated loss of synapses [46,47] originating from perforant path afférents from the entorhinal 
cortex which is affected in AD [45,46,48] Furthermore, loss of synapses in perforant path 
afférents correlated with memory impairment in aged mice and rats [49,50] and humans 
[46,48]. In addition, a spatial relation between Aß depositions and synapse loss has been 
reported in the hippocampus and entorhinal cortex of APP mutant Tg 2676 mice [49], sug-
gesting a causal role for Aß in AD associated neurodegeneration. 
Although the present findings point to close relationship between Aß depositions, decre-
ased GLUT-1 amount per capillary density, and tissue atrophy in the hippocampal DG sub-
region in transgenic APP/PS1 mice, the chronological order of these findings is not clear. 
We think it is unlikely that a decrease in GLUT-1 amount/capillary density is the primary 
event in AD and that a reduced availability of glucose to the brain initiates Aß deposition or 
neuronal damage and brain atrophy, since we did not find differences in GLUT-1 amount/ 
capillary density in our 8-month-old APP/PSl mice, while Aß deposition in the DG was 
already present. It could therefore be hypothesized that Aß deposition leads to a decreased 
GLUT-1 amount/capillary density causing a hypometabolic state, which is followed by 
atrophy of the DG. However it is also possible that Aß deposition may lead to neuronal da-
mage and atrophy, followed by a decreased demand for glucose, and a decreased GLUT-1 
amount /capillary density as a consequence. These hypotheses are also strengthened by 
the measured significant correlation between hippocampal atrophy and GLUT-1 amount/ 
capillary density. 
However the first hypothesis is most likely since a reduced cerebral glucose uptake by 
individuals genetically at risk for AD supports the notion that glucose deprivation prece-
des neuronal degeneration. [51,52]. Furthermore, other studies have shown that reduction 
in the cerebral glucose metabolism represent a true loss in functional activity, and is not 
caused by brain atrophy [53], indicating that a decreased GLUT-1 amount/capillary density 
may precede neuronal atrophy and is not caused by atrophy. Further support to this notion 
comes from a study demonstrating that Aß peptide impaired glucose transport in neurons, 
which may lead to neurodegeneration [54]. 
In conclusion, the present findings indicate that ageing causes a decrease in GLUT-1 amount 
and capillary density in the hippocampus of both wild type and transgenic mice and the 
decrease in GLUT-1 amount is more pronounced in APP/PSl mice. Further a reduced 
total amount of GLUT-1 in the hippocampus of 18-month-old APP/PSl mice results from 
a decrease in GLUT-1 amount/capillary density and not from a reduced capillary density. 
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We suggest that Aß load in the hippocampus precedes the reduction of GLUT-1 and when 
the Aß load in the hippocampus reaches a sufficient amount, this may lead to a decreased 
GLUT-1 amount/capillary density which further impairs energy metabolism followed by 
hippocampal atrophy. 
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Abstract 
Hyperhomocysteinemia and factors of homocysteine metabolism, s-adenosylhomocystei-
ne (AdoHcy) and s-adenosylmethionine (AdoMet), may play a role in Alzheimer disease 
(AD). With liquid-chromatography tandem-mass-spectrometry AdoMet and AdoHcy were 
determined in brains of 8 and 15-month-old APP/PSl Alzheimer mice, and the possible 
role of these methylation metabolites in AD brains investigated. AdoMet brain levels did 
not differ at 8-months, but were significantly lower in 15-month-old wildtype mice com-
pared to APP/PSl mice. AdoHcy levels did not differ between genotypes. These findings 
indicate that alterations in AdoMet are a consequence of AD rather than a cause. During 
aging, AdoMet levels were only decreased in wildtype mice whereas AdoHcy levels dimi-
nished in both genotypes. In conclusion AdoMet levels in APP/PS1 mice are not decreased 
during aging, probably by less demand due to neurodegeneration. No effect of cholesterol 
or DHA enriched diets on AdoMet or AdoHcy levels were found. 
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Introduction 
The most pronounced pathological features in the human Alzheimer (AD) brain are amy-
loid-ß (Aß) depositions, intracellular tangles and neurodegeneration. Although the cause 
of the disease is largely unknown, the Aß protein is seen as one of the major contributors 
[!]• 
Aß is produced by cleavage of the amyloid precursor protein (APP) by the β and γ se-
cretases, BACE and Presenilin (PS). Missense mutations in either APP or the γ-secretase 
complex (PS1 and PS2) , cause overproduction of Aß, and early onset AD. Early onset 
AD represents only 5% of all AD cases and therefore explains only a small part of the 
cause of the disease. In addition, many studies show that Aß depositions do not correlate 
well with neuronal damage and cognitive decline. Therefore, it is suggested that beside 
Aß, other risk factors play an important role in the development of AD. Nowadays more 
and more consensus is reached about vascular disorders being major risk factors for AD. 
Hyperhomocysteinemia for example, was until recently believed to be a risk factor for 
cardiovascular disorders [2] and associated with an increased risk of AD [3,4]. It could 
therefore be suggested that hyperhomocysteinemia, cardiovascular disorders and AD are 
interrelated with each other. However, this is currently under debate because of recent 
homocysteine-lowering intervention studies, showing no relation between cardiovascular 
disease and hyperhomocysteinemia [5,6]. In addition it is unclear whether lowering of 
homocysteine (Hey) by folic acid intake, can diminish AD prevalence or improve cogni-
tion [7,8], because recent large randomized Hey lowering intervention trials did not show 
beneficial effect of lowering Hey with folate and vitamin B12 on cognitive function [7]. 
It could therefore be suggested that hyperhomocysteinemia itself is not causing AD, and 
that other factors of the Hey metabolism, such as s-adenosylhomocysteine (AdoHcy) and 
s-adenosylmethionine (AdoMet), probably play a more important role in vascular disease 
[9] and AD development [10-12]. 
AdoMet is a biological methyl donor and is a product of the conversion of methionine and 
ATP. Transfer of the methylgroup from AdoMet leads to the formation of AdoHcy which in 
turn inhibits cellular methylation and eventually will be hydrolyzed into Hey. Methylation 
is required in many essential biological processes, such as gene expression, regulation of 
protein function and neurotransmitter synthesis, and altered methylation patterns might 
play a role in AD [10-12]. 
Indeed, there are studies showing a role for AdoMet and AdoHcy in AD [11-13]. It is sug-
gested that DNA methylation for example, is involved in amyloid precursor protein (APP) 
processing and Aß production through the regulation of Presenilin 1 (PS 1 ) expression. Exo-
genous AdoMet may silence β and γ secretases, and thereby reducing Aß production [13]. 
Other studies have shown decreased AdoMet and AdoHcy levels in the cerebrospinal fluid 
(CSF) of AD patients compared to age matched healthy volunteers [11,12]. 
Until now, most studies determined AdoMet and AdoHcy levels in cerebrospinal fluid 
(CSF) of AD patients [14]. However, AdoMet and AdoHcy remain mostly intracellular and 
do not pass membranes easily, and it could therefore be possible that AdoMet and AdoHcy 
levels in brain tissue comprise a more reliable reflection of AD processes than CSF or se-
rum levels which are a 100-fold lower. 
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There is only one study describing AdoMet levels in brain tissue of AD patients [12]. That 
study reported severely decreased AdoMet levels. Although the authors carefully matched 
with respect to postmortem time since AdoMet levels decrease with more than 60% and 
AdoHcy levels increase with 80% within 15 hours after death [12], it is not certain whether 
these changes are equal for all AD subjects and age-matched controls. Therefore, the re-
sults of this study might be difficult to interpret. In addition, it is still unknown whether 
alterations in AdoMet and AdoHcy levels are cause or consequence of AD. We therefore 
investigated AdoMet and AdoHcy levels in brain tissue of 8 and 15-month-old wild type 
and APP/PS1 double transgenic Alzheimer mice 
In addition we investigated the effect of aging and the effects of cholesterol and doco-
sahexanoic acid (DHA) containing diets on AdoMet and AdoHcy levels. These nutritional 
components influence vascular health [17,18] and the risk of developing AD [15-17], and it 
could be hypothesized that AdoMet and AdoHcy levels may be influenced subsequently. 
Materials and Methods 
Animals and diets. 
The APPswe/PSldE9 founders were obtained from Johns Hopkins University, Baltimore, 
MD, USA (D. Borchelt and J. Jankowsky, Dept. of Pathology) and a breeding colony was 
established at the Radboud University Nijmegen Medical Centre, The Netherlands. Male 
APP/PS1 transgenic mice and their wild type littermates were randomly assigned to diffe-
rent diet groups. The number of animals per group was decided on the basis of availability. 
The experimental diets differed with respect to the composition of the 5% fat in the diets 
[16] but are all isocalonc. Feeding the diets started at 2 months of age. 
Transgenic mice and their wild type littermates were fed either a Typical Western Diet 
(TWD), containing 1% cholesterol, a high percentage of saturated fatty acids (SFA=53%), 
and long chain poly unsaturated fatty acid (LCPUFA) ratio of n6/n3 = 22.5, or a DHA diet 
containing 0 4% DHA, a low percentage SFA (20%), and a lc-PUFA ratio of n6/n3=2.5, or 
a standard control diet (STD), with 38% SFA and lc-PUFA ratio of n6/n3= 7.5. 
In total 82 mice were used, table 1 describes the number of mice used in each experiment. 
The mice were selected upon availability from another existing study performed in our 
own lab (submitted). 
Throughout the experiments the animals were housed individually in a controlled environ-
ment (the mice were housed in the central animal facility with the temperature controlled 
at 210C, and an artificial 12:12 h light:dark cycle (lights on at 07.00 am)), with some cage 
enrichment, consisting of an Iglo and some nesting material. 
Food and water were available ad libitum. The experiments were performed according to 
Dutch regulations of the Animal Experimentation Act and the EC Directive 86/609 and 
were ethically approved by the Ethical Review Committee of the Radboud University Nij-
megen Medical Centre. 
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STD= standard diet, TWD= Typical Western Diet, containing 1% cholesterol, DHA= docosahexa-
noic acid diet, containing 0.4% of DHA. Wt=wild type mice. Tg= transgenic APP/PS1 mice. 
Brain sample collection and storage. 
Directly following anesthesia with Nembutal (60 mg/kg, i.p.) (Ceva Santa Animals BV, 
Maassluis), ail mice were weighed and thereafter decapitated and the brains were remo­
ved from the skull. The entire brain, without the spinal cord was thereafter dissected into 
3 smaller pieces, of which the frontal part of the brain was used for this experiment. All 
pieces were snap frozen in liquid nitrogen and were kept frozen at -80oC. 
An 40 mg tissue piece, containing the frontal part of the brain was prepared by sonification 
in 800 μΙ cold PBS, and thereafter centrifuged at 40C at 14000 rpm for 5 min. The super­
natant was removed and diluted 8 times. One part was used for HPLC tandem MS measu­
rements, and another part for determination of the protein amount in the sample using the 
Lowry method [18]. 
S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy) 
measurements. 
As previously described by Gellekink et al [19], AdoMet and AdoHcy levels in brain tissue 
were measured using liquid chromatography tandem mass spectrometry (LC-MS/MS). 
In short, after addition of the internal standards AdoMet-d3 and AdoHcy-d5 to the pretre-
ated tissue sample( see above), solid phase extraction (SPE) columns containing phenyl 
boronic acid (PBA) were used to bind AdoMet and AdoHcy and their internal standards 
and to deproteinize the samples. 
AdoMet and AdoHcy were eluted in 0.1 Ν formic acid and measured with the LC tandem 
mass spectrometer (MS/MS)(Quatro LC from Micromass), in the positive-ion mode. 
Statistics. 
Linear regression analysis was used to verify the linearity of the calibration curves. In order 
to analyze the possible differences between the two genotypes and the different diet groups 
a Multivariate ANOVA was conducted with the between group factors diet and genotype. 
In order to investigate effects of aging in the 2 different genotypes a Multivariate ANOVA 
was used with the between group factors age and genotype. 
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Results 
No changes in bodyweight were found between the genotypes, nor the two different age 
groups nor diet groups. 
Genotype effects: 
No changes in AdoMel and AdoHcy levels, and consequently in the ratio between AdoMet 
and AdoHcy levels (methylation index), were observed between 8-month-old wild type 
andAPP/PSl mice (Fig. la, bande). 
In addition, also in 15-month-old mice no changes were observed in AdoHcy levels bet-
ween the genotypes (Fig. lb). However we did observe a significant decrease in AdoMet 
levels in 15-month-old wild type mice compared to APP/PS1 mice (Fig. la; F(l,45)=7.54, 
p<0.01). Consequently, the AdoMet/AdoHcy ratio is increased in the APP/PS1 mice (Fig. 
lc;((l,45)=7.17,p<0.01). 
Aging effects 
AdoHcy levels significantly decrease during aging in both wildtype and APP/PS1 mice 
(F(l,79)=9.50, p<0.01). Due to an interaction between genotype and age in AdoMet levels 
and the ratio between AdoMet and AdoHcy levels (methylation index), the effects of aging 
in wild type and APP/PS1 mice were determined separately for these parameters. 
A significant decrease in AdoMet levels during aging was only found in wild type mice 
(F(l,42)=8.09, p<0.01) and not in APP/PS1 mice. 
Thus, AdoHcy decreased in both wild type and APP/PS1 mice during aging, whereas Ado-
Met only decreased in wild type mice. Consequently, the AdoMet/AdoHcy ratio (methyla-
tion index) in wildtype mice did not alter due to aging, but was significantly increased in 
APP/PS1 mice with aging (Fig. If; F(l,35)=6.61, p=0.01). 
Diet effects 
Neither a cholesterol nor a DH A containing diet did alter AdoMet or AdoHcy levels in brain 
tissue of 8 and 15-month-old APP/PS 1 and wild type mice as compared to the standard diet 
(data not shown). 
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Fig. 1. Levels of s-ademylmethkmine (AdoMet; A,D) ands-adenosylhomocysteine (AdoHcy; B,E) and the methylation index (AdoMet/ 
AdoHcy; C,F) in brain tissue of 8 and 15-month-old APP/PSI mice and their wild type littermates. Values represent mean and SEM. * 
p<0.01. 
Discussion 
In this study we showed that AdoMet tissue levels did not differ between 8-month-old 
APP/PSl mice and wild type mice, but are decreased in 15-month-old wild type mice 
compared to APP/PSl mice Moreover, tissue levels of AdoHcy decreased in both wild 
type and APP/PS1 mice during aging, whereas AdoMet only decreases in wild type mice. 
Because AdoMet and AdoHcy brain levels in (young) 8-month-old mice are unchanged, 
in contrast to the (old) 15-month-old mice, these results indicate that alterations in AdoMet 
are a consequence of AD rather than a cause In addition, we showed that a cholesterol 
containing or DHA enriched diet did not affect AdoMet or AdoHcy levels in brain tissue of 
APP/PSl and wild type mice. 
This is the first study describing AdoMet and AdoHcy levels in brain tissue of aging mice 
Stramentinoli et al [20] described, decreased AdoMet levels [20] in brain tissue of aging 
rats In addition they measured the synthesis of AdoMet by adenosyl transferase and Ado-
Met utilization by COMT, and they concluded that a decrease in AdoMet levels is due to 
increased utilization during aging Increased utilization may also be the explanation for the 
decrease in AdoMet and AdoHcy in our wild type mice It could be suggested that in the 
APP/PSl mice, AdoMet levels do not decrease because of less demand caused by neurode-
generation In a subgroup of liltermates of the 15-month-old mice used in this study, we 
observed hippocampal atrophy in APP/PSl mice compared to wild type mice (not shown), 
which may express neurodegeneration 
If the above mentioned hypothesis is valid, and AdoMet remains unaltered in aged APP/ 
PS1 mice because of less demand for methylation due to neurodegeneration, AdoHcy le-
vels will also be expected to be decreased or unchanged. Indeed, AdoHcy levels are similar 
in the 15-month-old wild type mice and APP/PSl mice 
All together, the fact that AdoMet levels in APP/PSl mice are not decreased during aging 
(in contrast to the wild type mice) is probably a consequence of neurodegeneration rather 
than a cause for AD. 
The finding that AdoMet levels do not differ between the genotypes in 8-month-old mice, 
but are significantly different in 15-month-old APP/PSl mice compared to their wild type 
littermates also indicate that alterations in AdoMet levels are a consequence of AD rather 
than a cause 
In this experiment we have only measured AdoMet and AdoHcy levels, it would however 
be of great value to measure in future studies more components from the methylation cycle 
such as homocysteine itself and some of the enzymes involved in the synthesis or utiliza-
tion of AdoMet, to validate our conclusions 
The finding that cholesterol or DHA containing diets do not alter AdoMet or AdoHcy levels 
in brain tissue of either wild type or APP/PSl mice, but in contrast do have effects on AD 
pathology and cerebral hemodynamics [15-17], suggests that AdoMet and AdoHcy are not 
directly involved in cerebral vascular diseases (which is in agreement with other studies 
[5,6]), and are no important key players in the mechanisms explaining the effects of cho-
lesterol and DHA in AD pathology 
no 
Main Conclusions 
We measured AdoMet and AdoHcy levels in brain tissue of 8 and 15-month-old wild type 
and APP/PS1 mice, to investigate whether there is a role for these metabolites of methyla-
tion in the AD brain. The finding that AdoMet levels do not differ between the genotypes in 
(young) 8-month-old mice, but are different in (older) 15-month-old APP/PS1 mice com­
pared to their wild type Iittermates, suggests that alterations in AdoMet are a consequence 
of AD rather than a cause, and possibly the result of neurodegeneration. 
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The possibility that the risk for Alzheimer's disease (AD) can be reduced by diet or life-
style is of great importance and suggests a preventative treatment in Alzheimer's disease. 
Lipid diets and lipid metabolism play a role in both Alzheimer's disease and cardiovascular 
disease. In addition a link between cardiovascular disease and Alzheimer has been sugge-
sted [1-6]. It could therefore be hypothesized that dietary lipids influence AD progression 
via effects on the vasculature. 
Epidemiological studies have repeatedly shown that dietary intake of DHA decreases, and 
high serum cholesterol levels increase the risk of AD [3,7-11]. In this thesis we therefore 
focus on the effect of docosahexanoic acid (DHA), an omega-3 long chain polyunsaturated 
fatty acid from fish oil, and cholesterol containing diets, on cerebral hemodynamics in 
transgenic APP/PSl Alzheimer mice. 
In the first part of this chapter I will give a summary of our most important findings. This 
summary will contain a description of the mechanism by which cholesterol and DHA con-
taining diets may influence the course of AD followed by a description of some of the con-
sequences of AD development. In the second part of this chapter I will provide a general 
discussion with concluding remarks and some future perspectives. 
DHA in AD development 
Many animal, epidemiological and clinical studies have shown that high DHA consump-
tion is associated with reduced risk of AD [7,9,11-14]. The underlying mechanisms howe-
ver are still largely unknown. It is found that DHA decreases the amount of Aß deposition 
in plaques and cerebral amyloid angiopathy [13-15], protects against dendritic pathology 
[16], prevents neuronal apoptosis induced by soluble amyloid-ß peptide [17], increases sy-
naptic protein and phospholipid densities [18,19] and inhibits degradative endopeptidase 
activities [20]. However the results of the experiments described in this thesis (chapter 2 
and chapter 3) show that changes in the cerebral circulation may play a crucial role. 
We have shown in APP/PSl mice, that a DHA containing diet (which also contains a 
small amount of EPA) is able to alter the relative cerebral blood volume (rCBV; a possible 
measure for cerebral hemodynamics) already at 8-month of age, whereas diet induced 
changes in Aß plaque load were not yet detected (chapter 3). This indicates that a DHA 
diet may cause alterations in cerebral hemodynamics in APP/PSl mice before changes in 
the Aß plaque load occur. 
In 15-month-old APP/PSl mice fed the DHA containing diet both changes in Aß plaque 
load and rCBV occurred simultaneously. The rCBV slightly increased, probably caused 
by vasodilatation, and vascular and parenchymal Aß plaque load decreased. But more 
importantly we also observed improved spatial memory in these 15-month-old mice fed 
DHA (chapter 3). 18-month-old mice fed the DHA diet only showed increased rCBV 
combined with a decreased vascular Aß load (chapter 2). No changes in parenchymal Aß 
levels were found, but this could be due to the extensive Aß pathology in 18-month-old 
APP/PSl mice, and it may therefore be difficult to induce diet effects on that age. 
Nonetheless we conclude that DHA intake inhibits AD pathology by decreasing the 
amount of Aß, and improves cognition and accordingly delays progression of AD de-
velopment. We hypothesize that this delay in progression of AD due to DHA intake is 
Π4 
caused by improvement of vascular health, since the AD related changes in this APP/PS1 
mouse model fed a DHA containing diet show that alterations in cerebral hemodynamics 
occur before Aß plaque load diminishes (Table and Fig. l)(chapter 3). 
Table 1. Summary of the main effects of a DHA and TWD diet in APP/PS1 mice 
Effects of DHA diet in APP/PS1 













Effects of TWD diet in APP/PS1 mice 








Table I. Summary of the main effects of a DHA and TWD diet in APP/PS1 mice. ND= not deter­
mined, ^increased, l=decreased, *=tendency. 
In addition, DHA may also have influenced the neuronal membrane fluidity, since the ratio 
between omega-3 and omega-6 fatty acids was increased in mice fed a DHA diet, which 
is an indicator for increased membrane fluidity. According to Wolozin's theory [6] it is hy­
pothesized that rigid neuronal membranes produce more Aß, and consequently more fluid 
membranes might diminish the amount of Aß deposition (Fig 1). 







B_^ssS^» Improved energy metabolism 
Improved brain perfusion 
Fig 1: Schematic overview of the two main hypothesis involved in the mechanism by which high die-
tary DHA levels influence AD development. Grey arrows refer to the membrane fluidity hvpothesis of 
Wolozin [18]. Black arrows refer to the hypoperfusion hypothesis [17,22-23]. 
Cholesterol in AD development 
In contrast to the protective effects of DHA in AD, other dietary lipids increase the risk of 
developing AD. For example, a high cholesterol containing diet, causing hypercholestero-
lemia is an important risk factor for vascular disorders, and a link between hypercholes-
terolemia, cardiovascular diseases and AD has been suggested [3,8,10,21,22]. At present, 
the mechanism by which cholesterol increases the risk of AD, is not completely clear. The 
results of the studies presented in chapter 2 and 3 however show, that like DHA, also 
cholesterol affects AD development via the cerebral circulation. In 8-month-old APP/PS1 
mice no effects of a typical western diet (TWD) containing 1 % cholesterol were noticed on 
Aß deposition, rCBV or cognition, whereas in 15-month-old mice, decreased rCBV levels 
were found (chapter 3). During further aging, also the parenchymal Aß levels increased 
(chapter 2). All together the results of the experiments in chapter 2 and 3 indicate that a 
TWD diet first changes the cerebral circulation before altering the Aß load (table 1). 
In addition, the observation that cholesterol levels do not change in brain homogenates 
from mice fed high a cholesterol-enriched diet, may indicate that cholesterol is not incor-
porated in brain tissue as a result of cholesterol intake. Membrane fluidity is therefore not 
influenced by administration of dietary cholesterol. Wolozin's theory in which he hypothe-
sizes that high cholesterol in neuronal membranes increases amyloid-ß (Aß) production 
[6] does not seem applicable here. In the hypoperfusion theory (Fig. 2) it is proposed that 
hypoperfusion of specific brain areas due to for example atherosclerosis is a primary event, 
and ultimately leads to a lowered energy metabolism (energy crisis), an overproduction of 
Aß and cognitive impairment [23-27]. Since we found a decreased rCBV before changes 
in Aß load occurred in TWD fed mice, the hypoperfusion hypothesis seems much more 
likely (Chapter 2 and 3). 
Increased cholesterol levels 





Fig 2: Schematic overview of the two main hypothesis involved in the mechanism bv which high 
dietary cholesterol levels influence AD development. Grey arrows refer to the membrane fluidity 
hypothesis ofWolozin [18]. Black arrows refer to the hypoperfusion hypothesis [17,22-23]. 
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AD as a vascular disorder 
Thus, changes in the cerebral circulation due to cholesterol and DH A containing diets seem 
to precede changes in Aß plaque load. Since environmental factors such as lifestyle and 
diet are important factors in AD development these findings suggest that vascular impair-
ment plays a larger role in AD than always assumed. 
The importance of vascular factors in AD emerge from the results described in chapter 2 
and 3. In chapter 2 a decreased rCBV was noticed in 18-month-old APP/PS1 mice com-
pared to age matched wild type littermates. In addition chapter 3 shows that 8-month-old 
mice show mild Aß pathology and cognitive impairment, which is aggravated in 15-month-
old mice. These 15-month-oId mice also display decreased rCBV and hippocampal atrophy 
(chapter 3). 
Although it is largely unclear in which order changes in Aß load, rCBV and hippocampal 
atrophy occur and cause cognitive impairment, it is likely that they contribute to neuro-
degeneration and ultimately cognitive impairment together. This fortifies the hypothesis 
that AD is not a single nosological entity. However, Aß deposition must be involved in 
cognitive impairment in this mouse model, since at 8 months of age both Aß deposition 
and cognitive impairment are already present at the same time, without changes in rCBV 
or atrophy. We therefore suggest that aggravation of AD only happens when changes in the 
brain circulation develop, which arc subsequently followed by cell death and hippocampal 
atrophy (chapter 3). 
Consequences of AD 
Besides alterations in cerebral hemodynamics, Aß plaque load and atrophy in the brains of 
AD patients, a reduced glucose metabolism and loss of the glucose transporter-1 (GLUT-
I) [28,29] is also frequently mentioned. It could be that loss of GLUT-1 is caused by 
a decrease in capillary density, and this decrease in capillary density might also explain 
the observed decrease in rCBV in APP/PS1 mice. However, the experiments described in 
chapter 4 show that there is a decreased GLUT-1 amount but no decrease in capillary den-
sity in APP/PS1 mice compared to wild type littermates. This indirectly confirms that the 
decrease in rCBV (chapter 3) in APP/PS1 mice must be due to vasoconstriction, and that 
a decreased GLUT-I amount is probably caused by a decreased GLUT-1 amount per capil-
lary (expression), which indeed was the case (chapter 4). The decrease in GLUT-1 expres-
sion could be cause or consequence of AD. However, we showed that a certain amount of 
Aß deposition must be reached before it affects GLUT-I expression, demonstrating that 
reduced glucose metabolism is probably a consequence of amyloid deposition (chapter 4). 
A reduced glucose metabolism might be partly responsible for the lowered energy meta-
bolism/energy crisis in AD brain regions (Fig 1 and 2). Accordingly it could be suggested 
that an energy crisis is an essential step in AD pathogenesis (Fig 3). For instance, it has 
already been shown that hypoperfusion causes an energy crisis which ultimately leads to 
an overproduction of Aß and cognitive impairment [24], furthermore a decreased GLUT-I 
expression due to Aß also indicates the presence of an energy crisis and in this way creates 
a virtuous circle (Fig 3). 
Besides an altered glucose metabolism, the homocysteine (Hey) metabolism seems also to 
be involved AD [30,31]- However, since recently performed large Hey lowering interven-
tion studies did not show beneficial effects on AD development, it is suggested that other 
factors of the Hey metabolism may be involved. In chapter 5 we therefore determined 
brain s-adenosylmethionine (AdoMet) and s-adenosylhomocysteine (AdoHcy) levels in 
the brains of 8 and 15-month-old wild type and APP/PS1 mice. AdoMet and AdoHcy are 
involved in all biological methylation processes in the body and also play an important 
role in vascular disease [32] and AD [33-35]. The results presented in chapter 5 show that 
during aging in wild type mice AdoMet and AdoHcy levels decrease. Although APP/PS 1 
mice also show a decrease in AdoHcy levels during aging, no decrease in AdoMet levels 
could be observed. The absence of a decrease in AdoMet levels in APP/PS 1 mice during 
aging compared to the presence of a decrease in wild type mice, causes a significant diffe-
rence between the 2 genotypes at 15 months of age. However, since differences in AdoMet 
levels are not present in 8-month-old mice, it could be concluded that they are a consequen-
ce of AD rather than a cause, and probably the result of neurodegeneration (chapter 5). 
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Fig 3' Schematic overview of the proposed sequence of events in the development of AD 
Concluding remarks 
Although chapter 1 to 5 provide many novel insights in AD pathology, it should be kept in 
mind that all experiments are performed in a mouse model for AD. The APP/PS1 mouse 
used in this thesis is an Aß-producing-model, in which the only difference with wild types 
are the presence of transfected human mutated genes encoding for the amyloid precursor 
protein (APP) and the presenilin 1 (PS1) resulting in the production of human Aß. We 
investigated the effects of dietary intervention and the role of hemodynamic alterations 
π κ 
in AD development, and showed that hemodynamic alteration due to cholesterol or DHA 
containing diets occur before changes in Aß plaque load are present. Whether there is 
a causal role for hemodynamic alterations in AD development, regardless of diet inter-
ventions, is still unclear and no major objective in this thesis. However, it would have 
been impossible to investigate this with our APP/PS1 mouse model due to its enormous 
promoter driven production of Aß. We nevertheless showed that in young (8-month-old) 
APP/PS1 mice compared to wild type mice already some Aß pathology combined with 
mild cognitive impairment was present, which became aggravated in older ( 15-month-old) 
mice and accompanied with a decrease in rCBV. Therefore, based on these results we can 
already conclude that changes in hemodynamics play a major role in progression and ag-
gravation of AD. 
In order to give a definitive answer on the question whether changes in the hemodynamics 
play a causal role in the development of AD we suggest to utilize another experimental 
model. The use of AD patients or other volunteers is not an option, because these kind of 
studies will be very time consuming and expensive. For example, the patient should be 
included in the study already many years before clinical onset and followed until death in 
order to confirm AD pathology. In addition, many expensive hemodynamic measurements 
and cognition tests should be performed over time. Thus, an experimental animal model, 
which expresses idiopathically/spontaneously some Aß pathology and presents cognitive 
decline during aging with a relatively short lifespan would be preferable. 
For example, aged non human primates, such as the squirrel monkey or the rhesus mon-
keys, develop age associated behavioural and brain abnormalities similar to those that oc-
cur in individuals with AD [36,37]. The squirrel monkeys develop more cerebrovascular 
Aß in the natural course of aging [36], whereas the rhesus monkey develops more abundant 
parenchymal Aß [37]. In addition, they develop hypertension and atherosclerosis [38-40]. 
Thus in order to find out whether hemodynamic alterations in spontaneously arising AD 
could be causal, future research should focus on models for idiopathic AD such as the 
rhesus or squirrel monkey. With MR methods, comparable as those described in this thesis, 
hemodynamic parameters such as the CBV and CBF could be visualized and quantified 
repeatedly during aging. However, other parameters such as blood pressure (bp) should be 
determined as well, since bp is much easier to determine in monkeys compared to mice, 
and many studies show a relation between dementia and high bp in mid-life or low bp in 
late-life (reviewed in [41]). 
Nonetheless, experimental research in mice is much cheaper, faster and less complicated 
due to less ethical concerns compared to experiment with monkeys, and it is therefore more 
likely to be continued in our laboratory. It would however be very valuable to use positron 
emission tomography (PET) scans with the radiotracer Pittsburgh Compound-B (PiB) or 
other MR1 techniques [42] instead of immunohistochemical studies, for visualizing Aß in 
vivo, in order to minimize animal use. In addition, it would be interesting to use arterial 
spin labeling (ASL) techniques for determination of the cerebral blood flow in specific 
brain regions. This technique provides more accurate CBF values compared to our used 
MRS technique, but was not available at the time. MRS techniques instead should be used 
to get a greater insight in energy- and glucose metabolism, and may help to further confirm 
the importance of an energy crisis partly due to hypoperfusion in AD (Fig. 2). 
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Anyhow, this thesis provides evidence on the importance of cerebral hemodynamic which 
implicates that AD prevention should focus more on keeping hemodynamic parameters 
in a normal range already during early-life. Dietary intervention may be a important tool 
herein. Chapter 2 and 3 for example showed that cholesterol or DHA containing diets first 
alter rCBV before changes in Aß plaque load or cognition were noted. The mechanism by 
which cholesterol and DHA influence the rCBV in AD development is still unknown, and 
future research should focus on this mechanism. 
Unraveling this mechanism may have important consequences for AD treatment, because 
therapeutic intervention directly upon this mechanism may improve AD treatment signi-
ficantly. 
Nonetheless this thesis already shows that dietary intervention has a great impact on AD 
development. A DHA containing diet improves spatial memory and decreases parenchymal 
and vascular Aß load. A high cholesterol containing diet however aggravates AD patho-
logy. From these results it could be concluded that consuming DHA, and keeping serum 
cholesterol levels low, will be beneficial for AD patients. However, the work described in 
this thesis suggests that a "healthy diet" (DHA rich and cholesterol poor) should already be 
started early in life. This also needs to be confirmed in clinical intervention studies. Until 
now it has been shown to be very difficult in human studies to observe the same major 
effects as found in our experimental animal study. Most clinical studies supplement for a 
rather short time [9,43,44], and start too late i.e. supplement to already cognitive impaired 
patients or in aged persons [9,11,43,44]. From the data described in this thesis it could be 
suggested that a healthy diet is of most benefit in young/ postpuberal individuals. 
Altogether, AD is a multi-factorial disease in which vascular factors play a dominant role 
already early in the course of the disease. This suggests, that treatment of vascular disor-
ders might be an important target for prevention of AD. 
In addition , the possibility that the risk for AD can be reduced by preventative strategies 
like diet is of great importance and promises to be a successful strategy in the treatment of 
AD and cardiovascular disease. In the ideal situation, long-term clinical studies, in which 
individuals are supplemented with experimental diets starting from young adult age, are 
necessary to confirm the importance of a "healthy" diet (DHA rich and cholesterol poor) in 
delaying AD onset and improving cognitive function. However, this kind of research is for 
many individual projects too expensive and too much time consuming, and theoretically 
could only be performed in a large collaboration and subsidized by different governments. 
Thus for the time being we should focus on experimental animal models resembling the 
human situation as much as possible. 
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De ziekte van Alzheimer (AD) is de meest voorkomende oorzaak van dementie. Op het 
moment lijden ongeveer 130.000 Nederlanders aan de ziekte van Alzheimer. Het grootste 
risico om de ziekte van Alzheimer te ontwikkelen is toenemende leeftijd. De gemiddelde 
levensverwachting neemt nog steeds toe in onze westerse samenleving en dus zal ook het 
aantal Alzheimerpatienten toenemen. In 2050 zullen meer dan 300.000 Nederlanders Alz-
heimerpatiënt zijn. Dat is één op 57 Nederlanders. 
Tijdens deze ziekte sterven geleidelijk zenuwcellen af (neurodegeneratie) in specifieke ge-
bieden van het brein zoals de hippocampus (een gebied in de hersenen dat betrokken is bij 
het opslaan van nieuwe herinneringen die betrekking hebben op feiten en gebeurtenissen) 
en de cortex. Ook zijn er kluwens van draadvormige eiwitten (tangles) in de hersencel-
len aanwezig die het functioneren van de zenuwcel onmogelijk maken. Tevens worden er 
eiwitophopingen, voornamelijk bestaand uit het eitwit ß-amyloid (Aß), buiten de zenuw-
cellen (seniele plaques) en in de wand van de bloedvaten (cerebrale amyloid pathologie) 
gevonden. 
De oorzaak van de ziekte is nog steeds grotendeels onbekend maar steeds meer onder-
zoek laat zien dat voeding een belangrijke rol speelt bij het ontstaan en het beloop van de 
ziekte van Alzheimer. Het is bijvoorbeeld gebleken dat mensen met een hoge cholesterol-
bloedspiegel, een hoger risico hebben op de ontwikkeling van AD. En mutaties in genen 
die betrokken zijn bij het cholesterol metabolisme lijken ook geassocieerd te zijn met de 
ontwikkeling van AD. 
Het gebruik van visolie (ofwel omega-3 vetzuren zoals DH A en EPA) daarentegen lijkt het 
risico op de ontwikkeling van AD juist te verlagen en het geheugen verbeteren. Verder is 
uit dierexperimenteel onderzoek gebleken dat het vetzuur DHA uit visolie de vorming van 
Aß sterk tegengaat. In hoofdstuk 1 van dit proefschrift zijn de belangrijkste effecten van 
cholesterol en DHA op de ontwikkeling van AD weergegeven. 
Kortom, cholesterol en DHA beïnvloeden het risico op de ontwikkeling van AD, maar 
tot op heden is het onderliggende mechanisme nog onbekend. Het wordt gesuggereerd 
dat voeding de ontwikkeling van AD beïnvloedt door de doorbloeding van de hersenen 
te veranderen. Cholesterol kan bijvoorbeeld zorgen voor aderverkalking (athérosclérose), 
waardoor er minder zuurstof en voedingstoffen via het bloed in de hersenen aankomen 
(verminderde doorbloeding van de hersenen), de hersencellen noodlijdend worden en bij-
voorbeeld het Aß eiwit gaan vormen. Uiteindelijk zou dit alles dan leiden tot neurodegene-
ratie en cognitieve achteruitgang (figuur 1). 
Onderzoek naar omega-3 vetzuren heeft juist aangetoond dat het gebruik van visolie (DHA 
en EPA) de vasculaire gezondheid ten goede komt. Het kan dus worden gesuggereerd dat 
omega-3 juist de doorbloeding van de hersenen verbetert, en op deze manier Aß depositie 
tegengaat en cognitieve achteruitgang afremt. 
DHA en cholesterol in de ontwikkeling van Alzheimer 
In hoofdstuk 2 en 3 van dit proefschrift is gekeken op welke manier cholesterol en DHA 
de ontwikkeling van de ziekte van Alzheimer beïnvloeden, en of veranderingen in de cere-
brale doorbloeding hieraan ten grondslag kunnen liggen. In figuur 1 en 2 wordt een sche-
matisch overzicht gegeven van de 2 meest waarschijnlijke hypotheses die de rol van cho-
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Fig 1: Schematisch overzicht van de twee belangrijkste hypothesen die de effecten van cholesterol 
op neuronale degeneratie en cognitieve achteruitgang kunnen verklaren. De grijze pijlen geven de 
membraan vloeibaarheid-hypothese weer (Wolozin theorie). Zwarte pijlen geven de hypoperfusie 
theorie weer (gebaseerd op een theorie van Farkas, 2001 en de la Torre. 2002). 
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Fig 2: Schematisch overzicht van de twee belangrijkste hypothesen die de effecten van DHA op 
neuronale degeneratie en cognitieve achteruitgang kunnen verklaren. De grijze pijlen geven de mem­
braan vloeibaarheid-hypothese weer (Wolozin theorie). Zwarte pijlen geven de hypoperfusie theorie 
weer (gebaseerd op een theorie van Farkas, 2001 en de la Torre, 2002). 
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lesterol en DHA op de ontwikkeling van AD zouden kunnen verklaren In dit proefschrift 
werd gebruik gemaakt van dubbel transgene Alzheimer muizen (APPswe/PSldE9) Dit 
zijn muizen die 2 gemuteerde humane genen bezitten (APPswe en PSldE9), die verant-
woordelijk zijn voor de vorming van het Aß proteine. Deze muizen vormen al op jonge 
leeftijd Aß deposities in het brein en vertonen cognitieve achteruitgang Alle muizen kre-
gen een cholesterol verrijkt typisch westers dieet (TWD), een DHA verrijkt dieet (waar ook 
een kleine hoeveelheid EPA inzit), of een standaard (STD) controle dieet. 
DHA 
In hoofdstuk 2 lieten wij zien dat een DHA verrijkt dieet in 18 maanden oude APPswe/ 
PSldE9 muizen, de cerebrale doorbloeding verandert (de relatieve cerebrale bloedvolumes 
(rCBV) verhoogt) en de hoeveelheid Aß verlaagt Vervolgens wilden we weten welk van 
deze mechanismen als eerste verandert om oorzaak en gevolg te achterhalen 
In hoofdstuk 3 hebben we daarom gebruikt gemaakt van 2 jongere groepen muizen (8 en 15 
maanden oud) en lieten we zien dat veranderingen in de doorbloeding als eerste optreden 
onder invloed van een DHA bevattend dieet Tevens hebben we vastgesteld dat een DHA 
dieet de cognitie verbetert in APPswe/PSldE9 muizen. 
Kortom, een DHA verrijkt dieet in APPswe/PSldE9 muizen lijkt AD pathologie te vermin-
deren door de Aß levels te verlagen, en de cognitie te verbeteren. Wij hypothetiseren dat 
een verbetering van de vasculaire gezondheid hieraan ten grondslag ligt. 
Cholesterol 
In hoofdstuk 2 en 3 laten we tevens zien dat ook een cholesterol verrijkt dieet (typisch 
westers dieet; TWD) de ontwikkeling van de ziekte van Alzheimer lijkt te beïnvloeden via 
de doorbloeding. 
In 15 maanden oude muizen zien we een verlaging van de rCBV, die in 18 maanden oude 
dieren wordt gevolgd door een verhoging van het aantal Aß plaques Tevens verandert de 
hoeveelheid cholesterol in het brein weefsel met onder invloed van een cholesterol dieet 
Dit impliceert dat de "theorie van Wolozin", waarin hij hypothetiseert dat cholesterol in 
neuronale membranen de hoeveelheid Aß zou verhogen en vervolgens cognitieve achter-
uitgang zou veroorzaken, hier niet van toepassing is, maar juist de hypoperfusie theorie 
(Fig 1) 
De ziekte van Alzheimer als vasculaire aandoening? 
De resultaten van de dieet experimenten lieten dus duidelijk zien dat de doorbloeding een 
belangrijke rol speelt in de ontwikkeling van AD, aangezien bij zowel het DHA en choles-
terol dieet de rCBV als eerste veranderde Ook tussen de transgene APPswe/PSldE9 en de 
wild type (controle) muizen zien we verschillen in de doorbloeding. Dit impliceert dat ook 
hier een veranderde doorbloeding van invloed kan zijn op AD ontwikkeling In hoofdstuk 
3 lieten we zien dat 15 maanden oude APPswe/PS1dE9 muizen een lagere rCBV hebben 
dan de wild type dieren, dit duidt erop dat er een hypoperfusie optreedt. 
Echter, in jongere (8 maanden oud) dieren werd al cognitieve achteruitgang en Aß patho-
logie gezien, zonder veranderingen in doorbloeding Dit zou kunnen betekenen dat in dit 
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muismodel veranderingen in de doorbloeding niet de causale factor is. 
Maar omdat in 15 maanden oude AD muizen de Aß pathologie en cognitieve achteruitgang 
verergert in de aanwezigheid van een verlaagde rCBV, kunnen we suggereren dat verhevi-
ging van de ziekte van Alzheimer alleen optreedt wanneer er een verminderde doorbloe-
ding (hypoperfusie) ontstaat. 
Om definitief een antwoord te geven op de vraag of Alzheimer primair een vasculaire aan-
doening is, dient meer onderzoek uitgevoerd te worden. Het zou dan verstandig zijn ook 
een diermodel te gerbuiken waarin AD spontaan ontstaat en dat niet is gebaseerd op een 
niet fysiologische overproductie van Aß door een promotor. 
Gevolgen van AD pathologie 
Naast veranderingen in de cerebrale doorbloeding, de hoeveelheid Aß plaques en neurode-
generatie in de hersenen van AD patiënten, wordt er ook regelmatig een verlaagd glucose 
metabolisme en een verlies van glucose transporters (GLUT-1) waargenomen. Het is dus 
mogelijk dat een verlaging van GLUT-1 wordt veroorzaakt door een verminderde bloedvat 
dichtheid. 
Voeding 
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Fig 3: Schematisch overzicht van de gesuggereerde opeenvolging van gebeurtenissen in de ontwik-
keling van de ziekte van Alzheimer. 
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Dit zou dan direct de verklaring kunnen zijn voor de gevonden verlaging in rCBV. Echter, 
de resultaten in hoofdstuk 4 laten zien dat er geen verlaging is van het aantal bloedvaten, 
en impliceert dus dat de verlaging in rCBV wordt veroorzaakt door vasoconstrictie (samen-
knijpen van de bloedvaten), en de verlaging van de GLUT-1 wordt veroorzaakt door een 
verlaging van de hoeveelheid GLUT-1 per oppervlakte bloedvat. Inderdaad vonden we dat 
er een verminderde hoeveelheid GLUT-1 per bloedvat was, maar de oorzaak hiervan bleef 
nog onbekend. Uiteindelijk lieten we zien dat er een bepaalde hoeveelheid Aß aanwezig 
moet zijn in de buurt van de bloedvaten voordat de hoeveelheid GLUT-1 per bloedvat 
vermindert, en dat de verlaging van GLUT-1 niet simpel een gevolg is van neurodegenera-
tie. Hieruit kan worden geconcludeerd dat een verlaging van de GLUT-1 hoeveelheid per 
bloedvat een gevolg/ consequentie is van amyloidpathologie. 
Vervolgens zou een verlaagd glucosemetabolisme kunnen leiden tot een energiecrisis in 
neuronale cellen door een tekort aan voedingstoffen (Fig 3). Het is dus mogelijk dat het 
ontstaan van een energiecrisis een essentiële stap is in AD. We hebben bijvoorbeeld ook al 
laten zien in hoofdstuk 3 dat hypoperfusie wellicht een energiecrisis veroorzaakt en wordt 
gevolgd door een overproductie van Aß en uiteindelijk cognitieve achteruitgang. Kortom, 
wij suggereren dat het ontstaan van een energiecrisis door enerzijds hypoperfusie, en an-
derzijds een afname aan GLUT-1 transporters een sleutelrol speelt in AD Pathogenese (Fig 
3). 
In hoofdstuk 5 tonen we dat naast een verlaagd glucose metabolisme ook het homocystei-
nemetabolisme een rol lijkt te spelen in de ontwikkeling van AD. 
Homocysteine (Hey) is een afbraakproduct van de menselijke eiwitstofwisseling, en lijkt 
een risicofactor te zijn voor het ontstaan van hart- en vaatziekten en via deze weg ook voor 
de ontwikkeling van AD. Toch bleek uit studies waarin Hey verlaagd werd geen verbe-
tering in cognitie op te treden. Dit impliceert dat wellicht een andere factor dan Hey een 
rol speelt bij de ontwikkeling van AD. In hoofdstuk 5 bestudeerden wij 2 andere factoren 
van het Hey metabolisme, namelijk s-adenosylmethionine (AdoMet) en s-adenosylhomo-
cysteine (AdoHcy). Beiden metabolieten zijn betrokken bij alle methyleringsprocessen in 
het lichaam. Methylering is een belangrijk biochemisch proces in het lichaam waarbij een 
methylgroep (CH3) wordt overgedragen aan een ander molecuul. Als dit proces niet goed 
verloopt kan dat consequenties hebben voor bijvoorbeeld gen expressie, regulatie van eiwit 
functie en de synthese van neurotransmitters. Wij laten zien dat er bij veroudering in wild 
type muizen een afname optreedt in de hoeveelheid AdoMet en AdoHcy. In transgene AD 
muizen is er geen afname in AdoMet te zien, waarschijnlijk door neurodegeneratie. Dit 
leidt tot een verschil in AdoMet levels tussen de wild type en transgene AD muizen op een 
leeftijd van 15 maanden. Aangezien dit verschil niet aanwezig is in 8 maanden oude dieren, 
kan er worden geconcludeerd dat de veranderde AdoMet levels in AD muizen een gevolg 
zijn van AD in plaats van een oorzaak, maar wel kunnen bijdragen aan het ziekteproces. 
Slotopmerkingen 
De ziekte van Alzheimer is een multifactoriële ziekte waarin vasculaire factoren een es-
sentiële rol lijken te spelen al vroeg in de ontwikkeling van de ziekte. Behandeling van 
vasculaire aandoeningen zou dus ook kunnen bijdragen aan de remming van de ontwikke-
1̂ 0 
ling van de ziekte van Alzheimer. 
De bevinding dat interventie in het voedingspatroon het risico en de ernst van de ziekte 
van Alzheimer kan beïnvloeden, lijkt een succesvolle strategie te kunnen worden in de 
preventie van AD. 
De eventuele bescherming van DHA tegen cognitieve achteruitgang, en het verergeren van 
AD pathologie door hoog serumcholesterol zal nog bevestigd moeten worden in langdu-
rige klinische interventiestudies. Tot op heden zijn de "ideale" interventiestudics, waarin 
vanaf jonge leeftijd gesuppleerd wordt met bijvoorbeeld DHA en hemodynamische en 
cognitieve parameters regelmatig bepaald worden, niet haalbaar door enorme kosten. Dus 
voorlopig zullen we ons zeker moeten focussen op diermodellen die de humane situatie zo 
veel mogelijk nabootsen en op verschillende nieuwe geavanceerde technieken die ook in 
het klinisch onderzoek gebruikt worden. 

Chapter 8 
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amyloid precursor protein 
area under peak 
blood brain barrier 
bovine serum albumin 
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Cornu Ammonis 3 
Cerebral Amyloid Angiopathy 
critically attained threshold of cerebral hypoperfusion 
cerebral blood flow 
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gas chromatography-flame ionization detector 
gas-chromatography-mass spectrometry 
glucose transporter-1 
high density lipoprotein 
intra peritoneal 
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long chain poly unsaturated fatty acids 
low density lipoprotein 
low density lipoprotein receptor 
low density lipoprotein receptor related protein 
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magnetic resonance imaging 
magnetic resonance spectroscopy 
mono unsaturated fatty acids 
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phosphate buffered saline 
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presenilin 1 
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werth, the Netherlands. 
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and DHA on hemodynamic parameters and Alzheimer pathology in APP/PSl mice. Oral 
presentation at the 6th Endo-N euro-Psycho Meeting 2006, Doorwerth, the Netherlands. 
Hooijmans CR, van der Zee CEEM, Dederen PJ, van Groen Τ, Broersen LM, Liitjohann 
D, Heerschap A, Kiliaan AJ. The effects of dietary cholesterol and DHA on Cerebral vas­
culature, Alzheimer pathology and cognition in APP/PSl mice: "Resolving the chicken 
and egg issue". Oral presentation at the annual Maikammer lipid meeting, Maikammer, 
Germany. 
Hooijmans CR, van der Zee CEEM, Dederen PJ, van Groen Τ, Broersen LM, Liitjohann 
D, Heerschap A, Kiliaan AJ. The role of high cholesterol and fish oil in the development 




Carlijn Regina Hooijmans werd geboren op 16 maart 1981 in Leidschendam. Na het be-
halen van haar VWO diploma aan het Adelbert College te Wassenaar is Carlijn in 1999 
begonnen met de studie Biomedische Gezondheidswetenschappen aan de Katholieke Uni-
versiteit van Nijmegen. Al gauw werd het duidelijk dat haar interesse vooral uitging naar 
het ontstaan en beloop van ziekten bij de mens, en daarom koos zij voor het hoofdvak 
Pathobiologie. Haar brede interesse zorgde er voor dat zij de kans pakte om haar studie uit 
te breiden van 4 naar 5 jaar, en zij koos voor 3 bijvakken (Neurologie, Hematologie en On-
cologie) in plaats van 1 bijvak. Gedurende haar studie voltooide zij 2 stages. Tijdens haar 
eerste stage van 6 maanden op de afdeling Psycho-Neuro-Farmacologie, werd de rol van 
dopamine receptoren in de nucleus accumbens in het anti-parkinson effect van SK.F83959 
bestudeerd. Zij werd hierbij begeleid door M.M. Verheij en Prof. Dr. A.R. Cools. Haar 
tweede stage van 6 maanden vond plaats op de afdeling Reumatologie van het Nijmegen 
Centre for Molecular Life Sciences en werd begeleid door Drs. K. Nabbe en Dr. RL.E.M 
van Lent. Zij heeft daar onderzoek gedaan naar de rol van zuurstofradicalen in Fcy-receptor 
aangestuurde activatie van macrofagen. Gedurende haar studententijd heeft zij eerstejaars 
studenten begeleid, en is zij voorzitter geweest van de reiscommissie van de Medische Fa-
culteit Vereniging Nijmegen. Tevens is zij student-lid geweest van de opleidingscommissie 
Biomedische Wetenschappen onder leiding van Dr J.G.M. Kooloos en later Prof. Dr. J.L. 
Willems. In augustus 2004 behaalde Carlijn haar doctoraal diploma. 
Op 1 september 2004 is zij begonnen aan haar promotie onderzoek, beschreven in dit proef-
schrift, op de afdeling Anatomie van de Radboud Universiteit Nijmegen, onder begeleiding 
van Dr. A.J. Kiliaan. Tijdens haar promotie onderzoek heeft zij vele studenten en stagiaires 
begeleid en presenteerde ze haar werk op nationale en internationale congressen. 
Sinds 1 oktober 2008 is zij werkzaam in het Centraal Dieren Laboratorium Nijmegen als 
post-doc onderzoeker, onder leiding van Prof. Dr. M.J. Ritskes-Hoitinga en Dr. Ir. B. Save-
nije, met als kerntaak het ontwikkelen van richtlijnen voor meta-analyse van dierproeven 
ten behoeve van betere wetenschap en de implementatie van de 3V's (Vervanging, Verfij-
ning en Vermindering van proefdiergebruik). 
Naast haar universitaire loopbaan is Carlijn tevens betrokken bij ontwikkelingssamenwer-
king. Vanaf september 2001 is zij jaarlijks werkzaam als vrijwilliger in "Open Arms Ma-
lawi", en draagt zij bij aan de verzorging van HIV weeskinderen. Tevens heeft zij Open 
Arms in Nederland geregistreerd als Algemeen Nut beogende Instelling en is zij verant-
woordelijk voor de fondsenwerving van dit project in Nederland. 
Dankwoord 
Nu, na 4 jaar hard werken en veel plezier, het laatste (en waarschijnlijk het meest gelezen) 
gedeelte van dit proefschrift. Aangezien er vele mensen betrokken zijn geweest bij de tot-
standkoming van dit proefschrift wil ik hen hier bedanken voor wat zij, op wat voor manier 
dan ook, hebben bijgedragen. 
Maar het waren natuurlijk niet alleen mensen die mij geholpen hebben, want zonder mijn 
muisjes op typisch westerse (hamburger) en visrijke voeding, waren de nieuwe bevindin-
gen van dit proefschrift niet aan het licht gekomen en was er überhaupt geen proefschrift. 
Dit gezegd hebbende, wil ik nu overgaan tot het bedanken van allereerst mijn co-promotor, 
Amanda en promotoren Arend en Merel. 
Amanda, zonder jou was er geen proefschrift. Door jouw enorme passie voor onderzoek 
heb je ook mijn onderzoeksvuur aangestoken. Ik hoop dan ook in mijn toekomst in het 
onderzoek werkzaam te blijven, en ooit ook zelf zo'n mooi project te kunnen opstarten en 
begeleiden. Ik heb heel veel van je geleerd, en wens je alle succes toe in de toekomst. 
Na 2,5 jaar kreeg ik eindelijk een definitieve promotor. Merel, ik heb de werkbesprekingen 
als zeer prettig ervaren en waardeer enorm je enthousiasme en de rust die je uitstraalt en 
vervolgens ook weet over te brengen. Ik ben erg blij dat ik jouw team op het CDL mocht 
komen versterken. 
Arend, bedankt voor de kennis die je mij hebt bijgebracht met betrekking tot de bijzondere 
wereld van de "magnetische resonantie". Tevens ben ik erg blij met al die uren dat ik heb 
mogen meten in het CDL waar ik ook enorm veel van heb geleerd. Maar dit had niet zo 
leuk en leerzaam geweest zonder de mentale en technische ondersteuning van de mensen 
uit de radiologie-groep. Bob en Andor bedankt daarvoor, en ook voor alle lekkere appel-
taarten, moorkoppen en gezelligheid. 
Maar er zijn natuurlijk nog veel meer mensen die bedankt moeten worden. Jos, jouw hulp 
bij het maken van goede tiff-files, uitleg over de immunohistochemie en het gebruik van 
de Neurolucida hebben ervoor gezorgd dat ik vele manuscripten heb kunnen schrijven en 
illustreren. Bovendien heb ik genoten van alle koffiepauzes waarin de belangrijke zaken 
van de werkvloer en het leven werden besproken. 
Mare, elke keer dat ik weer in de welbekende aio-dip zat ben jij mijn steun en toeverlaat op 
de afdeling geweest. Altijd weer opbeurende woorden en de nodige lessen in verschillende 
belangrijke zaken van het leven, terwijl ik het mezelf gemakkelijk maakte op die oude 
blauwe sofa. Jij hebt mij veel geleerd, en ik heb jou gewaardeerd. Ook Jan Κ wil ik even 
noemen, voor zijn luisterend oor, droge opmerkingen en goede adviezen bij het begeleiden 
van studenten. 
Dit brengt mij natuurlijk logischerwijs op de studenten die bij mij stage hebben gelopen. 
Zonder hen was dit proefschrift lang niet zo dik geweest. Dus Femke, Katrien, Coen, Mar­
jolein, Erna, Arvela, Yael, Laurens, Piet, Mallaki, Anne, Linda en Maartje ik vond het erg 
leuk en leerzaam om jullie te begeleiden en hoop jullie in de toekomst nog eens tegen te 
komen. 
Al dacht ik mijn bureau (en directe omgeving daarvan) al erg gezellig gemaakt te hebben 
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met foto's, (kerst)verlichting en andere zaken, het kon nog beter, want de altijd kwekkende 
Annemieke, mama Annelieke en Albert (waarmee ik een passie voor Afrika deel), maakte 
de tijd op kamer 0.14 van de afdeling Anatomie nog veel aangenamer. 
Natuurlijk hebben ook de andere collega's van de afdeling Anatomie een belangrijke rol 
gespeeld in dit promotietraject, want zonder gezelligheid en enige afleiding op z'n tijd had 
ik dit proefschrift nooit tot een goed einde gebracht. Dirk, Jan V, Annemarie, Mark, Vera, 
Lidy en Marianne, bedankt. 
Ook al hoorde Theo niet echt bij de afdeling Anatomie, het leek wel zo. Theo, jouw hulp 
aan, en enorme betrokkenheid bij Open Arms Malawi, de vele biertjes bij de aesculaaf en 
nu de hulp bij het creëren van een mooi-ogend proefschrift heb ik heel erg gewaardeerd. 
Onmisbaar voor het verloop van dit onderzoek was Henk, die elke dag opnieuw mijn muis-
jes van hun speciale voeding en hele goede zorg voorzag. Maar hij zorgde ook voor de 
nodige technische ondersteuning en een geweldige trip naar Kuopio, Finland. 
Ik had dan geen collega aio's op de afdeling, maar wel in de omgeving. Liselore, al vanaf 
mijn eerste werkdag konden wij het goed vinden, zo goed dat we ook buiten het werk regel-
matig afspraken. Ik hoop dat dit zo zal blijven. Maar na die rokerige affaire in mijn keuken, 
kunnen we misschien beter afspreken in de toekomst gewoon uit eten te gaan. Nienke en 
Ilona door onze tripjes naar Madrid en Chicago, en de etentjes op z'n tijd, hebben we elkaar 
goed leren kennen en een geweldige tijd met elkaar gehad. Ik vond het ook super fijn dal 
jullie mij betrokken bij jullie werk- en literatuurbesprekingen. 
Naast leuke werkbezoeken aan Madrid en Chicago, ben ik ook een maand naar Bonn ge-
weest. Dieter, die Zeit in Ihrem Labor war mir sehr angenehm. Ich habe viel gelernt über 
Chromatographie aber mein Deutsch ist immer noch unter dem Mindestmaß©. Vielen 
Dank fur Ihre Hilfe und Gastfreundschaft. 
Ook mijn andere coauteurs wil ik nog even hartelijk danken. Heikki voor het verstrekken 
van de eerste groep al reeds verouderde muizen waardoor ik een vliegende start kon ma-
ken, Ineke voor het begeleiden van al het gedragswerk, Laus voor de muizenvoeding en de 
nodige statistische ondersteuning, Henk Β en Dinny voor alle analyses voor het AdoMet 
verhaal en de gezellige werkbesprekingen en Thomas, voor het corrigeren van de vele 
manuscripten. 
Nu komen we bij de mensen die mede verantwoordelijk zijn voor mijn geweldige leventje 
buiten het Radboud. 
Allereerst mijn Nijmeegse vriendengroep "het Genootschap". Na een geweldige studen­
tentijd hield "het genootschap' bestaande uit Janske, Ine, Lianne (tevens junior onderzoe­
ker en terecht mijn paranimf). Mare, Martijn, Lucas en Berry, gelukkig niet op te bestaan, 
en zijn zij (inclusief aanhang) tot op heden grotendeels verantwoordelijk voor de nodige 
ontspanning in mijn leven. De vele supergezellige activiteiten zoals; de mooie vakantie 
naar Zuid-Frankrijk, weekendjes weg, borreluurtjes in de Fuik en Camelot, verjaardagen, 
oud & nieuw-feestjes, stappen, skieen, het après-ski feest op de Korenmarkt, en vooral 
veel humor heeft er voor gezorgd dat we een hele hechte vriendengroep zijn, en dat is mij 
ontzettend veel waard! Ik zou jullie allemaal nog veel meer willen zeggen, maar dan komt 
er aan dit proefschrift nooit een eind, maar samenvattend bedankt voor alles, en wellicht 
komt het Genootschaps-appartementencomplex nog wel een keer van de grond ©. 
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Ook Judith, mijn paranimfen een van mijn beste vriendinnetjes vanaf 3 VWO wil ik noe-
men Ondanks het ver uit elkaar wonen en elkaar met heel veel meer zien, blijft onze 
vriendschap enorm vanzelfsprekend en hecht en gaan we elke date weer verder waar we 
gebleven zijn Janske, jou noem ik even speciaal omdatjij de vriendin bent waarmee ik alle 
studentenfeesten ben afgegaan, die vingerboontjes met haar handen eet, zorgt dat "stap-
pende" mannen weer veilig thuis komen", samen met mij enorm goed kan dansen op Abel, 
sneeuwstorm trotseert in Breda en vooral ook heel belangrijk voor me is. Karlijn, Yvonne 
en Annette, jullie zijn ook geweldige vriendinnen, en hopelijk blijven we ondanks grote 
afstanden toch regelmatig met elkaar afspreken 
Bijna 2 jaar van dit promotie traject heb ik vooral gesteund op jou Teun, bedankt voor alles 
en het was een geweldige tijd die ik nooit zal vergeten. 
Last but not least, mijn gehele familie en schoonfamilie Helaas kan ik met iedereen noe-
men, maar bij een paar belangrijke personen wil ik toch even kort stilstaan 
Lieve pap en mam, zonder jullie was dit alles er met geweest Jullie hebben mij altijd ge-
steund in alle beslissingen die ik neem, en stimuleren mij nog steeds om wat van mijn leven 
te maken en te doen wat ik leuk en belangrijk vind. Aangezien ik een heel gelukkig mens 
ben hebben jullie dus goed werk geleverd Ik ben ontzettend blij met jullie! 
Jas en Thijs, mijn broertjes Familie kan je niet uitzoeken, maar jullie zijn twee mannen die 
ik zelf uitgekozen zou hebben, en waar ik erg trots op ben! Ook wil ik Annelien en Karin 
niet vergeten, want ook de (ex)aanhang hoort erbij' Lieve Anne ik hoop datje nog lang bij 
ons blijft, en Karin, ik mis je nog steeds wel een beetje... 
Ook zijn er in de afgelopen jaren nieuwe mensen bij gekomen die een plekje in mijn hart 
verorverd hebben. Maarten en Yvonne (en de rest van de fam), met jullie heb ik maar ge-
boft, en ik vind het altijd heerlijk bij jullie. 
En dan mijn Opa'tje, ik ben zo blij dat u erbij kunt zijn' 
Als laatste Bram, jij maakt me heel erg gelukkig en zorgt voor de balans tussen werk en 
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